Gene editing systems targeting superoxide dismutase 1 (SOD1) and uses thereof
Patent Information
- Application Number
- PCT/US2026/023244
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-01-09
- Filing Date
- 2026-04-10
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for amyotrophic lateral sclerosis (ALS), particularly those targeting mutations in the SOD1 gene, lack effective genetic editing methods that can efficiently disrupt the SOD1 gene with minimal off-target effects.
Development of a gene editing system utilizing CRISPR nuclease polypeptides, such as Casl2i2, and RNA guides specifically designed to target the SOD1 gene, with optimized spacer and scaffold sequences, delivered via genetically modified viral vectors like AAV, to achieve high on-target editing efficiency and low off-target effects.
The system effectively disrupts the SOD1 gene, reducing SOD1 protein levels and showing promise in treating ALS, including familial forms, with minimal off-target genetic alterations.
Smart Images

Figure US2026023244_12112026_PF_FP_ABST
Abstract
Description
Attorney Docket No.: 063586-549001WOGENE EDITING SYSTEMS TARGETING SUPEROXIDE DISMUTASE 1 (SOD1) AND USES THEREOFCROSS REFERENCE TO RELATED APPLICATIONSThis application claims the benefit of the filing dates of U.S. Provisional Application No. 63 / 787,156, filed April 11, 2025, U.S. Provisional Application No. 63 / 804,220, filed May 12, 2025, U.S. Provisional Application No. 63 / 894,166, filed October 6, 2025, and U.S. Provisional Application No. 63 / 956,915, filed January 9, 2026, the entire contents of each of which are incorporated by reference herein.SEQUENCE LISTINGThe instant application contains a Sequence Listing which has been filed electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on April 10, 2026, is named 063586-549001WO_Seq-Listing_ST26.xml, and is 572,596 bytes in size.BACKGROUNDAmyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a nervous system disease that affects nerve cells in brain and spinal cord. ALS often starts with muscle twitching and weakness in an arm or leg, swallowing difficulty, and / or slurred speech. Over time, ALS causes loss of muscle control needed to move, speak, eat, and breathe. Currently, there is no cure for this fatal disease.Mutations in the SOD1 gene have been linked to familial ALS, while wild-type SOD1 is implicated in sporadic ALS. SOD1 encodes the superoxide dismutase 1 enzyme, which is responsible for destroying free superoxide radicals in the body. Exemplary SOD1 mutations associated with ALS include the A4V mutation, the H46R mutation, and the G93 A mutation. ALS-causing SOD1 mutations act in a dominant fashion: a single mutant copy of the SOD1 gene is sufficient to cause the disease. As such, genetic editing on the SOD1 gene would benefit treatment of ALS.SUMMARY OF THE INVENTIONThe present disclosure is based, at least in part, on the development of gene editing systems targeting the SOD1 gene, which successfully disrupted the SOD1 gene. Certain RNA guides involved in the gene editing system exhibited high on-site editing efficiency and low off-Attorney Docket No.: 063586-549001WOtarget effects. Since SOD1 gene is implemented in diseases such as amyotrophic lateral sclerosis (ALS), the gene editing system disclosed herein would benefit treatment of such target diseases.Accordingly, one aspect of the present disclosure features a gene editing system for genetic editing of a human superoxide dismutase 1 (SOD1) gene, comprising: (a) a CRISPR nuclease polypeptide or a first nucleic acid encoding the CRISPR nuclease polypeptide; and (b) an RNA guide (gRNA) or a second nucleic acid encoding the RNA guide. The gRNA comprises a spacer sequence specific to a target sequence within the SOD1 gene and the target sequence is adjacent to a protospacer adjacent motif (PAM) recognizable by the CRISPR nuclease polypeptide.In some embodiments, the CRISPR nuclease polypeptide is a Type V CRISPR nuclease. In some instances, the Type V CRISPR nuclease polypeptide comprises an amino acid sequence at least 90% identical to SEQ ID NO: 6 or SEQ ID NO: 9.In some embodiments, the Type V CRISPR nuclease polypeptide is a Casl2i2 polypeptide comprising an amino acid sequence at least 95% identical to SEQ ID NO: 6. Such a Casl2i2 polypeptide may comprises one or more mutations relative to SEQ ID NO: 6. The PAM corresponding to a Casl2i2 polypeptide comprises the motif of 5’-NTTN-3’, in which each N independently represents any nucleotide residue and the PAM being located 5’ to the target sequence.In some examples, the Casl2i2 polypeptide comprises the one or more mutations, which are at positions D581, G624, F626, N840, P868, 1926, V1030, E1035, and / or S1046 of SEQ ID NO: 6. The one or more mutations may be amino acid substitutions, for example, D581R, G624R, F626R, N840R, P868T, I926R, V1030G, E1035R, S1046G, or a combination thereof.In one specific example, the gene editing system comprises a Casl2i2 polypeptide, which comprises mutations at positions D581, D911, 1926, and V1030 (e.g., D581R, D911R, I926R, and V1030G). In another specific example, the gene editing system comprises a Casl2i2 polypeptide, which comprises mutations at positions D581, 1926, and V1030 (e.g., D581R, I926R, and V1030G). In yet another specific example, the gene editing system comprises a Casl2i2 polypeptide, which comprises mutations at positions D581, 1926, VI 030, and SI 046 (e.g., D581R, I926R, V1030G, and S1046G). In still another specific example, the gene editing system comprises a Casl2i2 polypeptide, which comprises mutations at positions D581, G624, F626, 1926, V1030, E1035, and S1046 (e.g., D581R, G624R, F626R, I926R, V1030G, E1035R, and S1046G). In another specific example, the gene editing system comprises a Casl2i2 polypeptide, which comprises mutations at positions D581, G624, F626, P868, 1926, V1030, E1035, and S1046 (e.g., D581R, G624R, F626R, P868T, I926R, V1030G, E1035R, andAttorney Docket No.: 063586-549001WOS1046G). In yet another specific example, the gene editing system comprises a Casl2i2 polypeptide, which comprises mutations at positions D581, G624, F626, N840, P868, 1926, V1030, E1035, and S1046 (e.g., D581R, G624R, F626R, N840R, P868T, I926R, V1030G, E1035R, and S1046G).The Casl2i2 polypeptide in the SOD 1 -target gene editing system provided herein may comprise the amino acid sequence of SEQ ID NO: 7. Alternatively, the Casl2i2 polypeptide in the SOD 1 -target gene editing system provided herein may comprise the amino acid sequence of SEQ ID NO: 8. In yet another example, the Casl2i2 polypeptide in the SOD 1 -target gene editing system provided herein may comprise the amino acid sequence of SEQ ID NO: 573.For gene editing systems involving a Casl2i2 polypeptide, the target sequence in the SOD1 gene may be within or near Exon 1, Exon 2, Exon 3, or Exon 4 of the SOD1 gene. For example, the target sequence may be one of those listed in Table 1 below. In some examples, the target sequence may be one of the following:(a) 5’ - CCCACACCTTCACTGGTCCA-3’ (SEQ ID NO: 41);(b) 5’- TGCTCGAAATTGATGATGCC-3’ (SEQ ID NO: 32);(c) 5’ - TCTTAAAGGAAAGTAATGGA-3’ (SEQ ID NO: 71);(d) 5’- TTATAAATAGGCTGTACCAG-3’ (SEQ ID NO: 134);(e) 5’- AATAGACACATCGGCCACAC-3’ (SEQ ID NO: 146); or(f) 5’- AAGATTCTGTGATCTCACTC-3’ (SEQ ID NO: 167).In some embodiments, the spacer sequences in the gRNA can be:(a) 5’- CCCACACCUUCACUGGUCCA-3’ (SEQ ID NO: 42);(b) 5’- UGCUCGAAAUUGAUGAUGCC-3’ (SEQ ID NO: 33);(c) 5’- UCUUAAAGGAAAGUAAUGGA-3’ (SEQ ID NO: 72);(d) 5’- UUAUAAAUAGGCUGU ACC AG-3’ (SEQ ID NO: 135);(e) 5’- AAUAGACACAUCGGCCACAC-3’ (SEQ ID NO: 147); or(f) 5’ - AAGAUUCUGUGAUCUCACUC-3’ (SEQ ID NO: 168).Any of the spacer sequences provided herein may be 20-30 nucleotide in length, for example, about 20-nucleotide in length.The gRNA provided herein comprises any of the spacer sequences disclosed herein and a scaffold sequence, which can be 23-36-nucleotide in length. For Casl2i2 polypeptides, the cognate scaffold sequence may comprise 5'-AGAAAUCCGUCUUUCAUUGACGG-3' (SEQ ID NO: 21). Exemplary gRNAs include, but are not limited to, the following:(a) 5 ’ - AGAAAUCCGUCUUUC AUUGACGGCCC AC ACCUUC ACUGGUCC A- 3’ (SEQ ID NO: 43);Attorney Docket No.: 063586-549001WO(b) 5 ’ - AGAAAUCCGUCUUUC AUUGACGGUGCUCGAAAUUGAUGAUGCC-3’ (SEQ IDNO: 34);(c) 5 ’ - AGAAAUCCGUCUUUC AUUGACGGUCUUAAAGGAAAGUAAUGGA-3’ (SEQ ID NO: 73);(d) 5 ’ - AGAAAUCCGUCUUUC AUUGACGGUUAUAAAUAGGCUGUACC AG-3’ (SEQ ID NO: 136);(e) 5 ’ - AGAAAUCCGUCUUUC AUUGACGGAAUAGAC AC AUCGGCC AC AC-3’ (SEQ ID NO: 148); or(f) 5 ’ - AGAAAUCCGUCUUUC AUUGACGGAAGAUUCUGUGAUCUC ACUC-3’ (SEQ ID NO: 169).In other embodiments, the SOD 1 -targeting gene editing system provided herein comprises a Type V CRISPR nuclease polypeptide, which comprises an amino acid sequence at least 95% identical to SEQ ID NO: 9. In some instances, the Type V CRISPR nuclease Type V-Sx3 may comprise one or more mutations relative to SEQ ID NO: 9. The PAM corresponding to such a Type V CRISPR nuclease comprises the motif of 5’-NTTR-3’, in which N represents any nucleotide residue and R is A or G and the PAM being located 5’ to the target sequence.In some examples, the Type V CRISPR nuclease polypeptide comprises the one or more mutations, which are amino acid substitutions at positions P14, D32, 161, E311, T338, and / or E736 in SEQ ID NO: 9. For example, the one or more amino acid substitutions are P14R, D32R, I61R, E311R, T338G, and / or E736G. Exemplary Type V CRISPR nuclease polypeptides may comprise the amino acid sequence of SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11.In some embodiments, the SOD 1 -targeting gene editing system provided herein comprises a CRISPR nuclease polypeptide, which comprises an amino acid sequence at least 95% identical to SEQ ID NO: 12 (Nuclease K). The PAM corresponding to such a CRISPR nuclease comprises the motif of 5’-NGG-3’, in which each N independently represents any nucleotide residue and the PAM being located 3’ to the target sequence.In some embodiments, the SOD 1 -targeting gene editing system provided herein comprises a CRISPR nuclease polypeptide, which comprises an amino acid sequence at least 95% identical to SEQ ID NO: 14 (Nuclease A). The PAM corresponding to such a CRISPR nuclease comprises the motif of 5’-NGG-3’, in which each N independently represents any nucleotide residue and the PAM being located 3’ to the target sequence.In some embodiments, the SOD 1 -targeting gene editing system provided herein comprises a CRISPR nuclease polypeptide, which comprises an amino acid sequence at least 95% identical to SEQ ID NO: 16 (Nuclease S). The PAM corresponding to such a CRISPRAttorney Docket No.: 063586-549001WOnuclease comprises the motif of 5’-ARCC-3’, in which R represents A or G and the PAM being located 3’ to the target sequence.In some embodiments, any of the CRISPR nuclease polypeptides disclosed herein may further comprise a nuclear localization signal (NLS). In some examples, the NLS may be located at the C-terminus of the CRISPR nuclease polypeptide. In some instances, the CRISPR nuclease polypeptide may further comprise a peptide linker connecting the CRISPR nuclease and the NLS. In some specific examples, the CRISPR nuclease polypeptide may comprise the amino acid sequence of SEQ ID NO: 573, e.g., SEQ ID NO: 574In some embodiments, the SOD 1 -targeting gene editing system provided herein comprises the first nucleic acid encoding the CRISPR nuclease polypeptide and the second nucleic acid encoding the gRNA. In some examples, the first nucleic acid and a complementary sequence thereof are located in a genetically modified viral genome, for example, a genetically modified adeno-associated viral (AAV) genome. In other examples, a complementary sequence of the first nucleic acid and the second nucleic acid are located in a genetically modified viral genome, for example, a genetically modified adeno-associated viral (AAV) genome.In some examples, the first nucleic acid encoding the CRISPR nuclease polypeptide in a genetically modified viral genome as disclosed herein is in operable linkage to a first promoter and the second nucleic acid encoding the gRNA is in operable linkage to a second promoter. In some instances, the first promoter and the second promoter are different promoters. In some instances, the first and second promoters are in opposite orientation, which drive transcription of the CRISPR nuclease polypeptide and the gRNA in opposite directions (see illustration in FIG. 21). In some specific examples, the first promoter may be a Ula promoter and the second promoter may be a U6 promoter.In some examples, the first nucleic acid encoding the CRISPR nuclease polypeptide may further comprise a nucleotide sequence encoding one or more microRNA (miRNA) binding sites. In some examples, the one or more miRNA binding sites comprise miR122 bindings site(s), miR183 binding site(s), or a combination thereof. In some specific examples, the one or more miRNA binding sites comprise three miR122 binding sites. In some examples, the miRNA binding site-encoding sequence is located downstream to the Casl2i2-coding sequence.Alternatively, the miRNA binding site-encoding sequence is located upstream to the Casl2i2-coding sequence. In some instances, the first nucleic acid may further comprise a polyA signal sequence, which may be located downstream to the Casl2i2-coding sequence (or downstream to the miRNA-encoding sequence, which is located downstream to the Casl2i2-coding sequence). Alternatively, or in addition, the second nucleic acid may further comprise aAttorney Docket No.: 063586-549001WOtranscription terminator sequence downstream to the coding sequence for the gRNA to terminate transcription of the gRNA driven by the second promoter.In some specific examples, the first nucleic acid encodes the Casl2i2 nuclease polypeptide comprising the amino acid sequence of SEQ ID NO: 573. In one specific example, the first nucleic acid comprises the nucleotide sequence of SEQ ID NO: 575. In some instances, the Casl2i2 nuclease polypeptide may further comprise a peptide linker of SEQ ID NO: 576 and an NLS of SEQ ID NO: 19.In one specific example, the genetically modified viral genome comprises, from 5’ to 3’, a Ula promoter, a nucleotide sequence encoding the CRISPR nuclease polypeptide such as the Casl2i2 nuclease polypeptide, a nucleotide sequence encoding one or more miRNA binding sites (e.g., one or more (e.g., 3) miR122 binding sites and / or one or more miR183 binding sites), a polyA signal sequence, a nucleotide sequence complementary to a coding sequence for the gRNA (e.g., Casl2i2_E2T2 (SEQ ID NO: 43)), and a nucleotide sequence complementary to a U6 promoter. Such a viral genome may comprise AAV2 inverted terminal repeats (ITRs) at both the 5’ end and the 3’ end. In some instances, the genetically modified viral genome may further comprise a nucleotide sequence complementary to a transcription terminator e.g., TTTTTTGCG) 5’ of the sequence complementary to the gRNA-coding sequence for terminating transcription of the gRNA.In another specific example, the genetically modified viral genome comprises, from 5’ to 3’, the U6 promoter, a nucleotide sequence encoding the gRNA (e.g., Casl2i2_E2T2), a complementary sequence of the polyA signal, a complementary sequence of the miRNA binding site-coding sequence, a complementary sequence of the CRISPR nuclease polypeptide such as the Casl2i2 nuclease polypeptide-coding sequence, and a complementary sequence of the Ula promoter. In some instances, the genetically modified viral genome may further comprise a transcription terminator sequence 3’ of the gRNA coding sequence.In some instances, the viral genome can be an AAV viral genome comprising inverted terminal repeats (ITRs) at both ends. Such a viral genome may be an AAV2 viral genome, which comprise AAV2s inverted terminal repeats (ITRs) at both the 5’ end and the 3’ end.In some embodiments, provided herein is a gene editing system for genetic editing of a human SOD1 gene, the gene editing system comprising a genetically modified viral particle, which comprises a viral capsid encapsulating a genetically modified viral genome, for example, the viral genomes disclosed herein. In some examples, the viral particle is an AAV viral particle. In one example, the AAV viral particle may comprise an AAV2 capsid. In another example, the AAV viral particle may comprise an AAV9 capsid. In one specific example, theAttorney Docket No.: 063586-549001WOAAV9 capsid may comprise blood-brain barrier (BBB)-penetrant capsid proteins.Also provide herein are a pharmaceutical composition comprising the gene editing system set forth described herein, and a kit comprising the CRISPR nuclease polypeptide or its encoding nucleic acid, and the gRNA or its encoding nucleic acid as disclosed herein.In other aspects, the present disclosure features a method for editing a human superoxide dismutase 1 (SOD1) gene, the method comprising contacting a host cell with the gene editing system provided herein to edit the SOD1 gene in the host cell. In some embodiments, the host cell is cultured in vitro. Alternatively, the contacting step is performed by administering the gene editing system to a subject comprising the host cell.Further, the present disclosure features a method for reducing SOD protein in target cells, comprising delivering any of the gene editing systems disclosed or a pharmaceutical composition comprising such to target cells to allow for genetic editing of the SOD1 gene in the target cells, thereby reducing therein the SOD protein encoded by the SOD1 gene. In some instances, the target cells are neuron cells. In some examples, the target cells are cultured in vitro. In other examples, the target cells are located in a subject who needs treatment (e.g., a human patient having ALS).In yet another aspect, the present disclosure features a method for treating amyotrophic lateral sclerosis (ALS) in a subject, the method comprising administering an effective amount of a gene editing system disclosed herein or a pharmaceutical composition comprising such to a subject in need thereof. In some embodiments, the subject is a human patient having familial ALS. In some examples, the human patient carries the D90A mutation in the SOD1 gene.Also within the scope of the present disclosure are any of the SOD 1 -targeting gene editing systems or pharmaceutical compositions comprising such for use in genetic editing an SOD1 gene in host cells and / or for use in treating a disease associated with the SOD1 gene, such as ALS, as well as use of such a gene editing system or a pharmaceutical composition comprising such for manufacturing a medicament for use in treatment of a target disease as disclosed herein.In addition, the present disclosure features an RNA guide (gRNA), comprising: (i) a spacer sequence that is specific to a target sequence in a human superoxide dismutase 1 (SOD1) gene, wherein the target sequence is 3’ to a protospacer adjacent motif (PAM) comprising the motif of 5’-TTN-3’, in which N represents any nucleotide residue. The target sequence comprises:(a) 5’ - CCCACACCTTCACTGGTCCA-3’ (SEQ ID NO: 41);(b) 5’- TGCTCGAAATTGATGATGCC-3’ (SEQ ID NO: 32);Attorney Docket No.: 063586-549001WO(c) 5’ - TCTTAAAGGAAAGTAATGGA-3’ (SEQ ID NO: 71);(d) 5’- TTATAAATAGGCTGTACCAG-3’ (SEQ ID NO: 134);(e) 5’- AATAGACACATCGGCCACAC-3’ (SEQ ID NO: 146); or(f) 5’- AAGATTCTGTGATCTCACTC-3’ (SEQ ID NO: 167).In some embodiments, the spacer sequence in the gRNA disclosed herein comprises: (a) 5’- CCCACACCUUCACUGGUCCA-3’ (SEQ ID NO: 42);(b) 5’- UGCUCGAAAUUGAUGAUGCC-3’ (SEQ ID NO: 33);(c) 5’- UCUUAAAGGAAAGUAAUGGA-3’ (SEQ ID NO: 72);(d) 5’- UUAUAAAUAGGCUGU ACC AG-3’ (SEQ ID NO: 135);(e) 5’- AAUAGACACAUCGGCCACAC-3’ (SEQ ID NO: 147); or(f) 5’ - AAGAUUCUGUGAUCUCACUC-3’ (SEQ ID NO: 168).In any of the gRNAs, the spacer sequence is 20-30 nucleotide in length, optionally about 20-nucleotide in length.The gRNA further comprises a scaffold sequence, which is 23-36-nucleotide in length. In some embodiments, the scaffold sequence comprises 5'-AGAAAUCCGUCUUUCAUUGACGG-3' (SEQ ID NO: 21).Exemplary gRNAs include:(a) 5 ’ - AGAAAUCCGUCUUUC AUUGACGGCCC AC ACCUUCACUGGUCCA-3’ (SEQ ID NO: 43);(b) 5 ’ - AGAAAUCCGUCUUUC AUUGAC GGUGCUCGAAAUUGAUGAUGCC-3’ (SEQ ID NO: 34);(c) 5 ’ - AGAAAUCCGUCUUUC AUUGAC GGUCUUAAAGG AAAGUAAUGGA-3’ (SEQ ID NO: 73);(d) 5 ’ - AGAAAUCCGUCUUUC AUUGAC GGUU AU AAAUAGGCUGU ACC AGS’ (SEQ ID NO: 136);(e) 5 ’ - AGAAAUCCGUCUUUC AUUGAC GG A AU AG AC AC AUCGGCC AC AC-3’ (SEQ ID NO: 148); or(f) 5 ’ - AGAAAUCCGUCUUUC AUUGACGGAAGAUUCUGUGAUCUC ACUC-3’ (SEQ ID NO: 169).Any of the gRNAs provided herein may comprise one or more modifications. Examples include 2’-O-methylation, phosphorothioate bond, or a combination thereof.In addition, the present disclosure provides a viral vector, comprising a first nucleic acid comprising a nucleotide sequence encoding a CRISPR nuclease polypeptide such as a Casl2i2 nuclease polypeptide (e.g., those disclosed herein such as the Casl2i2 nuclease polypeptideAttorney Docket No.: 063586-549001WOcomprising the amino acid sequence of SEQ ID NO: 573 or SEQ ID NO: 574 and a second nucleic acid comprising a nucleotide sequence encoding a gRNA targeting a human SOD1 gene (e.g., those disclosed herein such as Casl2i2_E2T2 (SEQ ID NO: 43)). The first nucleic acid is in operable linkage to a first promoter and the second nucleic acid is in operable linkage to a second promoter. In some embodiments, the first and second promoter are in opposite orientation. Alternatively, or in addition, the first and second promoters differ from each other. For example, the first promoter may be a Ula promoter and the second promoter may be a U6 promoter.In some embodiments, the first nucleic acid may further comprise a nucleotide sequence encoding one or more miRNA binding sites (e.g., miR122 binding site(s), miR183 binding site(s), or a combination thereof), optionally three miR122 binding sites. In some embodiments, the first nucleic acid may further comprise a polyA signal sequence following the coding sequence of the CRISPR nuclease such as the Casl2i2 nuclease polypeptide or following the coding sequence for the miRNA binding sites. Alternatively, or in addition, the second nucleic acid may further comprise a terminator sequence downstream to the gRNA coding sequence for terminating the transcription of the gRNA driven by the second promoter such as the U6 promoter.In some examples, the viral vector comprises, from 5’ to 3’, a Ula promoter, a nucleotide sequence encoding the CRISPR nuclease polypeptide such as the Casl2i2 nuclease polypeptide, a nucleotide sequence encoding one or more miRNA binding sites (e.g., one or more miR122 binding sites and / or one or more miR183 binding sites), optionally three miR122 binding sites, a polyA signal sequence, a nucleotide sequence complementary to a coding sequence for the gRNA, and a nucleotide sequence complementary to a U6 promoter. In some instances, the viral vector can be an AAV vector comprising 5’ end and 3’ end ITRs (e.g., ITRs from AAV2). See FIG. 22A as an example. The 5’ to 3’ orientation, when used under the context of a double stranded molecule (e.g., DNA), refers to the strand comprising the first nucleic acid encoding the CRISPR nuclease polypeptide (e.g., the Casl2i2 nuclease polypeptide) as disclosed herein.The details of one or more embodiments of the invention are set forth in the description below. Other features or advantages of the present invention will be apparent from the following drawings and detailed description of several embodiments, and also from the appended claims.Attorney Docket No.: 063586-549001WOBRIEF DESCRIPTION OF THE DRAWINGSThe following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure, which can be better understood by reference to the drawing in combination with the detailed description of specific embodiments presented herein.FIG. 1 is a graph showing the percentage (%) indels of SOD1 following delivery of plasmid-encoded Casl2i2 nuclease and guide RNAs for guides that produced at least 30% indels.FIG. 2 is a graph showing the percentage (%) indels of SOD1 following delivery of plasmid-encoded Type V CRISPR Nuclease Sx3 (Type V-Sx3 Sx3) and guide RNAs for guides that produced at least 25% indels.FIG. 3 is a graph showing the percentage (%) indels of SOD1 following delivery of plasmid-encoded CRISPR Nuclease K (NK) and guide RNAs for guides that produced at least 10% indels.FIG. 4 is a graph showing the percentage (%) indels of SOD1 following delivery of plasmid-encoded CRISPR Nuclease A (NA) and guide RNAs for guides that produced at least 10% indels.FIG. 5 is a graph showing the percentage (%) indels of SOD1 following delivery of plasmid-encoded CRISPR Nuclease S (NS) nuclease and guide E5T1. Mean + SEM of three technical replicates is shown.FIGs. 6A-6B are graphs showing disruption of SOD1 in iPSC-derived human motor neurons following different lentivirus-encoded Casl2i2 nuclease and guide RNAs for guides that produced at least 10% indels. FIG. 6A: percentage (%) indels. FIG. 6B: SOD1 protein knockdown.FIGs. 7A-7B are graphs showing disruption of SOD1 in iPSC-derived human motor neurons following different lentivirus-encoded Type V-Sx3 nuclease and guide RNAs for guides that produced at least 10% indels. FIG. 7A: percentage (%) indels. FIG. 7B: SOD1 protein knockdown.FIGs. 8A-8B include graphs showing the correlation of % indels of SOD1 and SOD1 protein knockdown measured in iPSC derived human motor neurons following delivery of lentivirus encoded Casl2i2 (FIG. 8A) and Type V-Sx3 (FIG. 8B) and guide RNAs. Mean + SEM of three technical replicates is shown.FIG. 9 includes graphs showing the correlation of % indels to SOD1 protein knockdownAttorney Docket No.: 063586-549001WOmeasured in iPSC derived human motor neurons following delivery of various doses of lentivirus encoding Casl2i2 and top guide RNAs as indicated of the disclosure. Mean + SEM of three technical replicates for indels is shown.FIG. 10 includes graphs showing the correlation of % indels to SOD1 protein knockdown measured in iPSC derived human motor neurons following delivery of various doses of lentivirus encoding Casl2i2 and guide RNAs as indicated. Mean + SEM of three technical replicates for indels is shown.FIG. 11A-11B include diagrams showing % indels and protein knockdown in iPSC-derived human motor neurons following delivery of AAV-encoded Casl2i2 and guide RNAs.FIG. 11A is a graph showing %indels of SOD1. FIG. 11B is a graph showing SOD1 protein knockdown. Mean of three technical replicates is shown.FIG. 12 is a graph showing the potency of Casl2i2 guides in HEK293T cells. Data is represented as mean of three technical replicates.FIGs. 13A-13D are graphs showing editing of SOD1 gene in brain and spinal cord of neonatal hG93A SOD1 transgenic mice following the delivery of AAVs carrying the various guide RNAs as indicated and the Casl2i2 nuclease. FIG. 13A: a graph showing the vector genomes per diploid genome (VG / DGE) in brain. FIG. 13B: a graph showing the SOD1 protein reduction in the brain. FIG. 13C: a graph showing VG / DGE in the spinal cord. FIG.13D: a graph showing the SOD1 protein reduction in the spinal cord.FIGs. 14A-14B include graphs showing the correlation of vector genomes (VG) per diploid genome (DGE) relative to the editing %. The shaded region from the graph on the left (FIG. 14A) is plotted on a different scale on the right (FIG. 14B) to facilitate a better visualization of the correlation.FIGs. 15A-15D are graphs showing features of vehicle or Casl2i2 plus guide RNA treated hG93Amales. FIGs. 15A and 15B are graphs showing features of vehicle or Casl2i2 / E3T20 guide treated hG93Amales. FIG. 15A: grip strength. FIG. 15B: survival rates of hG93Amice treated with PBS or Casl2i2 / E3T20, and survival rates of wildtype animals as a control. FIG. 15C: diagram showing survival in hG93A animals treated with PBS and Casl2i2 and guide E2T2, E1T3 or E4T4 at a low dose of 5.8E10 vg / animal. FIG. 15D: diagram showing survival in hG93A animals treated with PBS and Casl2i2 and guide E2T2, E1T3, or E4T4 at a high dose of 4E11 vg / animal and monitored post-treatment.FIGs. 16A and 16B are graphs showing features of Casl2i2ZE2T2 guide or Casl2i2ZE4T4 guide treated hG93Amales or non-transgenic animals. FIG. 16A: body weights.FIG. 16B: neuroscores.Attorney Docket No.: 063586-549001WOFIG. 17 is a graph showing the compound muscle action potential (CMAP) measured in vehicle, Casl2i2 / E2T2 or Casl2i2 / E4T4 guide treated hG93Amales or non-transgenic animals.FIGs. 18A-18G are graphs showing results from the Repeated Nerve Stimulation (RNS) showing decrement plotted as % of first stimulation (stim) in vehicle, Casl2i2 / E2T2, Casl2i2 / E4T4 guide treated hG93Amales or non-transgenic animals. FIG. 18A: a graph showing decrement at 3Hz measured after repeated nerve stimulation. FIG. 18B: a graph showing decrement at 6Hz measured after repeated nerve stimulation. FIG. 18C: a graph showing decrement at 10Hz measured after repeated nerve stimulation. FIG. 18D: a graph showing decrement at 20Hz measured after repeated nerve stimulation. FIG. 18E: a graph showing indel percentage. FIG. 18F: a graph showing SOD1 protein levels. FIG. 18G: a graph showing viral genome copies. Data shown in FIGs. 18E-18G were measured after 14-weeks inlife.FIG. 19 is a graph showing on-target activity for Casl2i2 guides E1T3, E2T2, E3T20, and E4T4 guides determined as % indels of SOD1.FIGs 20A-20C are graphs showing off-target activity for Casl2i2 guides E1T3 (FIG.20A), E2T2 (FIG. 20B), and E4T4 (FIG. 20C) guides determined as % indels of SOD1. ReSeq-. Re-Sequenced at 2x Original Depth.FIG. 21 is a diagram showing on-target and off-target editing activities of Casl2i2 C, a variant obtained from further Casl2i2 nuclease variant screening, as compared with Casl2i2 B.FIGs. 22A-22B include diagrams showing an exemplary AAV vector construct and SOD1 gene editing efficiency thereof. FIG. 22A: a schematic illustration of an exemplary AAV vector encoding a Casl2i2 nuclease polypeptide (SEQ ID NO: 574) and a guide RNA, the transcriptions of which are driven by two exemplary promoters, Ula and U6, in opposite orientation as indicated. The Casl2i2-coding sequence (codon optimized) is followed by microRNA (miRNA)-binding sites (here miR122-binding sites as an example) and a poly A signal (here the bovine growth factor polyA as an example). FIG. 22B: a diagram showing a dose-dependent editing efficacy of SOD1 using the AAV vector depicted in FIG. 22 A in a mouse model.DETAILED DESCRIPTIONAmyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease leading to paralysis and death typically 3-5 years post disease onset. In ALS, a weakened grip strength is a common early symptom. As the disease progresses, individuals may notice a gradual weakeningAttorney Docket No.: 063586-549001WOof their grip strength, particularly in the thumb and forefinger. Compound Muscle Action Potential (CMAP) studies measure the electrical response of muscles to nerve stimulation and can reveal motor neuron degeneration. CMAP studies are commonly used to monitor ALS progression. Repetitive nerve stimulation (RNS) is an electrophysiological study to measure motor responses where electrical stimulation is delivered to a motor nerve repeatedly several times per second.A number of mutations in the SOD1 gene (e.g., point mutations A4V, H46R, and G93 A) are reported to have linkage to ALS. These mutations affect structure and function of the resultant mutated SOD1 proteins, for example, misfolding of the protein, which results in protein aggregation and protein-like propagation of misfolded molecules. Berdynski et al., Scientific Reports, 12, 103 (2022). Thus, genetic editing of the SOD1 gene could benefit treatment of ALS.Accordingly, provided herein are gene editing systems targeting human SOD1 gene. Such a SOD 1 -targeting gene editing system comprises (a) a CRISPR nuclease polypeptide or a nucleic acid encoding such, and (b) an RNA guide (gRNA) or a nucleic acid encoding such. The CRISPR nuclease polypeptide may be a Type V CRISPR nuclease such as a Casl2i2 CRISPR nuclease, a Type V Nuclease Sx3, or a variant thereof as disclosed herein. Additional CRISPR nucleases such as Nuclease K, Nuclease A, and Nuclease S, or variants thereof are also provided herein for use in the gene editing system that targets SOD1. The gRNA in the gene editing system comprises a spacer sequence specific to a target sequence within the SOD1 gene, which is adjacent to a protospacer adjacent motif (PAM) recognizable by the CRISPR nuclease polypeptide, and a scaffold sequence specific to the CRISPR nuclease polypeptide. Also provided herein are methods of using the SOD 1 -targeting gene editing systems to genetically modify the SOD1 gene in host cells and for treating ALS in subjects (e.g., human patients) who need the treatment.I. CRISPR Nuclease-Mediated Gene Editing System Targeting SOD1 Gene Human SOD1 gene is located on chromosomal 21. The structural information of this gene can be found under Gene ID: 6647. Table 1 below provides exon sequences of human SOD I, with some intron boundary sequences provided.Attorney Docket No.: 063586-549001WOTable 1. Human SOD1 Gene Sequences for Guide DesignDescription Sequence* SEQ ID SODl Exon 1 GTTTGGGGCCAGAGTGGGCGAGGCGCGGAGGTCTGGCCTATAAAGTAGTCGC 1GGAGACGGGGTGCTGGTTTGCGTCGTAGTCTCCTGCAGCGTCTGGGGTTTCC GTTGCAGTCCTCGGAACCAGGACCTCGGCGTGGCCTAGCGAGTTATGGCGAC GAAGGCCGTGTGCGTGCTGAAGGGCGACGGCCCAGTGCAGGGCATCATCAAT TTCGAGCAGAAG SOD1 Exon 2 G AAAGT AAT GG AC C AGT GAAGGT GT GGGG AAGC AT T AAAGG AC T G AC T G AAG 2GCCTGCATGGATTCCATGTTCATGAGTTTGGAGATAATACAGCAG SODl Exon 3 GCTGTACCAGTGCAGGTCCTCACTTTAATCCTCTATCCAGAAAACACGGTGG 3GCCAAAGGATGAAGAGAG SODl Exon 4 GCATGTTGGAGACTTGGGCAATGTGACTGCTGACAAAGATGGTGTGGCCGAT 4GTGTCTATTGAAGATTCTGTGATCTCACTCTCAGGAGACCATTGCATCATTG GCCGCACACTGGTG SODl Exon 5 GTCCATGAAAAAGCAGATGACTTGGGCAAAGGTGGAAATGAAGAAAGTACAA 5AGACAGGAAACGCTGGAAGTCGTTTGGCTTGTGGTGTAATTGGGATCGCCCA ATAAACATTCCCTTGGATGTAGTCTGAGGCCCCTTAACTCATCTGTTATCCT GCTAGCTGTAGAAATGTATCCTGATAAACATTAAACACTGTAATCTTAAAAG TGTAATTGTGTGACTTTTTCAGAGTTGCTTTAAAGTACCTGTAGTGAGAAAC TGATTTATGATCACTTGGAAGATTTGTATAGTTTTATAAAACTCAGTTAAAA TGTCTGTTTCAATGACCTGTATTTTGCCAGACTTAAATCACAGATGGGTATT AAACTTGTCAGAATTTCTTTGTCATTCAAGCCTGTGAATAAAAACCCTGTAT GGCACTTATTATGAGGCTATTAAAAGAATCCAAATTCAAACTAAA SODl Intron cggcgtggcctagcgagttGTTTGGGGCCAGAGTGGGCGAGGCGCGGAGGTC 568 1- Exon 1- TGGCCTATAAAGTAGTCGCGGAGACGGGGTGCTGGTTTGCGTCGTAGTCTCC Intron 2 TGCAGCGTCTGGGGTTTCCGTTGCAGTCCTCGGAACCAGGACCTCGGCGTGG CCTAGCGAGTTATGGCGACGAAGGCCGTGTGCGTGCTGAAGGGCGACGGCCC AGT GC AGGGCATC AT CAAT TT CGAGCAGAAGg c aSODl Intron caactttgcacttttcttaaagGAAAGTAATGGACCAGTGAAGGTGTGGGGA 569 2-Exon 2 AGCATTAAAGGACTGACTGAAGGCCTGCATGGATTCCATGTTCATGAGTTTG GAGATAATACAGCAG SODl Intron tttttcttcttcttataaatagGCTGTACCAGTGCAGGTCCTCACTTTAATC 570 3- Exon 3 - CTCTATCCAGAAAACACGGTGGGCCAAAGGATGAAGAGAGgtaacaagatgc Intron 4 tSODl Intron tctgatgctttttcattattagGCATGTTGGAGACTTGGGCAATGTGACTGC 571 4-Exon 4- TGACAAAGATGGTGTGGCCGATGTGTCTATTGAAGATTCTGTGATCTCACTC Intron 5 TCAGGAGACCATTGCATCATTGGCCGCACACTGGTGgtaagttttcataSODl Intron atcttcttaaaattttttacagGTCCATGAAAAAGCAGATGACTTGGGCAAA 572 5 - Exon 5 GGTGGAAATGAAGAAAGTACAAAGACAGGAAACGCTGGAAGTCGTTTGGCTT GTGGTGTAATTGGGATCGCCCAATAAACATTCCCTTGGATGTAGTCTGAGGC CCCTTAACTCATCTGTTATCCTGCTAGCTGTAGAAATGTATCCTGATAAACA TTAAACACTGTAATCTTAAAAGTGTAATTGTGTGACTTTTTCAGAGTTGCTT TAAAGTACCTGTAGTGAGAAACTGATTTATGATCACTTGGAAGATTTGTATA GTTTTATAAAACTCAGTTAAAATGTCTGTTTCAATGACCTGTATTTTGCCAG ACTTAAATCACAGATGGGTATTAAACTTGTCAGAATTTCTTTGTCATTCAAG CCTGTGAATAAAAACCCTGTATGGCACTTATTATGAGGCTATTAAAAGAATC C AAAT T C AAAC T AAA*Exon sequences are shown as uppercase letters, lowercase letters indicate intronic sequences.Attorney Docket No.: 063586-549001WOThe gene editing system provided herein for genetic editing of a SOD1 gene (e.g., human SOD I) may comprise (i) a CRISPR nuclease or a first nucleic acid encoding the CRISPR nuclease; and (ii) an RNA guide targeting a genetic site within the S0D1 gene or a second nucleic acid encoding the RNA guide.A. CRISPR Nuclease PolypeptidesCRISPR nuclease refers to an RNA-guided endonuclease in a CRISPR editing system that is capable of cleaving DNA at specific sites guided by an RNA guide. In some embodiments, the CRISPR nuclease disclosed herein is a Type V CRISPR nuclease polypeptide, for example, a Casl2i2 nuclease or a Type V Nuclease Sx3 as provided herein. In other embodiments, the CRISPR nuclease may be Nuclease K, Nuclease A, or Nuclease S as also disclosed herein. Exemplary CRISPR nucleases for use in the SOD 1 -targeting gene editing system disclosed herein are provided in Table 2 below.Table 2. Exemplary CRISPR Nuclease PolypeptidesDescription Sequence SEQ IDCasl2i2 MSSAIKSYKSVLRPNERKNQLLKSTIQCLEDGSAFFFKMLQGLFGGITPEIVR 6 parent FSTEQEKQQQDIALWCAVNWFRPVSQDSLTHTIASDNLVEKFEEYYGGTASDA IKQYFSASIGESYYWNDCRQQYYDLCRELGVEVSDLTHDLEILCREKCLAVAT ESNQNNSIISVLFGTGEKEDRSVKLRITKKILEAISNLKEIPKNVAPIQEIIL NVAKATKETFRQVYAGNLGAPSTLEKFIAKDGQKEFDLKKLQTDLKKVIRGKS KERDWCCQEELRSYVEQNTIQYDLWAWGEMFNKAHTALKIKSTRNYNFAKQRL EQFKEIQSLNNLLVVKKLNDFFDSEFFSGEETYTICVHHLGGKDLSKLYKAWE DDPADPENAIVVLCDDLKNNFKKEPIRNILRYIFTIRQECSAQDILAAAKYNQ QLDRYKSQKANPSVLGNQGFTWTNAVILPEKAQRNDRPNSLDLRIWLYLKLRH PDGRWKKHHIPFYDTRFFQEIYAAGNSPVDTCQFRTPRFGYHLPKLTDQTAIR VNKKHVKAAKTEARIRLAIQQGTLPVSNLKITEISATINSKGQVRIPVKFDVG RQKGTLQIGDRFCGYDQNQTASHAYSLWEVVKEGQYHKELGCFVRFISSGDIV SITENRGNQFDQLSYEGLAYPQYADWRKKASKFVSLWQITKKNKKKEIVTVEA KEKFDAICKYQPRLYKFNKEYAYLLRDIVRGKSLVELQQIRQEI FRFIEQDCG VTRLGSLSLSTLETVKAVKGIIYSYFSTALNASKNNPISDEQRKEFDPELFAL LEKLELIRTRKKKQKVERIANSLIQTCLENNIKFIRGEGDLSTTNNATKKKAN SRSMDWLARGVFNKIRQLAPMHNITLFGCGSLYTSHQDPLVHRNPDKAMKCRW AAIPVKDIGDWVLRKLSQNLRAKNIGTGEYYHQGVKEFLSHYELQDLEEELLK WRSDRKSNIPCWVLQNRLAEKLGNKEAVVYIPVRGGRIYFATHKVATGAVSIV FDQKQVWVCNADHVAAANIALTVKGIGEQSSDEENPDGSRIKLQLTSCasl2i2 A MSSAIKSYKSVLRPNERKNQLLKSTIQCLEDGSAFFFKMLQGLFGGITPEIVR 7FSTEQEKQQQDIALWCAVNWFRPVSQDSLTHTIASDNLVEKFEEYYGGTASDA IKQYFSASIGESYYWNDCRQQYYDLCRELGVEVSDLTHDLEILCREKCLAVAT ESNQNNSIISVLFGTGEKEDRSVKLRITKKILEAISNLKEIPKNVAPIQEIIL NVAKATKETFRQVYAGNLGAPSTLEKFIAKDGQKEFDLKKLQTDLKKVIRGKS KERDWCCQEELRSYVEQNTIQYDLWAWGEMFNKAHTALKIKSTRNYNFAKQRL EQFKEIQSLNNLLVVKKLNDFFDSEFFSGEETYTICVHHLGGKDLSKLYKAWE DDPADPENAIVVLCDDLKNNFKKEPIRNILRYIFTIRQECSAQDILAAAKYNQQLDRYKSQKANPSVLGNQGFTWTNAVILPEKAQRNDRPNSLDLRIWLYLKLRHAttorney Docket No.: 063586-549001WODescription Sequence SEQ ID PDGRWKKHHIPFYDTRFFQEIYAAGNSPVDTCQFRTPRFGYHLPKLTDQTAIR VNKKHVKAAKTEARIRLAIQQGTLPVSNLKITEISATINSKGQVRIPVKFRVG RQKGTLQIGDRFCGYDQNQTASHAYSLWEVVKEGQYHKELGCFVRFISSGDIV SITENRGNQFDQLSYEGLAYPQYADWRKKASKFVSLWQITKKNKKKEIVTVEA KEKFDAICKYQPRLYKFNKEYAYLLRDIVRGKSLVELQQIRQEI FRFIEQDCG VTRLGSLSLSTLETVKAVKGIIYSYFSTALNASKNNPISDEQRKEFDPELFAL LEKLELIRTRKKKQKVERIANSLIQTCLENNIKFIRGEGDLSTTNNATKKKAN SRSMDWLARGVFNKIRQLAPMHNITLFGCGSLYTSHQDPLVHRNPDKAMKCRW AAIPVKDIGDWVLRKLSQNLRAKNRGTGEYYHQGVKEFLSHYELQDLEEELLK WRSDRKSNIPCWVLQNRLAEKLGNKEAVVYIPVRGGRIYFATHKVATGAVSIV FDQKQVWVCNADHVAAANIALTGKGIGEQSSDEENPDGSRIKLQLTSCasl2i2 B MSSAIKSYKSVLRPNERKNQLLKSTIQCLEDGSAFFFKMLQGLFGGITPEIVR 8FSTEQEKQQQDIALWCAVNWFRPVSQDSLTHTIASDNLVEKFEEYYGGTASDA IKQYFSASIGESYYWNDCRQQYYDLCRELGVEVSDLTHDLEILCREKCLAVAT ESNQNNSIISVLFGTGEKEDRSVKLRITKKILEAISNLKEIPKNVAPIQEIIL NVAKATKETFRQVYAGNLGAPSTLEKFIAKDGQKEFDLKKLQTDLKKVIRGKS KERDWCCQEELRSYVEQNTIQYDLWAWGEMFNKAHTALKIKSTRNYNFAKQRL EQFKEIQSLNNLLVVKKLNDFFDSEFFSGEETYTICVHHLGGKDLSKLYKAWE DDPADPENAIVVLCDDLKNNFKKEPIRNILRYIFTIRQECSAQDILAAAKYNQ QLDRYKSQKANPSVLGNQGFTWTNAVILPEKAQRNDRPNSLDLRIWLYLKLRH PDGRWKKHHIPFYDTRFFQEIYAAGNSPVDTCQFRTPRFGYHLPKLTDQTAIR VNKKHVKAAKTEARIRLAIQQGTLPVSNLKITEISATINSKGQVRIPVKFRVG RQKGTLQIGDRFCGYDQNQTASHAYSLWEVVKEGQYHKELRCRVRFISSGDIV SITENRGNQFDQLSYEGLAYPQYADWRKKASKFVSLWQITKKNKKKEIVTVEA KEKFDAICKYQPRLYKFNKEYAYLLRDIVRGKSLVELQQIRQEI FRFIEQDCG VTRLGSLSLSTLETVKAVKGIIYSYFSTALNASKNNPISDEQRKEFDPELFAL LEKLELIRTRKKKQKVERIANSLIQTCLENNIKFIRGEGDLSTTNNATKKKAN SRSMDWLARGVFNKIRQLATMHNITLFGCGSLYTSHQDPLVHRNPDKAMKCRW AAIPVKDIGDWVLRKLSQNLRAKNRGTGEYYHQGVKEFLSHYELQDLEEELLK WRSDRKSNIPCWVLQNRLAEKLGNKEAVVYIPVRGGRIYFATHKVATGAVSIV FDQKQVWVCNADHVAAANIALTGKGIGRQSSDEENPDGGRIKLQLTSCasl2i2 C MSSAIKSYKSVLRPNERKNQLLKSTIQCLEDGSAFFFKMLQGLFGGITPEIVR 573FSTEQEKQQQDIALWCAVNWFRPVSQDSLTHTIASDNLVEKFEEYYGGTASDA IKQYFSASIGESYYWNDCRQQYYDLCRELGVEVSDLTHDLEILCREKCLAVAT ESNQNNSIISVLFGTGEKEDRSVKLRITKKILEAISNLKEIPKNVAPIQEIIL NVAKATKETFRQVYAGNLGAPSTLEKFIAKDGQKEFDLKKLQTDLKKVIRGKS KERDWCCQEELRSYVEQNTIQYDLWAWGEMFNKAHTALKIKSTRNYNFAKQRL EQFKEIQSLNNLLVVKKLNDFFDSEFFSGEETYTICVHHLGGKDLSKLYKAWE DDPADPENAIVVLCDDLKNNFKKEPIRNILRYIFTIRQECSAQDILAAAKYNQ QLDRYKSQKANPSVLGNQGFTWTNAVILPEKAQRNDRPNSLDLRIWLYLKLRH PDGRWKKHHIPFYDTRFFQEIYAAGNSPVDTCQFRTPRFGYHLPKLTDQTAIR VNKKHVKAAKTEARIRLAIQQGTLPVSNLKITEISATINSKGQVRIPVKFRVG RQKGTLQIGDRFCGYDQNQTASHAYSLWEVVKEGQYHKELRCRVRFISSGDIV SITENRGNQFDQLSYEGLAYPQYADWRKKASKFVSLWQITKKNKKKEIVTVEA KEKFDAICKYQPRLYKFNKEYAYLLRDIVRGKSLVELQQIRQEI FRFIEQDCG VTRLGSLSLSTLETVKAVKGIIYSYFSTALNASKNNPISDEQRKEFDPELFAL LEKLELIRTRKKKQKVERIANSLIQTCLENNIKFIRGEGDLSTTRNATKKKAN SRSMDWLARGVFNKIRQLATMHNITLFGCGSLYTSHQDPLVHRNPDKAMKCRW AAIPVKDIGDWVLRKLSQNLRAKNRGTGEYYHQGVKEFLSHYELQDLEEELLK WRSDRKSNIPCWVLQNRLAEKLGNKEAVVYIPVRGGRIYFATHKVATGAVSIV FDQKQVWVCNADHVAAANIALTGKGIGRQSSDEENPDGGRIKLQLTSAttorney Docket No.: 063586-549001WODescription Sequence SEQ IDCasl2i2 C MSSAIKSYKSVLRPNERKNQLLKSTIQCLEDGSAFFFKMLQGLFGGITPEIVR 574 fusion FSTEQEKQQQDIALWCAVNWFRPVSQDSLTHTIASDNLVEKFEEYYGGTASDA IKQYFSASIGESYYWNDCRQQYYDLCRELGVEVSDLTHDLEILCREKCLAVAT ESNQNNSIISVLFGTGEKEDRSVKLRITKKILEAISNLKEIPKNVAPIQEIIL NVAKATKETFRQVYAGNLGAPSTLEKFIAKDGQKEFDLKKLQTDLKKVIRGKS KERDWCCQEELRSYVEQNTIQYDLWAWGEMFNKAHTALKIKSTRNYNFAKQRL EQFKEIQSLNNLLVVKKLNDFFDSEFFSGEETYTICVHHLGGKDLSKLYKAWE DDPADPENAIVVLCDDLKNNFKKEPIRNILRYIFTIRQECSAQDILAAAKYNQ QLDRYKSQKANPSVLGNQGFTWTNAVILPEKAQRNDRPNSLDLRIWLYLKLRH PDGRWKKHHIPFYDTRFFQEIYAAGNSPVDTCQFRTPRFGYHLPKLTDQTAIR VNKKHVKAAKTEARIRLAIQQGTLPVSNLKITEISATINSKGQVRIPVKFRVG RQKGTLQIGDRFCGYDQNQTASHAYSLWEVVKEGQYHKELRCRVRFISSGDIV SITENRGNQFDQLSYEGLAYPQYADWRKKASKFVSLWQITKKNKKKEIVTVEA KEKFDAICKYQPRLYKFNKEYAYLLRDIVRGKSLVELQQIRQEI FRFIEQDCG VTRLGSLSLSTLETVKAVKGIIYSYFSTALNASKNNPISDEQRKEFDPELFAL LEKLELIRTRKKKQKVERIANSLIQTCLENNIKFIRGEGDLSTTRNATKKKAN SRSMDWLARGVFNKIRQLATMHNITLFGCGSLYTSHQDPLVHRNPDKAMKCRW AAIPVKDIGDWVLRKLSQNLRAKNRGTGEYYHQGVKEFLSHYELQDLEEELLK WRSDRKSNIPCWVLQNRLAEKLGNKEAVVYIPVRGGRIYFATHKVATGAVSIV FDQKQVWVCNADHVAAANIALTGKGIGRQSSDEENPDGGRIKLQLTSSAGGGG SGGGGSGGGGSGKRPAAT KKAGQAKKKKT SSequence in boldface and italicized : peptide linker Sequence underlined : NLSCodon- atgagctctgccatcaagagctacaagtccgtgctgcggcccaacgagcggaa 586 optimized gaaccagctgctgaagtccaccatccagtgcctggaggacggctctgccttct coding tcttcaagatgctccaggggctgtttggcggcatcacccccgagatcgtgcgc sequence ttctccaccgagcaggagaagcagcagcaggacatcgccctgtggtgcgccgt ( opt33 ) for gaactggttccggcccgtgagtcaggacagcctgactcacaccattgccagcg Casl2i2_B acaacctggtggagaagtttgaggagtactacggaggcaccgcctccgacgcc atcaagcagtacttctccgccagcatcggcgagagctactactggaacgactg ccgccagcagtactacgacctgtgcagggagctgggcgtggaggtgagcgacc tgacccacgacctggagatcctgtgcagggagaagtgcctggccgtggccacc gagtccaaccagaacaactccatcatctccgtgctgttcggcaccggagagaa ggaggaccgcagcgtgaagctgcggatcaccaagaagatcctggaggccatct ccaacctgaaggagatccccaagaacgtggcccccatccaggagatcatcctg aacgtggccaaggccaccaaggagaccttccgccaggtgtacgctggcaacct gggcgctccctccaccctggagaagttcattgccaaggatggccagaaggagt tcgatctgaagaagctgcagaccgacctgaagaaggtgatccggggcaagagc aaggagcgcgactggtgctgccaggaggagctgcgctcctacgtggagcagaa caccatccagtacgacctgtgggcctggggcgagatgttcaacaaggcccaca ccgccctgaagatcaagagcacccggaactacaacttcgccaagcagcgcctg gagcagttcaaggagatccagagcctgaacaacctgctggtggtgaagaagct gaacgacttcttcgacagcgagttcttcagcggcgaggagacatacaccatct gcgtgcaccatctgggcggcaaggacctgtccaagctgtacaaggcttgggag gacgatcctgccgacccagagaacgccatcgtggtgctgtgcgacgacctgaa gaacaacttcaagaaggagcccatccgcaacatcctgcggtacatctt caeca tccggcaggagtgcagcgcccaggacatcctggccgctgccaagtacaatcag cagctggaccgctacaagagccagaaggccaaccccagcgtgctgggcaacca ggggttcacctggaccaacgccgtgatcctgcccgagaaggcccagcggaacg atcggcctaacagcctggatctgcgcatctggctgtacctgaagctgcggcac cccgacggcaggtggaagaagcaccacatccccttctacgacacccggttcttccaggagatctacgccgcaggcaacagccccgtggacacctgccagttccggaAttorney Docket No.: 063586-549001WODescription Sequence SEQ IDccccccggttcggataccacctgcccaagctgaccgaccagaccgccattcgc gtgaacaagaagcacgtgaaggccgccaagaccgaggcccggatccggctggc catccagcagggcaccctgcccgtgtccaacctgaagatcaccgagatcagcg ccaccatcaacagcaagggccaggtgcggatcccggtgaagttcagggtgggc cggcagaagggcaccctgcagatcggcgaccggttctgcggctacgaccagaa ccagaccgcctcccacgcctacagcctgtgggaggtggtgaaggaggggcagt ac ca caaggagc t g eg ctgccgggtgcggt teat cage tccggcgacatcgtg tccatcaccgagaaccgggggaaccagttcgaccagctgtcctacgagggcct ggcctatccccagtacgccgactggcggaagaaggccagcaagttcgtgagcc tgtggcagatcaccaagaagaacaagaagaaggagatcgtgaccgtggaggcc aaggagaagttcgacgccatctgcaagtaccagcctcggctgtacaagttcaa caaggagtacgcctacctgctgcgggacatcgtgcgcggcaagtccctggtgg agctgcagcagatccggcaggagatcttccgcttcatcgagcaggattgcggc gtgaccaggctgggctccctgagcctgagcacgctggagaccgtgaaggccgt gaagggcatcatctacagctacttctccaccgccctgaacgcctccaagaaca accccatctccgacgagcagcgcaaggagttcgaccccgagctgtttgccctg ctggagaagctggagctgatcaggacccggaagaagaagcagaaggtggagcg gatcgccaactccctgatccagacctgcctggagaacaacatcaagttcatcc ggggggagggcgatctgtccaccaccaacaacgccaccaagaagaaggccaac agccgcagcatggactggctggccaggggcgtgttcaacaagatccgccagct gg ccac ca t g ca caacatcaccctgtt egg ctgcggctccctgtacac cage c accaggaccccctggtgcacaggaaccccgacaaggccatgaagtgccggtgg gccgccatccccgtgaaggacatcggggactgggtgctgcggaagctgagcca gaacctgcgggccaagaatcgcggcacaggcgagtactaccaccagggggtga aggagttcctgtcccactacgagctgcaggacctggaggaggagctgctgaag tggcggagcgacaggaagtccaacatcccctgctgggtgctgcagaaccgcct ggccgagaagctgggcaacaaggaggccgtggtgtacatccccgtgcgcggcg gccggatctacttcgccacccacaaggtggccaccggcgccgtgagcatcgtg ttcgaccagaagcaggtgtgggtgtgcaacgccgaccacgtggccgccgccaa catcgccctgaccggcaagggcatcggccgccagtcctccgacgaggagaacc ccga eggegg ccggatcaagctgcagctgaccagcCodon- ATGAGCTCCGCCATCAAGAGCTACAAGAGCGTGCTGCGGCCCAACGAGCGGAA 587 optimized GAACCAGCTGCTGAAGAGCACCATCCAGTGCCTGGAGGACGGCAGCGCCTTCT coding TCTTCAAGATGCTGCAGGGCCTGTTCGGCGGCATCACCCCCGAGATCGTGCGG sequence TTCAGCACCGAGCAGGAGAAGCAGCAGCAGGACATCGCCCTGTGGTGCGCCGT ( opt35 ) GAACTGGTTCCGGCCCGTGAGCCAGGACAGCCTGACCCACACCATCGCCAGCG for ACAACCTGGTGGAGAAGTTCGAGGAGTACTACGGCGGCACCGCCAGCGACGCC Casl2i2 B ATCAAGCAGTACTTCAGCGCCAGCATCGGCGAGAGCTACTACTGGAACGACTG CCGGCAGCAGTACTACGACCTGTGCCGGGAGCTGGGCGTGGAGGTGAGCGACC TGACCCACGACCTGGAGATCCTGTGCCGGGAGAAGTGCCTGGCCGTGGCCACC GAGAGCAACCAGAACAACAGCATCATCAGCGTGCTGTTCGGCACCGGCGAGAA GGAGGACCGCAGCGTGAAGCTGCGGATCACCAAGAAGATCCTGGAGGCCATCA GCAACCTGAAGGAGATCCCCAAGAACGTGGCCCCCATCCAGGAGATCATCCTG AACGTGGCCAAGGCCACCAAGGAGACCTTCCGCCAGGTGTACGCCGGCAACCT GGGCGCCCCCAGCACCCTGGAGAAGTTCATCGCCAAGGACGGCCAGAAGGAGT TCGACCTGAAGAAGCTGCAGACCGACCTGAAGAAGGTGATCCGGGGCAAGAGC AAGGAGCGGGACTGGTGCTGCCAGGAGGAGCTGCGCTCCTACGTGGAGCAGAA CACC AT CC AGT ACGACCT GT GGGCCT GGGGCGAGAT GT TC AACAAGGCCC AC A CCGCCCTGAAGATCAAGAGCACCCGGAACTACAACTTCGCCAAGCAGCGGCTG GAGCAGTTCAAGGAGATCCAGAGCCTGAACAACCTGCTGGTGGTGAAGAAGCT GAACGACTTCTTCGACAGCGAGTTCTTCAGCGGCGAGGAGACCTACACCATCT GCGTGCACCACCTGGGCGGCAAGGACCTGTCCAAGCTGTACAAGGCCTGGGAGGACGACCCCGCCGACCCCGAGAACGCCATCGTGGTGCTGTGCGACGACCTGAAAttorney Docket No.: 063586-549001WODescription Sequence SEQ ID GAACAACTTCAAGAAGGAGCCCATCCGCAACATCCTGCGGTACATCTTCACCA TCCGGCAGGAGTGCAGCGCCCAGGACATCCTGGCCGCCGCCAAGTACAACCAG CAGCTGGACCGGTACAAGAGCCAGAAGGCCAACCCCAGCGTGCTGGGCAACCA GGGCTTCACCTGGACCAACGCCGTGATCCTGCCCGAGAAGGCCCAGCGGAACG ACCGGCCCAACAGCCTGGACCTGCGGATCTGGCTGTACCTGAAGCTGCGGCAC CCCGACGGCCGGTGGAAGAAGCACCACATCCCCTTCTACGACACCCGGTTCTT CCAGGAGATCTACGCCGCCGGCAACAGCCCCGTGGACACCTGCCAGTTCCGGA CCCCCCGGTTCGGCTACCACCTGCCCAAGCTGACCGACCAGACCGCCATCCGG GTGAACAAGAAGCACGTGAAGGCCGCCAAGACCGAGGCCCGGATCCGGCTGGC CATCCAGCAGGGCACCCTGCCCGTGTCCAACCTGAAGATCACCGAGATCAGCG CCACCATCAACAGCAAGGGCCAGGTGCGGATCCCCGTGAAGTTCCGGGTGGGC CGGCAGAAGGGCACCCTGCAGATCGGCGACCGGTTCTGCGGCTACGACCAGAA CCAGACCGCCTCCCACGCCTACAGCCTGTGGGAGGTGGTGAAGGAGGGCCAGT ACCACAAGGAGCTGCGGTGCCGGGTGCGGTTCATCAGCAGCGGCGACATCGTG AGCATCACCGAGAACCGGGGCAACCAGTTCGACCAGCTGTCCTACGAGGGCCT GGCCTACCCCCAGTACGCCGACTGGCGGAAGAAGGCCAGCAAGTTCGTGAGCC TGTGGCAGATCACCAAGAAGAACAAGAAGAAGGAGATCGTGACCGTGGAGGCC AAGGAGAAGTTCGACGCCATCTGCAAGTACCAGCCCCGGCTGTACAAGTTCAA CAAGGAGTACGCCTACCTGCTGCGCGACATCGTGCGCGGCAAGAGCCTGGTGG AGCTGCAGCAGATCCGGCAGGAGATCTTCCGGTTCATCGAGCAGGACTGCGGC GTGACCCGGCTGGGCAGCCTGAGCCTGAGCACCCTGGAGACCGTGAAGGCCGT GAAGGGCATCATCTACAGCTACTTCAGCACCGCCCTGAACGCCAGCAAGAACA ACCCCATCAGCGACGAGCAGCGGAAGGAGTTCGACCCCGAGCTGTTCGCCCTG CTGGAGAAGCTGGAGCTGATCCGGACCCGGAAGAAGAAGCAGAAGGTGGAGCG GATCGCCAACAGCCTGATCCAGACCTGCCTGGAGAACAACATCAAGTTCATCC GGGGCGAGGGCGACCTGAGCACCACCAACAACGCCACCAAGAAGAAGGCCAAC AGCCGGAGCATGGACTGGCTGGCCCGGGGCGTGTTCAACAAGATCCGGCAGCT GGCCACCATGCACAACATCACCCTGTTCGGCTGCGGCAGCCTGTACACCAGCC ACCAGGACCCCCTGGTGCACCGCAACCCCGACAAGGCCATGAAGTGCCGCTGG GCCGCCATCCCCGTGAAGGACATCGGCGACTGGGTGCTGCGGAAGCTGTCCCA GAACCTGCGGGCCAAGAACCGGGGCACCGGCGAGTACTACCACCAGGGCGTGA AGGAGTTCCTGAGCCACTACGAGCTGCAGGACCTGGAGGAGGAGCTGCTGAAG TGGCGGAGCGACCGGAAGAGCAACATCCCCTGCTGGGTGCTGCAGAACCGGCT GGCCGAGAAGCTGGGCAACAAGGAGGCCGTGGTGTACATCCCCGTGCGCGGCG GCCGGATCTACTTCGCCACCCACAAGGTGGCCACCGGCGCCGTGAGCATCGTG TTCGACCAGAAGCAGGTGTGGGTGTGCAACGCCGACCACGTGGCCGCCGCCAA CATCGCCCTGACCGGCAAGGGCATCGGCCGGCAGTCCAGCGACGAGGAGAACC CCGACGGCGGCCGGATCAAGCTGCAGCTGACCAGCCodon- ATGAGCTCCGCCATCAAGAGCTACAAGAGCGTGCTGCGGCCCAACGAGCGGAA 575 optimized GAACCAGCTGCTGAAGAGCACCATCCAGTGCCTGGAGGACGGCAGCGCCTTCT coding TCTTCAAGATGCTGCAGGGCCTGTTCGGCGGCATCACCCCCGAGATCGTGCGG sequence TTCAGCACCGAGCAGGAGAAGCAGCAGCAGGACATCGCCCTGTGGTGCGCCGT for GAACTGGTTCCGGCCCGTGAGCCAGGACAGCCTGACCCACACCATCGCCAGCG Casl2i2 C ACAACCTGGTGGAGAAGTTCGAGGAGTACTACGGCGGCACCGCCAGCGACGCC ATCAAGCAGTACTTCAGCGCCAGCATCGGCGAGAGCTACTACTGGAACGACTG CCGGCAGCAGTACTACGACCTGTGCCGGGAGCTGGGCGTGGAGGTGAGCGACC TGACCCACGACCTGGAGATCCTGTGCCGGGAGAAGTGCCTGGCCGTGGCCACC GAGAGCAACCAGAACAACAGCATCATCAGCGTGCTGTTCGGCACCGGCGAGAA GGAGGACCGCAGCGTGAAGCTGCGGATCACCAAGAAGATCCTGGAGGCCATCA GCAACCTGAAGGAGATCCCCAAGAACGTGGCCCCCATCCAGGAGATCATCCTG AACGTGGCCAAGGCCACCAAGGAGACCTTCCGCCAGGTGTACGCCGGCAACCT GGGCGCCCCCAGCACCCTGGAGAAGTTCATCGCCAAGGACGGCCAGAAGGAGTTCGACCTGAAGAAGCTGCAGACCGACCTGAAGAAGGTGATCCGGGGCAAGAGCAttorney Docket No.: 063586-549001WODescription Sequence SEQ ID AAGGAGCGGGACTGGTGCTGCCAGGAGGAGCTGCGCTCCTACGTGGAGCAGAA CACC AT CC AGT ACGACCT GT GGGCCT GGGGCGAGAT GT TC AACAAGGCCC AC A CCGCCCTGAAGATCAAGAGCACCCGGAACTACAACTTCGCCAAGCAGCGGCTG GAGCAGTTCAAGGAGATCCAGAGCCTGAACAACCTGCTGGTGGTGAAGAAGCT GAACGACTTCTTCGACAGCGAGTTCTTCAGCGGCGAGGAGACCTACACCATCT GCGTGCACCACCTGGGCGGCAAGGACCTGTCCAAGCTGTACAAGGCCTGGGAG GACGACCCCGCCGACCCCGAGAACGCCATCGTGGTGCTGTGCGACGACCTGAA GAACAACTTCAAGAAGGAGCCCATCCGCAACATCCTGCGGTACATCTTCACCA TCCGGCAGGAGTGCAGCGCCCAGGACATCCTGGCCGCCGCCAAGTACAACCAG CAGCTGGACCGGTACAAGAGCCAGAAGGCCAACCCCAGCGTGCTGGGCAACCA GGGCTTCACCTGGACCAACGCCGTGATCCTGCCCGAGAAGGCCCAGCGGAACG ACCGGCCCAACAGCCTGGACCTGCGGATCTGGCTGTACCTGAAGCTGCGGCAC CCCGACGGCCGGTGGAAGAAGCACCACATCCCCTTCTACGACACCCGGTTCTT CCAGGAGATCTACGCCGCCGGCAACAGCCCCGTGGACACCTGCCAGTTCCGGA CCCCCCGGTTCGGCTACCACCTGCCCAAGCTGACCGACCAGACCGCCATCCGG GTGAACAAGAAGCACGTGAAGGCCGCCAAGACCGAGGCCCGGATCCGGCTGGC CATCCAGCAGGGCACCCTGCCCGTGTCCAACCTGAAGATCACCGAGATCAGCG CCACCATCAACAGCAAGGGCCAGGTGCGGATCCCCGTGAAGTTCCGGGTGGGC CGGCAGAAGGGCACCCTGCAGATCGGCGACCGGTTCTGCGGCTACGACCAGAA CCAGACCGCCTCCCACGCCTACAGCCTGTGGGAGGTGGTGAAGGAGGGCCAGT ACCACAAGGAGCTGCGGTGCCGGGTGCGGTTCATCAGCAGCGGCGACATCGTG AGCATCACCGAGAACCGGGGCAACCAGTTCGACCAGCTGTCCTACGAGGGCCT GGCCTACCCCCAGTACGCCGACTGGCGGAAGAAGGCCAGCAAGTTCGTGAGCC TGTGGCAGATCACCAAGAAGAACAAGAAGAAGGAGATCGTGACCGTGGAGGCC AAGGAGAAGTTCGACGCCATCTGCAAGTACCAGCCCCGGCTGTACAAGTTCAA CAAGGAGTACGCCTACCTGCTGCGCGACATCGTGCGCGGCAAGAGCCTGGTGG AGCTGCAGCAGATCCGGCAGGAGATCTTCCGGTTCATCGAGCAGGACTGCGGC GTGACCCGGCTGGGCAGCCTGAGCCTGAGCACCCTGGAGACCGTGAAGGCCGT GAAGGGCATCATCTACAGCTACTTCAGCACCGCCCTGAACGCCAGCAAGAACA ACCCCATCAGCGACGAGCAGCGGAAGGAGTTCGACCCCGAGCTGTTCGCCCTG CTGGAGAAGCTGGAGCTGATCCGGACCCGGAAGAAGAAGCAGAAGGTGGAGCG GATCGCCAACAGCCTGATCCAGACCTGCCTGGAGAACAACATCAAGTTCATCC GGGGCGAGGGCGACCTGAGCACCACCAGAAACGCCACCAAGAAGAAGGCCAAC AGCCGGAGCATGGACTGGCTGGCCCGGGGCGTGTTCAACAAGATCCGGCAGCT GGCCACCATGCACAACATCACCCTGTTCGGCTGCGGCAGCCTGTACACCAGCC ACCAGGACCCCCTGGTGCACCGCAACCCCGACAAGGCCATGAAGTGCCGCTGG GCCGCCATCCCCGTGAAGGACATCGGCGACTGGGTGCTGCGGAAGCTGTCCCA GAACCTGCGGGCCAAGAACCGGGGCACCGGCGAGTACTACCACCAGGGCGTGA AGGAGTTCCTGAGCCACTACGAGCTGCAGGACCTGGAGGAGGAGCTGCTGAAG TGGCGGAGCGACCGGAAGAGCAACATCCCCTGCTGGGTGCTGCAGAACCGGCT GGCCGAGAAGCTGGGCAACAAGGAGGCCGTGGTGTACATCCCCGTGCGCGGCG GCCGGATCTACTTCGCCACCCACAAGGTGGCCACCGGCGCCGTGAGCATCGTG TTCGACCAGAAGCAGGTGTGGGTGTGCAACGCCGACCACGTGGCCGCCGCCAA CATCGCCCTGACCGGCAAGGGCATCGGCCGGCAGTCCAGCGACGAGGAGAACC CCGACGGCGGCCGGATCAAGCTGCAGCTGACCAGCType V MIKSIQLKVKGECPITKDVINEYKEYYNNCSDWIKNNLTSITIGEMAKFLQSL 9 CRISPR SDKEVAYISMGLSDEWKDKPLYHLFTKKYHTKNADNLLYYYIKEKNLDGYKGNNuclease TLNISNTSFRQFGYFKLVVSNYRTKIRTLNCKIKRKKIDADSTSEDIEMQVMY Sx3 EIIKYSLNKKSDWDNFISYIENVENPNIDNINRYKLLRECFCENENMIKNKLE LLSVEQLKKFGGCIMKPHINSMTINIQDFKIEEKENSLGFILHLPLNKKQYQI ELLGNRQIKKGTKEIHETLVDITNTHGENIVFTIKNDNLYIVFSYESEFEKEE VNFAKTVGLDVNFKHAFFVTSEKDNCHLDGYINLYKYLLEHDEFTNLLTEDERKDYEELSKVVTFCPFENQLLFARYNKMSKFCKKEQVLSKLLYALQKKLKDENRAttorney Docket No.: 063586-549001WODescription Sequence SEQ ID TKEYIYVSCVNKLRAKYVSYFILKEKYYEKQKEYDIEMGFVDDSTESKESMDK RRTEYPFRNTPVANELLSKLNNVQQDINGCLKNIINYIYKIFEQNGYKVVALE NLENSNFEKKQVLPTIKSLLKYHKLENQNVNDIKASDKVKEYIENGYYELMTN ENNEIVDAKYTEKGAMKVKNANFFNLMMKSLHFASVKDEFVLLSNNGKTQIAL VPSEFTSQMDSTDHCLYMKKNDKGKLVKADKKEVRTKQERHINGLNADFNAAN NIKYIVENEVWRGIFCTRPKKTEYNVPSLDTTKKGPSAILNMLKKIEAIKVLE TEKType V MIKSIQLKVKGECRITKDVINEYKEYYNNCSRWIKNNLTSITIGEMAKFLQSL 10 CRISPR SDKEVAYRSMGLSDEWKDKPLYHLFTKKYHTKNADNLLYYYIKEKNLDGYKGNNuclease TLNISNTSFRQFGYFKLVVSNYRTKIRTLNCKIKRKKIDADSTSEDIEMQVMY Sx3 EIIKYSLNKKSDWDNFISYIENVENPNIDNINRYKLLRECFCENENMIKNKLE Variant 1 LLSVEQLKKFGGCIMKPHINSMTINIQDFKIEEKENSLGFILHLPLNKKQYQI ELLGNRQIKKGTKEIHETLVDITNTHGENIVFTIKNDNLYIVFSYRSEFEKEE VNFAKTVGLDVNFKHAFFVGSEKDNCHLDGYINLYKYLLEHDEFTNLLTEDER KDYEELSKVVTFCPFENQLLFARYNKMSKFCKKEQVLSKLLYALQKKLKDENR TKEYIYVSCVNKLRAKYVSYFILKEKYYEKQKEYDIEMGFVDDSTESKESMDK RRTEYPFRNTPVANELLSKLNNVQQDINGCLKNIINYIYKIFEQNGYKVVALE NLENSNFEKKQVLPTIKSLLKYHKLENQNVNDIKASDKVKEYIENGYYELMTN ENNEIVDAKYTEKGAMKVKNANFFNLMMKSLHFASVKDEFVLLSNNGKTQIAL VPSEFTSQMDSTDHCLYMKKNDKGKLVKADKKEVRTKQERHINGLNADFNAAN NIKYIVENEVWRGIFCTRPKKTEYNVPSLDTTKKGPSAILNMLKKIGAIKVLE TEKType V MIKSIQLKVKGECRITKDVINEYKEYYNNCSRWIKNNLTSITIGEMAKFLQSL 11 CRISPR SDKEVAYRSMGLSDEWKDKPLYHLFTKKYHTKNADNLLYYYIKEKNLDGYKGNNuclease TLNISNTSFRQFGYFKLVVSNYRTKIRTLNCKIKRKKIDADSTSEDIEMQVMY Sx3 EIIKYSLNKKSDWDNFISYIENVENPNIDNINRYKLLRECFCENENMIKNKLE Variant 2 LLSVEQLKKFGGCIMKPHINSMTINIQDFKIEEKENSLGFILHLPLNKKQYQI ELLGNRQIKKGTKEIHETLVDITNTHGENIVFTIKNDNLYIVFSYRSEFEKEE VNFAKTVGLDVNFKHAFFVTSEKDNCHLDGYINLYKYLLEHDEFTNLLTEDER KDYEELSKVVTFCPFENQLLFARYNKMSKFCKKEQVLSKLLYALQKKLKDENR TKEYIYVSCVNKLRAKYVSYFILKEKYYEKQKEYDIEMGFVDDSTESKESMDK RRTEYPFRNTPVANELLSKLNNVQQDINGCLKNIINYIYKIFEQNGYKVVALE NLENSNFEKKQVLPTIKSLLKYHKLENQNVNDIKASDKVKEYIENGYYELMTN ENNEIVDAKYTEKGAMKVKNANFFNLMMKSLHFASVKDEFVLLSNNGKTQIAL VPSEFTSQMDSTDHCLYMKKNDKGKLVKADKKEVRTKQERHINGLNADFNAAN NIKYIVENEVWRGIFCTRPKKTEYNVPSLDTTKKGPSAILNMLKKIEAIKVLE TEK CRISPR MERELVLGIDYGGKYTGLAVVDRRHNQVLYANRLKMRDDVAGILKDRRKQRGI 12 Nuclease K RRTAQTKKKRLRELKNYLKSIGYNESTATFETVYSLAHKRGYDYADMPEEKTS (wildEEIEAMDVEERKQWEKEKQEWEETKRNSRHRKEVVKDVHKAMIEGRATEEQIK type) RVERIFNKQYRPKRFNNRILTKCKVEDCGVNTPLRKNVRDLLIENIVRFFPIE QSEKDNLKDAVLDKNRREEVKSFFRKHKTDEHIRKQVYDIADNKLSGRTVFCK EHILEHTEHSKEERKVFRLAPSLKTKIENVLAVIKDEILPKFTVNKVVMESNN FDIAAKTQGKKRLAKEEYGKGPREGKETRKEALLRETDGRCIYCGKSIDISNA HDDHIFPRKAGGLNIFANLVACCAVCNENKKGRTPLESGISPKPEIIAFMKND LKKKILEDARNINTVDFNKYMSHASIGWRYMRDRLRESAGNKKLPIERQSGIY TAYFRRWWGFKKERGNTLHHALDAVILASRKGYSDDGLVDMTLKPKYNKGGGF DSEKHLPEPIEFKRDKGSKGSALHDRNPLSYKKGIITRRFMVTEIECGKEDDV ISETYREKLKEAFKRFDTKKGKCLTDKEAKEAGFCIKKNELVMSLKCSIKGTG PGQMIRINNNVFKTNVHNVGVDVYLDEKGKKKAYERKNPRLSKHFIEPPPQPNGRVSFTLKRRDMVTVEGEDAIYRIKKLGTSPTIEAVVGSDGKTRTVSATKLTKAttorney Docket No.: 063586-549001WODescription Sequence SEQ ID ANSAE CRISPR MERELVLGIDYGGKYTGLAVVDRRHNQVLYANRLKMRDDVARILKDRRKQRGI 13 Nuclease K RRTAQTKKKRLRELKNYLKSIGYNESTATFETVYSLAHKRGYDYADMPEEKTS variant EEIEAMDVEERKQWEKEKQEWEETKRNSRHRKEVVKDVHKAMIEGRATEEQIK RVERIFNKQYRPKRFNNRILTKCKVEDCGVNTPLRKNVRDLLIENIVRFFPIE QSEKDNLKDAVLDKNRREEVKSFFRKHKTDEHIRKQVYDIADNKLSGRTVFCK EHILEHTEHSKEERKVFRLAPSLKTKIENVLAVIKDEILPKFTVNKVVMESNN FDIAAKTQGKKRLAKEEYGKGPREGKETRKEALLRETDGRCIYCGKSIDISNA HDDHIFPRKAGGLNIFANLVACCAVCNENKKGRTPLESGISPKPEIIAFMKND LKKKILEDARNINTVDFNKYMSHASIGWRYMRDRLRESAGNKKLPIERQSGIY TAYFRRWWGFKKERGNTLHHALDAVILASRKGYSDDGLVDMTLKPKYNKGGGF DSEKHLPEPIEFKRDKGSKGSALHDRNPLSYKKGIITRRFMVTEIECGKEDRV ISETYREKLKEAFKRFDTKKGKCLTDKEAKEAGFCIKKNELVMSLKCSIKGTG PGQMIRINNNVFKTNVHNVGVDVYLDEKGKKKAYERKNPRLSKHFIEPPPQPN GRVSFTLKRRDMVTVEGEDAIYRIKKLGTSPTIEAVVGSDGKTRTVSATKLTK ANSAE CRISPR MRNCKKDLYVEVTPMQKELVLGIDYGGKYTGLAVVDRRNNQVLYARTVKMRDD 14 Nuclease A VADILEGRREQRGIRRTGQTKKKRLRELKTYLKNIGGKYDESIGTFKNEPFMT (wildVYKLCHKRGYDYVEMPKEKTREEIEAMSADEKKQWEKEKKEWEETERNSRHRD type) EVTKDVRKIMSERDATEQQISHVIKIFNKQYRPKRFNNRILTKCKVEDCGVNT PLRKNVRDLLIKDIVRFLPLTQSEKAELEAHVLDKEGREKVKTFFRRHRINEF LRKQIYDIAFNQKLSGRTVFCKKHILEHEQHTKEERKVFRLAPSLKTKINNVL AVVKDEILPQFGINKVIMESNNFDIAARTKGKKRLAKDEYGKGHKEAKESLIE VLLRETKNQCVYCGKVITVTTANTDHIFPRKAGGINVFANLVACCRECNEKKK GRTPLESGVLPQPEITAHLENDLKKKILEDARNMNELNLNSIKYMSYASIGWR HMRDRLRGLIGNEELPIERQSGILTAYFRRWWGFRKERGNDIHHALDAVILAS RKDYTDDGVDMTLKPKSSNGREFDPEKHLPDTISFKRDKSNKGTPLYDKNPLS IKNSLITRRWMVTEIEHGKEDTIISDEYRKKLKEAFKHWGTSKGKCLTDEEAR QTGFYQRKNGNFMSLRCVEKGLGWGQMVKINNNAFKTNVHNIGVAVYLDEKGK KKAYEIKNPRLLKHFVEKPPEIKGKKLYTLRRGDYVTHESEDSVYRIKKLGTS PVLEAVVKGSIGRIRNSASATKLTKVSKPQKVF CRISPR MRNCKKDLYVEVTPMQKELVLGIDYGGKYTGLAVVDRRNNQVLYARTVKMRDD 15 Nuclease A VADILEGRREQRGRRRTGQTKKKRLRELKTYLKNIGGKYDESIGTFKNEPFMT Variant VYKLCHKRGYDYVEMPKEKTREEIEAMSADEKKQWEKEKKEWEETERNSRHRD EVTKDVRKIMSERDATEQQISHVIKIFNKQYRPKRFNNRILTKCKVEDCGVNT PLRKNVRDLLIKDIVRFLPLTQSEKAELEAHVLDKEGREKVKTFFRRHRINEF LRKQIYDIAFNQKLSGRTVFCKKHILEHEQHTKEERKVFRLAPSLKTKINNVL AVVKDEILPQFGINKVIMESNNFDIAARTKGKKRLAKDEYGKGHKEAKESLIE VLLRETKNQCVYCGKVITVTTANTDHIFPRKAGGINVFANLVACCRECNEKKK GRTPLESGVLPQPEITAHLENDLKKKILEDARNMNELNLNSIKYMSYASIGWR HMRDRLRGLIGNEELPIERQSGILTAYFRRWWGFRKERGNDIHHALDAVILAS RKDYTDDGVDMTLKPKSSNGREFDPEKHLPDTISFKRRKSNKGTPLYDKNPLS IKNSLITRRWMVTEIEHGKEDTIISDEYRKKLKEAFKHWGTSKGKCLTDEEAR QTGFYQRKNGNFMSLRCVEKGLGWGQMVKINNNAFKTNVHNIGVAVYLDEKGK KKAYEIKNPRLLKHFVRKPPEIKGKKLYTLRRGDYVTHESEDSVYRIKKLGTS PVLEAVVKGSIGRIRNSASATKLTKVSKPQKVF CRISPR MDREYLLEKIRDCNPDEI FTSFQIDTGAKYYGCTVLVKLPGVQKPIMVIADVL 16 Nuclease S TAIPKIEDIVAARSLNRGTRRTNKSKKRRNRKLRAAIGHIDGADKVLAYCKRR GVSYAFDQDEEETSAEDKRTRKSREEVLDKLKVVVRNEIPDEQQDFVYKTCEK LLNAEERKCRIKNRNPSKCDWEGCNQNVPASRNAIFETLEQTLYPWLTQIFRS SKSYVRLENELNECVKYLNSLDYRNKYSIEQTDDEEKQLDKQLNNELNKIRDIAttorney Docket No.: 063586-549001WODescription Sequence SEQ ID VKSHASKEHYREFSHYWTKYYRKQLANILKSSGTGRTTFCRQHSSMYVAKLIA GEVIPVKPEIYLKDIEGAAQKLTYAKLESYLLHSVLPTLKTIGITKIDSVCVE SASGSSPSKAKKQKRSDKAKKQKVSNKTKKQKCSDEEFQQGPMFKFDSRKDML LAEFDKLCAYCGEPLTGSYIENEHILPRSRFPYDSYFNILPACEKCNRRKGAR TPYEAGMTISTKALDAFDRYIKKKKFVHPSIWVKRNLLSGMTHQTNGDAEREL RFLCRKLFISGKHTQTPKRLARLIATSLSNATGIRPQIKSIPPKFVYFYRNAV LPDFNKYEDKKNGGVVNHIIDSALLGCDFPSPHYLLSGRYSGCEKYREFVDRL KDSFVAVDDSGMPICIPIRSETQFFQEQIDKRLPGYSKIDMSKMNWNSKRKIV SHYQPQRKVGYKLVAARDSIESIKDRLLDLNKKQGTDTVIRDATIESIRDEKL KSRMLNNPDRAAYYLIEYVQQSIKYGSNEEVYHPTAIEMKQMRDEFVNDDPEL YVTEDKELRKQVPNIFGMRIQTGQSESQISFHRVCTQGDTVHHHHYMQDIGIR HIAIVVHIDKKGKKQNQAITVTRQGKVYIGLGTARKSVDRSFGMTLQGRAFGE KGSRKKWDRQWHREFRAFCKATWNVERIHILTAGCVFIDTDGTTYFVRNMDSQ DKGIRIATAKRKFVEIERVFKSPHAYQKYLSKMNAITK CRISPR MDREYLLEKIRDCNPDEI FTSFQIDTGAKYYGCTVLVKLPGVQKPIMVIADVL 17 Nuclease S TAIPKIEDIVAARSLNRGRRRTNKSKKRRNRKLRAAIGHIDGADKVLAYCKRR Variant GVSYAFDQDEEETSAEDKRTRKSREEVLDKLKVVVRNEIPDEQQDFVYKTCEK LLNAEERKCRIKNRNPSKCDWEGCNQNVPASRNAIFETLEQTLYPWLTQIFRS SKSYVRLENELNECVKYLNSLDYRNKYSIEQTDDEEKQLDKQLNNELNKIRDI VKSHASKEHYREFSHYWTKYYRKQLANILKSSGTGRTTFCRQHSSMYVAKLIA GEVIPVKPEIYLKDIEGAAQKLTYAKLESYLLHSVLPTLKTIGITKIDSVCVE SASGSSPSKAKKQKRSDKAKKQKVSNKTKKQKCSDEEFQQGPMFKFDSRKDML LAEFDKLCAYCGEPLTGSYIENEHILPRSRFPYDSYFNILPACEKCNRRKGAR TPYEAGMTISTKALDAFDRYIKKKKFVHPSIRVKRNLLSGMTHQTNGDAEREL RFLCRKLFISGKHTQTPKRLARLIATSLSNATGIRPQIKSIPPKFVYFYRNAV LPDFNKYEDKKNGGVVNHIIDSALLGCDFPSPHYLLSGRYSGCEKYREFVDRL KDSFVAVDDSGMPICIPIRSETQFFQEQIDKRLPGYSKIDMSKMNWNSKRKIV SHYQPQRKVGYKLVAARDSIESIKDRLLDLNKKQGTDTVIRDATIESIRDEKL KSRMLNNPDRAAYYLIEYVQQSIKYGSNEEVYHPTAIEMKQMRDEFVNDDPEL YVTEDKELRKQVPNIFGMRIQTGQSESQISFHRVCTQGDTVHHHHYMQDRGIR HIAIVVHIDKKGKKQNQAITVTRQGKVYIGLGTARKSVDRSFGMTLQGRAFGE KGSRKKWDRQWHREFRAFCKATWNVERIHILTAGCVFIDTDGTTYFVRNMDSQ DKGIRIATAKRKFVEIERVFKSPHAYQKYLSKMNAITKIn some instances, the N-terminus Met residue in any of the exemplary CRISPR nucleases listed in the above Table 2 may be removed, for example, when the CRISPR nuclease is a portion of a fusion polypeptide comprising an N-terminal fusion partner (e.g., an NLS, a peptide linker, or another functional fragment).(a) Type V CRISPR NucleasesIn some embodiments, the SOD 1 -targeting gene editing system comprises a Type V CRISPR nuclease polypeptide or a nucleic acid encoding the Type V CRISPR nucleases. As used herein, the terms “Type V” and “Type V nuclease” refer to an RNA-guided CRISPR nuclease with a RuvC domain. Type V CRISPR-Cas systems are distinguished by a single RNA-guided RuvC domain-containing effector, Casl2. Yan et al., Science 10:1126 (2018). InAttorney Docket No.: 063586-549001WOsome embodiments, a Type V nuclease does not require a tracrRNA. In some embodiments, a Type V nuclease requires a tracrRNA. In some embodiments, the Type V nuclease is a Casl2i polypeptide, e.g., comprising the amino acid sequence of SEQ ID NO: 6 or a variant thereof. In some embodiments, the Type V nuclease is a Type V Nuclease Sx3 comprising the amino acid sequence of SEQ ID NO: 9 or a variant thereof as disclosed herein. See Table 2 above for examples, each of which is within the scope of the present disclosure. Large indels (~10bp) generated by Type V enzymes (nucleases) favor targeting across the entire gene to destabilize the protein compared with Type II enzymes that generate small indels and may not lower protein abundance.(i) Casl2i2 Nuclease PolypeptideIn some instances, the CRISPR nuclease polypeptide in the SOD 1 -targeting gene editing system is a Casl2i2 nuclease polypeptide. Casl2i polypeptides are smaller than other nucleases. For example, Casl2i2 is 1,054 amino acids in length, whereas S. pyogenes Cas9 (SpCas9) is 1,368 amino acids in length, S. thermophilus Cas9 (StlCas9) is 1,128 amino acids in length, FnCpfl is 1,300 amino acids in length, AsCpfl is 1,307 amino acids in length, and LbCpfl is 1,246 amino acids in length. Casl2i2 RNA guides, which do not require a trans-activating CRISPR RNA (tracrRNA), are also smaller than Cas9 RNA guides. The smaller Casl2i2 polypeptide and RNA guide sizes are beneficial for delivery. Compositions comprising a Casl2i2 polypeptide also demonstrate decreased off-target activity compared to compositions comprising an SpCas9 polypeptide. See, WO2019 / 178427 and W02021 / 202800, the relevant disclosures of each of which are incorporated by reference for the subject matter and purpose referenced herein. Furthermore, indels induced by compositions comprising a Casl2i2 polypeptide differ from indels induced by compositions comprising an SpCas9 polypeptide. For example, a Casl2i2 nuclease tends to generate indels larger than those generated by a Cas9.Casl2i2 nuclease is a type V CRISPR-Cas endonuclease that is capable of cleaving target double-strand DNAs guided by guide RNAs. Like other CRISPR nucleases, Casl2i2 comprises a RuvC nuclease domain, which cleavages the DNA strand adjacent to the 5’-NTTN-3’ PAM motif, in which each N independently represents any nucleotide A, C, G, or T. Casl2i2 nucleases can be found, e.g., in WO2019 / 178427 and W02021 / 202800, the relevant disclosures of each of which are incorporated by reference for the subject matter and purpose referenced herein.In some embodiments, the Casl2i2 polypeptide involved in the SOD1 gene editing compositions disclosed herein may comprise a Casl2i2 nuclease, which is a variant of a parentAttorney Docket No.: 063586-549001WOCasl2i2 enzyme set forth in SEQ ID NO: 6. See Table 2 above. Such a variant Casl2i2 nuclease may comprise an amino acid sequence at least 90% (e.g., at least 95%, at least 97%, at least 98%, at least 99%, or above) identical to SEQ ID NO: 6. Homology or identity can be determined by amino acid sequence alignment, e.g., using a program such as BLAST, ALIGN, or CLUSTAL, as described herein.The “percent identity” of two nucleic acids or of two amino acid sequences is determined using the algorithm of Karlin and Altschul Proc. Natl. Acad. Sci. USA 87:2264-68, 1990, modified as in Karlin and Altschul Proc. Natl. Acad. Sci. USA 90:5873-77, 1993. Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. J. Mol. Biol. 215:403-10, 1990. BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength- 12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to the protein molecules of the invention. Where gaps exist between two sequences, Gapped BLAST can be utilized as described in Altschul et al., Nucleic Acids Res. 25(17):3389-3402, 1997. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.The variant Casl2i2 nuclease may comprise one or more amino acid substitutions relative to SEQ ID NO: 6, for example, at positions D581, 1926, V1030, and optionally further at positions G624, F626, P868, E1035, and S1046 in SEQ ID NO: 6. In some instances, the original amino acid residue in SEQ ID NO: 6 at the just-noted positions (e.g., D581, G624, F626, 1926, and / or E1035 positions) may be replaced by R or a conservative substitution thereof (e.g., K). Alternatively, or in addition, the original amino acid residue in SEQ ID NO: 6 at the noted positions (e.g., VI 030 and / or SI 046) may be replaced with G or a conservative substitution thereof such as A. Further, the original amino acid residue at position P868 of SEQ ID NO: 6 may be replaced with T or a conservative substitution thereof such as S. Alternatively, or in addition, the original amino acid residue at position N840 of SEQ ID NO: 6 may be replaced with R or a conservative substitution thereof such as K.As used herein, a “conservative amino acid substitution” refers to an amino acid substitution that does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g., Molecular Cloning: A Laboratory Manual, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York,Attorney Docket No.: 063586-549001WO1989, or Current Protocols in Molecular Biology, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.In one example, the variant Casl2i2 nuclease comprises D581R, I926R, and V1030G relative to SEQ ID NO: 6. Such a Casl2i2 nuclease may comprise the amino acid sequence of SEQ ID NO: 7. In another example, the variant Casl2i2 nuclease comprises D581R, G624R, F626R, P868T, I926R, V1030G, E1035R, and S1046G relative to SEQ ID NO: 6. Such a Casl2i2 nuclease may comprise the amino acid sequence of SEQ ID NO: 8. In yet another example, the variant Casl2i2 nuclease comprises D581R, G624R, F626R, N840R, P868T, I926R, V1030G, E1035R, and S1046G relative to SEQ ID NO: 6. Such a Casl2i2 nuclease may comprise the amino acid sequence of SEQ ID NO: 573. See Table 2 above. Additional Casl2i2 variants can be found, e.g., WO2021 / 202800, the relevant disclosures of which are incorporated by reference for the subject matter and purpose referenced herein.(ii) Type V CRISP R Nuclease Sx3 PolypeptidesIn some instances, the Type V CRISPR nuclease for use in the SOD 1 -targeting gene editing system provided herein is Type V Nuclease Sx3 or a variant thereof (Type V-Sx3 nuclease polypeptide) as disclosed herein. See examples in Table 2 above.Type V-Sx3 nuclease comprises a RuvC nuclease domain, which coordinates cleavage of the DNA strand adjacent to the 5’-NTTR-3’ PAM motif, in which N represents any nucleotide A, C, G, or T.In some embodiments, the Type V-Sx3 nuclease polypeptide used in the gene editing system disclosed herein comprises the amino acid sequence of SEQ ID NO: 9. See Table 2 above. In other embodiments, the Type V-Sx3 nuclease polypeptide may comprise an amino acid sequence that is at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to SEQ ID NO: 9.In some instances, the Type V-Sx3 nuclease polypeptide of the present disclosure has enzymatic activity, e.g., nuclease or endonuclease activity similar to SEQ ID NO: 9, and comprising an amino acid sequence, which differs from the amino acid sequences of SEQ ID NO: 1 by 50, 40, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or 0 amino acid residue(s), when aligned using any of the previously described alignment methods.In some examples, the Type V-Sx3 nuclease polypeptide comprises an amino acidAttorney Docket No.: 063586-549001WOsequence at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or above) identical to SEQ ID NO: 9 and one or more mutations relative to SEQ ID NO: 9. In some examples, the mutations may be at position P14, D32, 161, E311, T338, E736, or a combination thereof in SEQ ID NO: 9. In some instances, the mutations are amino acid residue substitutions, for example, at the above noted position(s). In some examples, the amino acid residue substitution is P14R, D32R, I61R, E311R, T338G, E736G, or a combination thereof. In specific examples, the mutations are at positions P14R, D32R, I61R, and E311R in SEQ ID NO: 9, for example, P14R, D32R, I61R, and E311R. In other examples, the mutations are at positions P14R, D32R, I61R, E311, T338, and E736, for example, P14R, D32R, I61R, E311R, T338G, and E736G.Exemplary Type V-Sx3 nuclease polypeptides are provided in Table 2 above.Additional Type V-Sx3 nuclease polypeptides can be found, e.g., W02021 / 050534, WO2022 / 192391, W02024 / 020567, the relevant disclosures of which are incorporated by reference for the subject matter and purpose referenced herein.(b) Other CRISPR NucleasesAdditional CRISPR nucleases for use in the SOD 1 -targeting gene editing system disclosed herein include Nuclease K or a variant thereof (a.k.a., NK polypeptide), Nuclease A or a variant thereof (a.k.a. NA polypeptide), and Nuclease S or a variant thereof (a.k.a. NS polypeptide). Examples are provided in Table 2 above.( i) Nuclease K PolypeptidesIn some embodiments, the CRISPR nuclease polypeptide for use in the SOD 1 -targeting gene editing system is derived from Nuclease K, including both the wild-type Nuclease K (SEQ ID NO: 12), a variant thereof such as those disclosed herein (collectively Nuclease K polypeptides or NK polypeptides). The variant CRISPR nuclease polypeptides of Nuclease K may be produced via introducing one or more mutations to the reference CRISPR nuclease to modulate (e.g., enhance or reduce) one or more activities of the nuclease.The reference CRISPR Nuclease K (SEQ ID NO: 12; see Table 2 above) is a CRISPR nuclease that comprises both a RuvC nuclease domain and a HNH domain. The RuvC nuclease domain and the HNH nuclease domain coordinate cleavage of the DNA strand adjacent to the 5’-NGG-3’ PAM motif, in which N represents any nucleotide. Positions DIO, E315 and D500 are deemed the active sites in the RuvC domain and positions D374, H375, and N398 are deemed the active sites in the HNH domain. R482 and H497 may also be important for the nuclease activity of the RuvC domain. In addition to the nuclease domains, the referenceAttorney Docket No.: 063586-549001WOCRISPR nuclease of SEQ ID NO: 12 also includes a BH domain, a REC domain, a PLL domain, a WED domain, and a PID domain. Additional structural information for Nuclease K can be found in WO2024 / 206758, the relevant disclosures of which are incorporated by reference for the subject matter and purpose referenced herein.The Nuclease K polypeptide provided herein can contain one or more mutations relative to the reference Nuclease K (SEQ ID NO: 12), e.g., one or more amino acid residue substitutions, one or more deletions, one or more insertions, one or more fusions, or a combination thereof. In some instances, the alterations may be introduced into the BH domain, the WED, the PID, or a combination thereof of Nuclease K. In some instances, no alterations are introduced into the RuvC and / or the HNH nuclease domains of Nuclease K, or at the active sites and / or sites involved in activity in these domains as provided herein. Alternatively, conservative amino acid substitutions may be introduced into SEQ ID NO: 12, including in the RuvC and / or the HNH nuclease domains of Nuclease K.In some embodiments, the variant CRISPR nuclease polypeptide derived from Nuclease K provided herein may comprise one or more arginine substitutions, one or more lysine substitutions, or a combination thereof relative to SEQ ID NO: 12, for example, at position G42 and / or position D582. In some examples, the variant CRISPR nuclease polypeptide derived from Nuclease K may contain up to 20 arginine and / or lysine substitutions (e.g., up to 20 arginine substitutions, up to 20 lysine substitutions, or a combination thereof), e.g., up to 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 arginine substitutions, lysine substitutions, or a combination thereof.Alternatively, or in addition, the variant CRISPR nuclease polypeptide derived from Nuclease K provided herein may comprise one or more mutations ( / .< ., nickase mutations) within either the RuvC or the HNH nuclease domain to reduce or eliminate the nuclease activity of the target domain, thereby producing a variant with nickase activity. Such mutations may be deletions, insertions, amino acid substitutions, or a combination thereof. In some embodiments, the mutations within either the RuvC or the HNH nuclease domain of Nuclease K are amino acid substitutions, of which the substituting amino acid residue is not a conservative substitution of the native amino acid residue at the position of the mutation. For example, if the native amino acid residue is R, the substituting residue can be any amino acid residue except for K. Similarly, if the native amino acid residue is K, the substituting residue can be any amino acid residue except for R. Groups of conservative amino acid residue substitutions are provided herein.In some examples, the variant CRISPR Nuclease K polypeptide provided herein may share a sequence identity at least 90% (e.g., 95%, 97%, 98%, 99%, 99.5%, or greater) with SEQAttorney Docket No.: 063586-549001WOID NO: 12. Exemplary Nuclease K polypeptides are provided in Table 2 above. Additional Nuclease K variants can be found in WO2024 / 206758, the relevant disclosures of which are incorporated by reference for the subject matter and purpose referenced herein.(ii) Nuclease A PolypeptidesIn some embodiments, the CRISPR nuclease polypeptide for use in the SOD 1 -targeting gene editing system disclosed herein is derived from Nuclease A, including both the wild-type Nuclease A (SEQ ID NO: 14), a variant thereof such as those disclosed herein (collectively Nuclease A polypeptides or NA polypeptides). The variant CRISPR nuclease polypeptides of Nuclease A may be produced via introducing one or more mutations to the reference CRISPR nuclease to modulate (e.g., enhance or reduce) one or more activities of the nuclease.The reference CRISPR nuclease of Nuclease A (SEQ ID NO: 14) (see Table 2 above) is a CRISPR nuclease that comprises both a RuvC nuclease domain and a HNH domain. The RuvC nuclease domain and the HNH nuclease domain coordinate cleavage of the DNA strand adjacent to the 5’-NGG-3’ PAM motif, in which N represents any nucleotide. Positions D24, E335 and D524 are deemed the active sites in the RuvC domain, and positions D396, H397, and N420 are deemed the active sites in the HNH domain. R506 and H521 may also be important for nuclease activity of the RuvC domain. In addition to the nuclease domains, the reference CRISPR nuclease of SEQ ID NO: 14 also includes a BH domain, a REC domain, a PLL domain, a WED domain, and a PID domain. Additional structural information of Nuclease A can be found in WO2024 / 206758, the relevant disclosures of which are incorporated by reference for the subject matter and purpose referenced herein.The variant CRISPR nuclease polypeptide of Nuclease A as provided herein can contain one or more alterations relative to Nuclease A (SEQ ID NO: 14), e.g., one or more amino acid residue substitutions, one or more deletions, one or more insertions, one or more fusions, or a combination thereof. In some instances, the alterations may be introduced into the BH domain, the PLL domain, the WED domain, the PID domain, or a combination thereof. In some instances, no alterations are introduced into the RuvC and / or the HNH nuclease domains, or at the active sites and / or sites involved in activity in these domains as provided herein.Alternatively, conservative amino acid substitutions may be introduced into SEQ ID NO: 14, including in the RuvC and / or the HNH nuclease domains.In some embodiments, the variant CRISPR nuclease polypeptide of Nuclease A may comprise one or more arginine substitutions, one or more lysine substitutions, or a combination thereof relative to SEQ ID NO: 14, for example, at position 167, D568, and / or E706. In someAttorney Docket No.: 063586-549001WOexamples, the variant CRISPR nuclease polypeptide may contain up to 20 arginine and / or lysine substitutions (e.g., up to 20 arginine substitutions, up to 20 lysine substitutions, or a combination thereof), e.g., up to 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 arginine substitutions, lysine substitutions, or a combination thereof.Alternatively, or in addition, the engineered variant CRISPR nuclease polypeptide of Nuclease A disclosed herein may have an N-terminal truncation relative to Nuclease A of SEQ ID NO: 14. Such an engineered variant CRISPR nuclease polypeptide has a fragment at the N-terminus of Nuclease A deleted. Alternatively, or in addition, the engineered CRISPR nuclease polypeptide disclosed herein may have a C-terminal truncation relative to the reference CRISPR nuclease A of SEQ ID NO: 14.Alternatively, or in addition, any of the variant CRISPR nuclease polypeptides of Nuclease A provided herein may comprise one or more nickase mutations within either the RuvC or the HNH nuclease domain to reduce or eliminate the nuclease activity of the target domain, thereby producing a variant with nickase activity. Such mutations may be deletions, insertions, amino acid substitutions, or a combination thereof. In some embodiments, the mutations within either the RuvC or the HNH nuclease domain are amino acid substitutions, of which the substituting amino acid residue is not a conservative substitution of the native amino acid residue at the position of the mutation. For example, if the native amino acid residue is R, the substituting residue can be any amino acid residue except for K. Similarly, if the native amino acid residue is K, the substituting residue can be any amino acid residue except for R. Groups of conservative amino acid residue substitutions are provided herein.In some examples, the variant CRISPR nuclease polypeptide provided herein may share a sequence identity at least 90% (e.g, 95%, 97%, 98%, 99%, 99.5%, or greater) with SEQ ID NO: 14. Exemplary Nuclease A polypeptides are provided in Table 2 above. Additional Nuclease A variants can be found in WO2024 / 206758, the relevant disclosures of which are incorporated by reference for the subject matter and purpose referenced herein.(Hi) Nuclease S PolypeptidesIn some embodiments, the CRISPR nuclease polypeptide for use in the SOD 1 -targeting gene editing system provided herein is derived from Nuclease S, including both the wild-type Nuclease S (SEQ ID NO: 16), a variant thereof such as those disclosed herein (collectively Nuclease S polypeptides or NS polypeptides). The variant CRISPR nuclease polypeptides of Nuclease S may be produced via introducing one or more mutations to the reference CRISPR nuclease to modulate (e.g., enhance or reduce) one or more activities of the nuclease.Attorney Docket No.: 063586-549001WOThe reference CRISPR nuclease of SEQ ID NO: 16 (Table 2 above) is a CRISPR nuclease that comprises both a RuvC nuclease domain and a HNH domain. The RuvC nuclease domain and the HNH nuclease domain coordinate cleavage of the DNA strand adjacent to 5’-NRCC-3’, 5’-NRNC-3’, 5’NRYM-3’, or 5’-ARCC-3’ PAM motif, in which N represents any nucleotide, R represents A or G, Y represents C or T, and M represents A or C. Positions D25, E371 and D604 are deemed the active sites in the RuvC domain, and positions E447, H448, and N471 are deemed the active sites in the HNH domain. R580 and H601 may also be important for the nuclease activity of the RuvC domain. In addition to the nuclease domains, the reference CRISPR Nuclease S of SEQ ID NO: 16 also includes a BH domain, a REC domain, a PLL domain, a WED domain, and aPID domain. Additional structural information of Nuclease S can be found in WO2024 / 206759, the relevant disclosures of which are incorporated by reference for the subject matter and purpose referenced herein.The Nuclease S polypeptide provided herein can contain one or more alterations relative to the reference CRISPR Nuclease S of SEQ ID NO: 16, e.g., one or more amino acid residue substitutions, one or more deletions, one or more insertions, one or more fusions, or a combination thereof. In some instances, the alterations may be introduced into the BH domain, in the REC domain, in the PID domain, or a combination thereof. In some instances, no alterations are introduced into the RuvC and / or the HNH nuclease domains, or at the active sites and / or sites involved in activity in these domains as provided herein. Alternatively, conservative amino acid substitutions may be introduced into SEQ ID NO: 16, including in the RuvC and / or the HNH nuclease domains.In some embodiments, the variant CRISPR nuclease polypeptide provided herein may comprise one or more arginine substitutions, one or more lysine substitutions, or a combination thereof relative to SEQ ID NO: 16, for example, at position T72, W509, and / or 1845. In some examples, the variant CRISPR nuclease polypeptide may contain up to 20 arginine and / or lysine substitutions (e.g., up to 20 arginine substitutions, up to 20 lysine substitutions, or a combination thereof). In some instances, the arginine and / or lysine substitutions may be located in the BH domain, in the REC domain, in the HNH nuclease domain, in the PID domain, or a combination thereof of Nuclease S.Alternatively, or in addition, the variant CRISPR nuclease polypeptide derived from Nuclease S provided herein may comprise one or more nickase mutations within either the RuvC or the HNH nuclease domain to reduce or eliminate the nuclease activity of the target domain, thereby producing a variant with nickase activity. Such mutations may be deletions, insertions, amino acid substitutions, or a combination thereof. In some embodiments, theAttorney Docket No.: 063586-549001WOmutations within either the RuvC or the HNH nuclease domain are amino acid substitutions, of which the substituting amino acid residue is not a conservative substitution of the native amino acid residue at the position of the mutation. For example, if the native amino acid residue is R, the substituting residue can be any amino acid residue except for K. Similarly, if the native amino acid residue is K, the substituting residue can be any amino acid residue except for R. Groups of conservative amino acid residue substitutions are provided herein.In some examples, the variant CRISPR nuclease polypeptide provided herein may share a sequence identity at least 90% (e.g., 95%, 97%, 98%, 99%, 99.5%, or greater) with SEQ ID NO: 16. Exemplary Nuclease S polypeptides are provided in Table 2 above. Additional Nuclease S variants can be found in WO2024 / 206759, the relevant disclosures of which are incorporated by reference for the subject matter and purpose referenced herein.Any of the CRISPR nuclease polypeptides disclosed herein may further comprise one or more functional motifs in addition to the nuclease domain. For example, the CRISPR nuclease polypeptide comprises at least one (e.g., two, three, four, five, six, or more, identical or different) nuclear localization signal (NLS). In some embodiments, the CRISPR nuclease polypeptide comprises at least one (e.g., two, three, four, five, six, or more, identical or different) nuclear export signal (NES). In some embodiments, the CRISPR nuclease polypeptide comprises at least one (e.g., two, three, four, five, six, or more) NLS and at least one (e.g., two, three, four, five, six, or more) NES. In some examples, the CRISPR nuclease polypeptide may comprise one NLS at the C-terminus. In other examples, the CRISPR nuclease polypeptide may comprise one NLS at the N-terminus and one NLS at the C-terminus. In some instances, the N- terminus and C-terminus NLS motifs can be identical. Suitable NLS motifs known in the art can be used in the CRISPR nuclease polypeptides disclosed herein. Examples of the NLS and peptide linker fragments are provided in Table 3 below.Table 3. Exemplary Functional FragmentsDescription Sequence SEQ ID SV40 NLS KRTADGSEFESPKKKRKV 18 Nucleoplasmin NLS KRP AAT KKAGQ AKKKK 19 XTEN linker SGGSSGGSSGSETPGTSESATPESSGGSSGGSS 20 Peptide linker SAGGGGSGGGGSGGGGSG 576 miR122 binding CAAACACCATTGTCACACTCC 577 site*miR183 binding AGTGAATTCTACCAGTGCCATA 578Attorney Docket No.: 063586-549001WOsite*U6 promoter GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACA 579AGGCT GT T AGAGAGAT AAT TGGAAT T AAT TT GACT GT AAAC AC AAA GATATTAGTACAAAATACGTGACGTAGAAAGTAATAATTTCTTGGG TAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTATCATATGC TTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTT GTGGAAAGGACGAAACACCGUla promoter ATGGAGGCGGTACTATGTAGATGAGAATTCAGGAGCAAACTGGGAA 580AAGCAACTGCTTCCAAATATTTGTGATTTTTACAGTGTAGTTTTGG AAAAACTCTTAGCCTACCAATTCTTCTAAGTGTTTTAAAATGTGGG AGCCAGTACACATGAAGTTATAGAGTGTTTTAATGAGGCTTAAATA TTTACCGTAACTATGAAATGCTACGCATATCATGCTGTTCAGGCTC CGTGGCCACGCAACTCATACTbGH Poly A signal CTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGT 581GCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAA TAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTA TTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGA AGAGAATAGCAGGCATGCTGGGGA AAV2 ITR ( left ) CTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCC 582GACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCG CAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCT AAV2 ITR (right ) AGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCG 583CTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACC TTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGTranscription TTTTTTGCGTerminator*: the miRNA binding sites refer to the DNA sequence corresponding to the RNA sequence in the target mRNAAny of the CRISPR nuclease polypeptides disclosed herein may have its native N- terminus methionine residue removed, for example, when an exogenous functional fragment (e.g., an NLS or a peptide linker) is linked to the N-terminus of the CRISPR nuclease polypeptide.(c) Preparation of CRISPR NucleasesIn some embodiments, the CRISPR nuclease polypeptide disclosed in the present disclosure can be prepared by the conventional recombinant technology. For example, nucleic acids encoding the CRISPR nuclease polypeptide can be cloned into one expression vector, the coding sequence being in operable linkage to a suitable promoter. The expression vector can be introduced into suitable host cells, which can be cultured under suitable conditions allowing for the production of the polypeptide, which can be isolated and purified from the cell culture. Optionally, the CRISPR nuclease polypeptide can be complexed with an RNA guide to form aAttorney Docket No.: 063586-549001WOcomplex.Suitable host cells are not particularly limited, and various known cells can be preferably used. Specific examples of the host cell include bacteria such as E. coli, yeasts (budding yeast, Saccharomyces cerevisiae, and fission yeast, Schizosaccharomyces pombe), nematodes (Caenorhabditis elegans), Xenopus laevis oocytes, and animal cells (for example, CHO cells, COS cells and HEK293 cells). The method for transferring the expression vector described above into host cells, i.e., the transformation method, is not particularly limited, and known methods such as electroporation, the calcium phosphate method, the liposome method and the DEAE dextran method can be used.After a host is transformed with the expression vector, the host cells may be cultured, cultivated or bred, for production of the CRISPR nuclease polypeptide. After expression of the CRISPR nuclease polypeptide, the host cells can be collected and CRISPR nuclease polypeptide purified from the cultures etc. according to conventional methods (for example, filtration, centrifugation, cell disruption, gel filtration chromatography, ion exchange chromatography, etc.).A variety of methods can be used to determine the level of production of the CRISPR nuclease in a host cell. Such methods include, but are not limited to, for example, methods that utilize either polyclonal or monoclonal antibodies specific for the CRISPR nuclease polypeptide or a labeling tag as described elsewhere herein. Exemplary methods include, but are not limited to, enzyme-linked immunosorbent assays (ELISA), radioimmunoassays (MA), fluorescent immunoassays (FIA), and fluorescent activated cell sorting (FACS). These and other assays are well known in the art (See, e.g., Maddox et al., J. Exp. Med. 158:1211
[1983] ).The present disclosure provides methods of in vivo expression of the CRISPR nuclease polypeptide in a cell, comprising providing a polyribonucleotide encoding the CRISPR nuclease polypeptide to a host cell wherein the polyribonucleotide encodes the CRISPR nuclease polypeptide, expressing the CRISPR nuclease polypeptide in the cell, and obtaining the CRISPR nuclease polypeptide from the cell.The present disclosure further provides methods of in vivo expression of the CRISPR nuclease polypeptide in a cell, comprising providing a polyribonucleotide (e.g., an mRNA molecule) encoding the CRISPR nuclease polypeptide to a host cell located in a subject such as a human patient. In some examples, the polyribonucleotide encoding the CRISPR nuclease polypeptide can be delivered to the cell with an RNA guide and, once expressed in the cell, the CRISPR nuclease polypeptide and the RNA guide form a complex.Attorney Docket No.: 063586-549001WOB. RNA GuidesIn some embodiments, the gene editing system described herein comprises an RNA guide targeting a SOD1 gene, for example, targeting exon 1, exon 2, exon 3, exon 4, or exon 5. The RNA guide may direct the CRISPR nuclease contained in the gene editing system as described herein to a SOD1 target sequence.Those skilled in the art reading the below examples of particular kinds of RNA guides will understand that, in some embodiments, an RNA guide is SOD1 target-specific. That is, the RNA guide binds specifically to a SOD1 target sequence (e.g., within a cell such as a neuron cell) and not to non-targeted sequences (e.g., non-specific DNA or random sequences within the same cell).In some embodiments, the RNA guide comprises a spacer sequence followed by a scaffold sequence, referring to the sequences in the 5’ to 3’ direction. In other embodiments, the RNA guide comprises a scaffold sequence followed by a spacer sequence, referring to the sequences in the 5’ to 3’ direction. The orientation of the spacer sequence and the scaffold sequence may depend on the type of CRISPR nuclease used in the same gene editing system. For example, when a Type V CRISPR nuclease polypeptide is used, the corresponding RNA guide may have the scaffold sequence at the 5’ end and the spacer sequence at the 3’ end. On the other hand, when a Nuclease K, Nuclease A. or Nuclease S polypeptide is used, the corresponding RNA guide may have the spacer sequence at the 5’ end and the scaffold sequence at the 3’ end.In some embodiments, the spacer sequence and the scaffold sequence(s) of the RNA guide are present within the same RNA molecule. For example, the spacer and scaffold sequences are linked directly to one another. Alternatively, a short linker may be present between the spacer and scaffold sequences, e.g., an RNA linker of 1, 2, or 3 nucleotides in length.(i) Spacer SequenceThe RNA guide provided herein comprises a spacer sequence specific to a target sequence with an SOD1 gene, for example, within or near exon 1, exon 2, exon 3, exon 4, or exon 5 of the SOD1 gene. In some instances, the target sequence is within an exon. In some instances, the target sequence is within an intron site that is close to an exon. In other instances, the target sequence is at the junction of an intron and an exon. The target sequence is adjacent to a protospacer adjacent motif (PAM).As used herein, the term “protospacer adjacent motif’ or “PAM” refers to a DNAAttorney Docket No.: 063586-549001WOsequence adjacent to a target sequence (e.g., an SOD1 target sequence) to which a complex comprising an RNA guide (e.g., an / -targeting RNA guide) and a CRISPR nuclease binds. In a double-stranded DNA molecule, the strand containing the PAM motif is called the “PAM-strand” and the complementary strand is called the “non-PAM strand.” The RNA guide binds to a site in the non-PAM strand that is complementary to a target sequence disclosed herein. In some embodiments, the PAM strand is a coding (e.g., sense) strand. In other embodiments, the PAM strand is a non-coding (e.g., antisense strand).Each CRISPR nuclease recognizes a distinct PAM. For example, a Casl2i2 nuclease polypeptide as disclosed herein recognizes a PAM of 5’-NTTN-3’ (N being any of A, T, G, and C), which is located 5’ to the target sequence. A Type V Nuclease Sx3 polypeptide as disclosed herein recognizes a PAM of 5’-NTTR-3’ (N being any of A, T, G, and C; and R being A or G), which is located 5’ to the target sequence. Both Nuclease K and Nuclease A polypeptides recognize a PAM of 5’-NGG-3’ (N being any of A, T, G, and C), which is located 3’ to the target sequence. A Nuclease S polypeptide as disclosed herein recognizes a PAM of 5’-ARCC-3’ (R being A or G), which is located 3’ to the target sequence.As used herein, the term “target sequence” refers to a DNA fragment adjacent to a PAM motif (on the PAM strand). The complementary region of the target sequence is on the non-PAM strand. A target sequence may be immediately adjacent to the PAM motif. Alternatively, the target sequence and the PAM may be separated by a small sequence segment (e.g., up to 5 nucleotides, for example, up to 4, 3, 2, or 1 nucleotide). A target sequence may be located at the 3’ end of the PAM motif or at the 5’ end of the PAM motif, depending upon the CRISPR nuclease that recognizes the PAM motif, which is known in the art. For example, a target sequence is located at the 3’ end of a PAM motif for a CRISPR nuclease such as those disclosed herein. In some embodiments, the target sequence is a sequence within an SOD1 gene.As used herein, the term “adjacent to” refers to a nucleotide or amino acid sequence in close proximity to another nucleotide or amino acid sequence. In some embodiments, a nucleotide sequence is adjacent to another nucleotide sequence if no nucleotides separate the two sequences (i.e., immediately adjacent). In some embodiments, a nucleotide sequence is adjacent to another nucleotide sequence if a small number of nucleotides separate the two sequences (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides). In some embodiments, a first sequence is adjacent to a second sequence if the two sequences are separated by about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotides. In some embodiments, a first sequence is adjacent to a second sequence if the two sequences are separated by up to 2 nucleotides, up to 5 nucleotides, up to 8 nucleotides, up to 10 nucleotides,Attorney Docket No.: 063586-549001WOup to 12 nucleotides, or up to 15 nucleotides. In some embodiments, a first sequence is adjacent to a second sequence if the two sequences are separated by 2-5 nucleotides, 4-6 nucleotides, 4-8 nucleotides, 4-10 nucleotides, 6-8 nucleotides, 6-10 nucleotides, 6-12 nucleotides, 8-10 nucleotides, 8-12 nucleotides, 10-12 nucleotides, 10-15 nucleotides, or 12-15 nucleotides.As used herein, the term “spacer” or “spacer sequence” is a portion in an RNA guide that is the RNA equivalent of a target sequence (a DNA sequence) in the gene for editing (here SODi The spacer contains a sequence capable of binding to the non-PAM strand via basepairing at the site complementary to the target sequence (in the PAM strand). Such a spacer is also known as specific to the target sequence. In some instances, the spacer may be at least 75% identical to the target sequence (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%), except for the RNA-DNA sequence difference. In some instances, the spacer may be 100% identical to the target sequence except for the RNA-DNA sequence difference.In some embodiments, the spacer sequence of the RNA guide provided herein may have a length of between 12-30 nucleotides (e.g., 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides) and is complementary to a non-PAM strand sequence. In some examples, the spacer sequence may be between 20-30 nucleotides, for example, about 20 nucleotides.As used herein, the term “complementary” refers to a first polynucleotide (e.g., a spacer sequence of an RNA guide) that has a certain level of complementarity to a second polynucleotide (e.g., the complementary sequence of a target sequence) such that the first and second polynucleotides can form a double-stranded complex via base-pairing to permit an effector polypeptide that is complexed with the first polynucleotide to act on (e.g., cleave) the second polynucleotide. In some embodiments, the first polynucleotide may be substantially complementary to the second polynucleotide, i.e., having at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% complementarity to the second polynucleotide. In some embodiments, the first polynucleotide is completely complementary to the second polynucleotide, i.e., having 100% complementarity to the second polynucleotide. The percent identity between two such nucleic acids can be determined manually by inspection of the two optimally aligned nucleic acid sequences or by using software programs or algorithms (e.g., BLAST, ALIGN, CLUSTAL) using standard parameters.In some examples, the spacer sequence may be specific to a target sequence within exon 1, exon 2, exon 3, exon 4, or exon 5 of the SOD1 gene. In some examples, the spacer sequenceAttorney Docket No.: 063586-549001WOmay be specific to an intron target sequence near exon 1, exon 2, exon 3, exon 4, or exon 5 of the SOD1 gene. In some examples, the spacer sequence may be specific to a target sequence within a sequence shown in Table 1. Exemplary spacer sequences for the CRISPR nuclease polypeptides provided herein can be found in Table 6 below.In some embodiments, a spacer sequence provided herein may comprise only RNA bases. In some embodiments, the spacer sequence may comprise a DNA base (e.g., the spacer comprises at least one thymine). In some embodiments, the spacer sequence may comprise RNA bases and DNA bases (e.g., the spacer sequence comprises at least one thymine and at least one uracil).(ii) Scaffold SequenceIn some embodiments, the RNA guide comprises a backbone or scaffold sequence that is recognizable by the CRISPR nuclease polypeptide in the same SOD1 -targeting gene editing system. “Recognizable” means that the CRISPR nuclease polypeptide can interact with the scaffold sequence in the RNA guide to form a ribonucleoprotein complex for exerting the desired gene editing effect. In some embodiments, the scaffold sequence of the RNA guide has a length of between 12-100, 13-75, 14-50, or 15-40 nucleotides (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides).Table 4 below lists exemplar scaffold sequences for the CRISPR nuclease polypeptides disclosed herein.Table 4. Exemplary CRISPR Nuclease Scaffold SequencesDescription Sequence SEQ IDScaffold AGAAAUCCGUCUUUCAUUGACGG 21 for Casl2i2Scaffold CUUGUUGUAUAUGUCCUUUUAUAGGUAUUAAACAAC 22 for Type VNucleaseSx3Scaffold AAGGGCGACGGCCCAGUGCAGUUACAGUUAAGGCUCUGAAAAGAGCCUUAAU 23 for CRISPR UGUAAAACGCCUAUACAGUGAAGGGAUAUACGCUUGGGUUUGUCCAGCCUGA Nuclease K GCCUCUAUGCCAGAAAUGGCGCCUUCAUCGUGGGUUAGGACAUUUAAAUUUA AAAACUAUUCAGCACUGUUUGCUCUUGUCAGCUUGGUGGCAGAScaffold GUUACAGUUAAGGCUCUUUGGAAACAAAGAAGCCUUAAUUGUAAAACGCCUA 24 for CRISPR UAUGGUAAAGUGAUGUACGUUUGGGUAUAUAUCGCCAGCCUGAACCUCUACG Nuclease A CCAGAAAUGGCAGCUUUAUCAUGGGUUAGGACGAUAUUUAAAAAACUUUCUGCGGCUUGCUUACUUUAGUAAGCUUUGUGGCUGAGGCAGAAUUCCUUAttorney Docket No.: 063586-549001WOScaffold GUUGUAUUCGGAUGGGAGUAAAAGGUUGAGUACACCUGGAAACAAAACGACA 25 for CRISPR UAAAGGUGUUCUCCCAUCUGUGUACAAAGAGCAGAUAUAUGAGUUGAUAAGU Nuclease S AAUAUGUUGCACGUAUGGACUUUGACAGUCUGUACCUCUGCGUGAAAGACAU AUUGCGUUAUUCAUAUAUCUGUGAGUCUGUUCUAAAUUUAAAGGUUUAGGGAAIn some embodiments, the scaffold sequence may have at least 90% identity (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to a sequence listed in Table 4. In some examples, the scaffold sequence has at least 90% identity (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to SEQ ID NO: 21 or SEQ ID NO: 22, when the CRISPR nuclease polypeptide in the SOD 1 -targeting gene editing system is a Type V CRISPR nuclease, such as a Casl2i2 polypeptide or a Type V-Sx3 nuclease polypeptide. Additional scaffold sequence for use in constructing the RNA guides provided herein in association with Type V CRISPR nucleases can be found, e.g., in WO2021050534 or WO2022192391, the relevant disclosures of each of which are incorporated by reference herein for the subject matter and purpose referenced herein.In other embodiments, the scaffold sequence has at least 90% identity (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to SEQ ID NO: 23 or SEQ ID NO: 24, when the CRISPR nuclease polypeptide in the SOD 1 -targeting gene editing system is a Nuclease A polypeptide or a Nuclease K polypeptide. Additional scaffold sequence for use in constructing the RNA guides provided herein in association with these CRISPR nucleases can be found, e.g., in WO2024 / 206758, the relevant disclosures of each of which are incorporated by reference herein for the subject matter and purpose referenced herein.In other embodiments, the scaffold sequence has at least 90% identity (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity) to SEQ ID NO: 25, when the CRISPR nuclease polypeptide in the SOD 1 -targeting gene editing system is a Nuclease S polypeptide. Additional scaffold sequence for use in constructing the RNA guides provided herein in association with Nuclease S polypeptides can be found, e.g., in WO WO2024 / 206759, the relevant disclosures of each of which are incorporated by reference herein for the subject matter and purpose referenced herein.(iii) Exemplary RNA GuidesThe present disclosure provides RNA guides that comprise any and all combinations of the scaffolds and spacers described herein (e.g., as set forth in Table 6 below) in association with the CRISPR nuclease polypeptides as indicated. In some embodiments, the sequence of an RNA guide has at least 90% identity (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Attorney Docket No.: 063586-549001WO98%, or 99% identity) to a gRNA sequence provided in Table 6. In some embodiments, an RNA guide has a sequence of any of those provided in Table 6.In specific examples, when the SOD 1 -targeting gene editing system uses a Casl2i2 nuclease polypeptide, the RNA guides include Casl2i2 E1T3, Casl2i2 E2T2, Casl2i2 E2T14, Casl2i2 E3T20, Casl2i2 E4T4, and Casl2i2 E4T12 provided in Table 6 below.In some examples, the RNA guides (gRNAs) for use in the SOD 1 -targeting gene editing systems disclosed herein may comprise one or more modifications. In specific examples, the gRNAs disclosed herein may contain 1-3 (e.g., 1, 2, or 3) 2’-O-methylated bases and 1-3 (e.g., 1, 2, or 3) phosphorothioate bonds at the 5’ end, at the 3’ end, or both. Alternatively, the gRNAs may not be modified, for example, expressed from a vector.Any of the RNA guides provided in the present disclosure, either in modified form or unmodified form, is within the scope of the present disclosure.(iv) Nucleic Acid ModificationsThe RNA guides provided herein (as well as other nucleic acid components in the gene editing system, such as a messenger RNA encoding the CRISPR nuclease polypeptide) may include one or more covalent modifications with respect to a reference sequence, in particular the parent polyribonucleotide, which are included within the scope of the present disclosure.Exemplary modifications can include any modification to the sugar, the nucleobase, the internucleoside linkage (e.g., to a linking phosphate / to a phosphodiester linkage / to the phosphodiester backbone), and any combination thereof. Some of the exemplary modifications provided herein are described in detail below.The nucleic acid components (e.g., the RNA guide or the mRNA) may include any useful modification, such as to the sugar, the nucleobase, or the intemucleoside linkage (e.g., to a linking phosphate / to a phosphodiester linkage / to the phosphodiester backbone). One or more atoms of a pyrimidine nucleobase may be replaced or substituted with optionally substituted amino, optionally substituted thiol, optionally substituted alkyl (e.g., methyl or ethyl), or halo (e.g., chloro or fluoro). In certain embodiments, modifications (e.g., one or more modifications) are present in each of the sugar and the intemucleoside linkage. Modifications may be modifications of ribonucleic acids (RNAs) to deoxyribonucleic acids (DNAs), threose nucleic acids (TNAs), glycol nucleic acids (GNAs), peptide nucleic acids (PNAs), locked nucleic acids (LNAs) or hybrids thereof). Additional modifications are described herein.In some embodiments, the modification may include a chemical or cellular induced modification. For example, some nonlimiting examples of intracellular RNA modifications areAttorney Docket No.: 063586-549001WOdescribed by Lewis and Pan in “RNA modifications and structures cooperate to RNA guideprotein interactions” from Nat Reviews Mol Cell Biol, 2017, 18:202-210.Different sugar modifications, nucleotide modifications, and / or internucleoside linkages (e.g., backbone structures) may exist at various positions in the sequence. One of ordinary skills in the art will appreciate that the nucleotide analogs or other modification(s) may be located at any position(s) of the sequence, such that the function of the sequence is not substantially decreased. The sequence may include from about 1% to about 100% modified nucleotides (either in relation to overall nucleotide content, or in relation to one or more types of nucleotide, / .< ., any one or more of A, G, U or C) or any intervening percentage (e.g., from 1% to 20%>, from 1% to 25%, from 1% to 50%, from 1% to 60%, from 1% to 70%, from 1% to 80%, from 1% to 90%, from 1% to 95%, from 10% to 20%, from 10% to 25%, from 10% to 50%, from 10% to 60%, from 10% to 70%, from 10% to 80%, from 10% to 90%, from 10% to 95%, from 10% to 100%, from 20% to 25%, from 20% to 50%, from 20% to 60%, from 20% to 70%, from 20% to 80%, from 20% to 90%, from 20% to 95%, from 20% to 100%, from 50% to 60%, from 50% to 70%, from 50% to 80%, from 50% to 90%, from 50% to 95%, from 50% to 100%, from 70% to 80%, from 70% to 90%, from 70% to 95%, from 70% to 100%, from 80% to 90%, from 80% to 95%, from 80% to 100%, from 90% to 95%, from 90% to 100%, and from 95% to 100%).In some embodiments, sugar modifications (e.g., at the 2’ position or 4’ position) or replacement of the sugar at one or more ribonucleotides of the sequence may, as well as backbone modifications, include modification or replacement of the phosphodiester linkages. Specific examples of a sequence include, but are not limited to, sequences including modified backbones or no natural intemucleoside linkages such as internucleoside modifications, including modification or replacement of the phosphodiester linkages. Sequences having modified backbones include, among others, those that do not have a phosphorus atom in the backbone. For the purposes of this application, and as sometimes referenced in the art, modified RNAs that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides. In particular embodiments, a sequence will include ribonucleotides with a phosphorus atom in its intemucleoside backbone.Modified sequence backbones may include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates such as 3 ’-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates such as 3 ’-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates,Attorney Docket No.: 063586-549001WOthionoalkylphosphotriesters, and boranophosphates having normal 3’-5’ linkages, 2’-5’ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3’-5’ to 5’-3’ or 2’-5’ to 5’-2’. Various salts, mixed salts and free acid forms are also included. In some embodiments, the sequence may be negatively or positively charged.The modified nucleotides, which may be incorporated into the sequence, can be modified on the internucleoside linkage (e.g., phosphate backbone). Herein, in the context of the polynucleotide backbone, the phrases “phosphate” and “phosphodiester” are used interchangeably. Backbone phosphate groups can be modified by replacing one or more of the oxygen atoms with a different substituent. Further, the modified nucleosides and nucleotides can include the wholesale replacement of an unmodified phosphate moiety with another internucleoside linkage as described herein. Examples of modified phosphate groups include, but are not limited to, phosphorothioate, phosphoroselenates, boranophosphates, boranophosphate esters, hydrogen phosphonates, phosphoramidates, phosphorodiamidates, alkyl or aryl phosphonates, and phosphotriesters. Phosphorodithioates have both non-linking oxygens replaced by sulfur. The phosphate linker can also be modified by the replacement of a linking oxygen with nitrogen (bridged phosphoramidates), sulfur (bridged phosphorothioates), and carbon (bridged methylene-phosphonates).The a-thio substituted phosphate moiety is provided to confer stability to RNA and DNA polymers through the unnatural phosphorothioate backbone linkages. Phosphorothioate DNA and RNA have increased nuclease resistance and subsequently a longer half-life in a cellular environment.In specific embodiments, a modified nucleoside includes an alpha-thio-nucleoside (e.g., 5’-<9-(l-thiophosphate)-adenosine, 5’-<9-(l-thiophosphate)-cytidine (a-thio-cytidine), 5’-< -(l-thiophosphate)-guanosine, 5’-< -(l-thiophosphate)-uridine, or 5’-< -(l-thiophosphate)-pseudouridine).Other internucleoside linkages that may be employed according to the present disclosure, including internucleoside linkages which do not contain a phosphorous atom, are described herein.In some embodiments, one or more of the nucleotides of an RNA guide comprises a 2’-( -methyl phosphorothioate modification. In some embodiments, each of the first three nucleotides of the RNA guide comprises a 2’-(9-methyl phosphorothioate modification. In some embodiments, each of the last four nucleotides of the RNA guide comprises a 2’-(9-methyl phosphorothioate modification. In some embodiments, each of the first to last, second to last, and third to last nucleotides of the RNA guide comprises a 2’-(9-methyl phosphorothioateAttorney Docket No.: 063586-549001WOmodification, and wherein the last nucleotide of the RNA guide is unmodified. In some embodiments, each of the first three nucleotides of the RNA guide comprises a 2’-(9-methyl phosphorothioate modification, and each of the first to last, second to last, and third to last nucleotides of the RNA guide comprises a 2’-(9-methyl phosphorothioate modification.In some embodiments, an mRNA molecule encoding a CRISPR nuclease polypeptide may include one or more post-transcriptional modifications (e.g., capping, cleavage, polyadenylation, splicing, poly-A sequence, methylation, acylation, phosphorylation, methylation of lysine and arginine residues, acetylation, and nitrosylation of thiol groups and tyrosine residues, etc). The one or more post-transcriptional modifications can be any post-transcriptional modification, such as any of the more than one hundred different nucleoside modifications that have been identified in RNA (Rozenski, J, Crain, P, and McCloskey, J.(1999). The RNA Modification Database: 1999 update. Nucl Acids Res 27: 196-197) In some embodiments, the first isolated nucleic acid comprises messenger RNA (mRNA). In some embodiments, the mRNA comprises at least one nucleoside selected from the group consisting of pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5 -hydroxyuridine, 3 -methyluridine, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurinom ethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine, 1-taurinom ethyl -4-thio-uri dine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-l -methylpseudouridine, 2-thio-l-methyl-pseudouridine, 1 -methyl- 1-deaza-pseudouri dine, 2-thio-l-m ethyl- 1-deaza-pseudouri dine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, and 4-methoxy-2-thio-pseudouridine. In some embodiments, the mRNA comprises at least one nucleoside selected from the group consisting of 5-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-cytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-l-methyl-pseudoisocytidine, 4-thio- 1 -methyl- 1 -deaza-pseudoisocytidine, 1 -methyl- 1 -deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, and 4-methoxy-l-methyl-pseudoisocytidine. In some embodiments, the mRNA comprises at least one nucleoside selected from the group consisting of 2-aminopurine, 2, 6-diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2, 6-diaminopurine, 7-deaza-8-aza-2, 6-diaminopurine, 1-Attorney Docket No.: 063586-549001WOmethyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine, N6-glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonyl carbamoyladenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine, and 2-methoxy-adenine. In some embodiments, mRNA comprises at least one nucleoside selected from the group consisting of inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-m ethoxy-guanosine, 1 -methylguanosine, N2-m ethylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, l-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, and N2,N2-dimethyl-6-thio-guanosine.The mRNA sequence may or may not be uniformly modified along the entire length of the molecule. For example, one or more or all types of nucleotides (e.g., naturally-occurring nucleotides, purine or pyrimidine, or any one or more or all of A, G, U, C, I, pU) may or may not be uniformly modified in the sequence, or in a given predetermined sequence region thereof. In some embodiments, the sequence includes a pseudouridine. In some embodiments, the sequence includes an inosine, which may aid in the immune system characterizing the sequence as endogenous versus viral RNAs. The incorporation of inosine may also mediate improved RNA stability / reduced degradation. See for example, Yu, Z. et al. (2015) RNA editing by AD ARI marks dsRNA as “self’. Cell Res. 25, 1283-1284, which is incorporated by reference in its entirety.C. Exemplary SODl-Targeting Gene Editing SystemsThe gene editing systems targeting the SOD1 gene comprises (a) a CRISPR nuclease polypeptide as disclosed herein(e.g., a Type V nuclease polypeptide such as a Casl2i2 nuclease polypeptide) or a nucleic acid encoding such, and (b) a gRNA as also disclosed herein (e.g., those provided in Table 6 such as Casl2i2_E2T2 (SEQ ID NO: 43)) or a nucleic acid encoding such.In some embodiments, the SOD 1 -targeting gene editing system comprises the CRISPR nuclease polypeptide (e.g., a Type V nuclease polypeptide such as a Casl2i2 nuclease polypeptide) and the gRNA (e.g., those provided in Table 6 such as Casl2i2_E2T2), which may form a ribonucleoprotein complex (RNP), which can be delivered to host cells for gene editing.In other instances, the CRISPR nuclease-encoding nucleic acid may be a messengerAttorney Docket No.: 063586-549001WORNA molecule. A gene editing system comprising such a messenger RNA molecule may be formulated into a composition, which comprises one or more lipid excipients. In some examples, the lipid excipients may form lipid nanoparticles (LNPs), which associate with, or encapsulate, components of the gene editing system (e.g., the mRNA and optionally the gRNA (e.g., those provided in Table 6 such as Casl2i2_E2T2)).In other embodiments, the SOD 1 -targeting gene editing system may comprise a nucleic acid encoding the CRISPR nuclease polypeptide. In some instances, the nucleic acid encoding the CRISPR nuclease polypeptide (e.g., a Casl2i2 polypeptide as disclosed herein) may be located in a vector (e.g., a DNA plasmid). In some examples, the nucleic acid encoding the CRISPR nuclease polypeptide (e.g, a Casl2i2 polypeptide as disclosed herein) may be located in a genetically modified viral genome (e.g, a genetically modified adeno-associated viral (AAV) genome, or a genetically modified adenoviral vector (AdV) genome), which may be encapsulated by a viral capsid. In some examples, such a vector or viral genome may be designed to produce both the CRISPR nuclease polypeptide and the gRNA (e.g., those provided in Table 6).In some embodiments, the SOD 1 -targeting gene editing system disclosed herein comprises a genetically modified viral particle comprising a viral capsid encapsulating a genetically modified viral genome. In some instances, the viral particle is derived from a capsid virus such as AAV. In some instances, the genetically modified viral particle (e.g., an AAV viral particle) is replication-defective. As used herein, a genetically modified viral genome refers to viral genomic nucleic acid that is genetically modified relative to the wild-type viral genome to incorporate one or more genes of interest (here a gene encoding any of the Casl2i2 nuclease polypeptides disclosed herein and optionally a gene encoding any of the SOD1-targeting gRNAs as also disclosed herein). Such a genetically modified viral genome can deliver the gene(s) of interest (GOI) to host cells, where the proteins or nucleic acids encoded by the GOIs are expressed. The viral genomic nucleic acid can be further modified to remove viral elements not necessary for assembly of the viral genome into viral particles. Depending upon the type of the viral particle (e.g., derived from a DNA virus or RNA virus), the viral genomic nucleic acid in the genetically modified viral particle may be a DNA molecule (e.g., a double-strand DNA (dsDNA) or a single-strand DNA (ssDNA)) or an RNA molecule. In some examples, the genetically engineered viral genome comprises a first nucleic acid encoding the CRISPR nuclease polypeptide as disclosed herein or a complementary sequence thereof and a second nucleic acid encoding the gRNA as also disclosed herein or a complementary sequence thereof. The first nucleic acid can be in operable linkage to a first promoter and the secondAttorney Docket No.: 063586-549001WOnucleic acid encoding the gRNA can be in operable linkage to a second promoter. In some instances, the first promoter and the second promoter are different promoters, for example, the first promoter is a Ula promoter and the second promoter is a U6 promoter. In some instances, the first and second promoters can be in opposite orientation (see illustration in FIG. 22A).In some examples, the first nucleic acid encoding the CRISPR nuclease polypeptide may further comprise a nucleotide sequence encoding one or more miRNA binding sites. The miRNA binding site-coding sequence may be either downstream to or upstream to the coding sequence for the CRISPR nuclease polypeptide. microRNAs are small, single-stranded, noncoding RNA molecules that modulates mRNA translation. miRNAs typically have 19-25 nucleotides in length and can bind to particular regions in a mRNA via base-pairing to inhibit mRNA translation to proteins. The regions in mRNA that bind miRNAs are the miRNA binding sites. In some instances, a miRNA can destabilize a mRNA via, e.g., degrading the mRNA or shortening the polyA tail of the mRNA. Alternatively, a miRNA may block translation.In some instances, the miRNA binding sites in the viral genome can be binding sites for one or more tissue-specific miRNAs, which are selectively expressed or enriched in particular tissues. Due to the inhibitory activity of the miRNAs in the specific tissues, expression of the Casl2i2 nuclease polypeptide would be inhibited in such specific tissues, allowing for detargeting the specific tissues. Exemplary tissue-specific miRNAs include miR124-3p (enriched in brain tissue), miR9-5p (enriched in brain tissue), miRl-3p (enriched in skeletal and cardiac muscle), miR133a-3p (enriched in muscle tissues), miR122 (enriched in liver cells), miR192 (enriched in liver cells), miR194 (enriched in liver cells), miR148a (enriched in liver cells), miRl (enriched in dorsal root ganglion or DRG), miR16 (enriched in DRG), miR206 (enriched in DRG), miR21-5p (enriched in DRG), miR146a (enriched in DRG), miR155 (enriched in DRG), and miRl 83 (enriched in DRG). Tissue-specific miRNAs can be found in public microRNA databases, for example, the TSmiRNA database.In some examples, the viral genome may comprise one or more liver-specific miRNA binding sites to de-target liver. In one specific example, the viral genome may comprise one or more (e.g., three miR122 binding sites. Alternatively, or in addition, the viral genome may comprise one or more DRG-specific miRNA binding sites to de-target DRG. In one specific example, the viral genome may comprise one or more miRl 83 binding sites.In some instances, the first nucleic acid may also comprise a polyA signal sequence (e.g., the polyA signal sequence from bovine growth factor or bGH) downstream to the coding sequence for the CRISPR nuclease polypeptide, e.g., following coding sequence for the miRNA binding sites. Exemplary sequences of the promoters, the miR122 binding site, the miRl 83Attorney Docket No.: 063586-549001WObinding site, and the polyA signal sequence are provided in Table 3 above. In some instances, the transcript (mRNA) encoded by the first nucleic acid, driven by the first promoter (e.g., Ula), may comprise, from 5’ to 3’, coding region for the CRISPR nuclease polypeptide (e.g., the Casl2i2 nuclease polypeptide as disclosed herein), coding sequence for the one or more miRNA-binding sites, and the polyA signal.In some specific examples, the Casl2i2 nuclease polypeptide encoded by the first nucleic acid may comprise the amino acid sequence of SEQ ID NO: 573, which may be encoded by the nucleotide sequence of SEQ ID NO: 575. Such a Casl2i2 nuclease polypeptide may further comprise an NLS (e.g., SEQ ID NO: 19) located at the C-terminus. In some instances, the NLS may be connected to the nuclease moiety via a peptide linker (e.g., SEQ ID NO: 576). Such a fusion polypeptide may comprise the amino acid sequence of SEQ ID NO: 574. Alternatively, or in addition, the gRNA encoded by the second nucleic acid may comprise a spacer sequence of SEQ ID NO: 42. In some instances the gRNA encoded by the second nucleic acid may be Casl2i2_E2T2 (SEQ ID NO: 43).In some embodiments, the first promoter (e.g., Ula) and the second promoter (e.g., U6) in the genetically modified viral genome disclosed herein can be in opposite orientation, which means that the transcription of the CRISPR nuclease polypeptide (e.g., the Casl2i2 nuclease polypeptide) driven by the first promoter and transcription of the gRNA driven by the second promoter are in opposite directions. See illustration in FIG. 22A. When the viral genome is single-stranded, such a viral genome would comprise: (a) the first nucleic acid (comprising coding sequence for the CRISPR nuclease and optionally a sequence encoding one or more miRNA binding sites and / or a polyA signal), and (b) complementary sequences of the second nucleic acid encoding the gRNA coding sequence. Alternatively, the single-stranded viral genome may comprise (a) the second nucleic acid encoding the gRNA, and (b) a complementary sequence of the first nucleic acid. In either case, (a) and (b) each may be in operable linkage to a promoter (e.g., the first and second promoters disclosed herein). In some instances, a transcription terminator sequence can be included downstream to the gRNA coding sequence to terminate transcription of the gRNA driven by the second promoter as disclosed herein.When the viral genome is double-stranded, the first nucleic acid (comprising coding sequence for the CRISPR nuclease and optionally a sequence encoding one or more miRNA binding sites and / or a polyA signal) in operable linkage to the first promoter and the second nucleic acid (comprising a coding sequence for the gRNA and optionally a terminator sequence) in operable linkage to the second promoter would be located on opposite strands.Attorney Docket No.: 063586-549001WOIn one specific example, the genetically modified viral genome comprises, from 5’ to 3’, the Ula promoter, a nucleotide sequence encoding the Casl2i2 nuclease polypeptide, a nucleotide sequence encoding one or more miRNA binding sites such as one or more (e.g., three) miR122 binding sites, the poly A signal sequence, a nucleotide sequence complementary to the coding sequence for the gRNA (e.g., Casl2i2_E2T2), and a sequence complementary to the U6 promoter. In some instances, a complementary sequence of the transcription terminator sequence may be located 5’ of the complementary sequence for the gRNA coding sequence to terminate transcription of the gRNA. Such a genetically modified viral genome may be a ssDNA viral genome (e.g., an AAV genome). An example of such a viral construct design is provided in FIG. 22A. AAV constructs having the orientation of the two promoters disclosed herein for driving expression of the CRISPR nuclease and guide RNA can result in enhanced expression of the guide RNAs in neuron cells, which would be expected to improve gene editing efficiency.In other specific examples, the genetically modified viral genome comprises, from 5’ to 3’, a hSyn promoter, a nucleotide sequence encoding one or more NLSs (e.g., three), a nucleotide sequence encoding the Casl2i2 nuclease polypeptide followed by an NLS, a poly A signal sequence, a nucleotide sequence complementary to the coding sequence for the gRNA, and a nucleotide sequence complementary to the U6 promoter. In some instances, a complementary sequence of a transcription terminator sequence may be located 5’ of the complementary sequence for the gRNA coding sequence to terminate transcription of the gRNA. Such a genetically modified viral genome may be a ssDNA viral genome (e.g., an AAV genome).In yet other specific examples, the genetically modified viral genome comprises, from 5’ to 3’, a hSyn promoter, a nucleotide sequence encoding the Casl2i2 nuclease polypeptide followed by a peptide linker and an NLS, a polyA signal sequence, a nucleotide sequence complementary to the coding sequence for the gRNA, and a nucleotide sequence complementary to the U6 promoter. In some instances, a complementary sequence of a transcription terminator sequence may be located 5’ of the complementary sequence for the gRNA coding sequence to terminate transcription of the gRNA. Such a genetically modified viral genome may be a ssDNA viral genome (e.g, an AAV genome).In other examples, the genetically modified viral genome (single-stranded) may comprise a complementary sequence of any of the above-disclosed genomic designs. In yet other examples, the genetically modified viral genome disclosed herein may be a doublestranded molecule comprising one strand with any of the above-disclosed genomic designs andAttorney Docket No.: 063586-549001WOa complementary strand thereof.The genetically modified viral genome disclosed herein may further comprise viral genomic elements necessary for producing and / or packaging the viral genomic nucleic acid into the viral particle, for example, packaging signals and terminal repeats. Such viral genomic elements for use in viral particle-mediated gene delivery systems are well known in the art.The genetically modified viral particle disclosed herein can be prepared by conventional methods. For example, a viral vector (a DNA vector) comprising the elements in the viral genome disclosed herein can be delivered into packaging cells, which are engineered to produce viral proteins needed for producing the viral genomic nucleic acids and viral particle assembly. Alternatively, the viral vector comprising the elements in the viral vectors disclosed herein can be delivered into host cells, together with DNA plasmids for producing the viral proteins. Viral particles produced in the packaging cells or host cells can then be collected.As used herein, the term “viral vector” refers to a DNA plasmid or construct comprising the elements contained in the genetically modified viral genome as disclosed herein for use in producing viral particles comprising the genetically modified viral genome. Any of the viral vectors such as AAV vectors is within the scope of the present disclosure.Genetically Modified AAV ParticlesIn some instances, the genetically modified viral particle for use in the SOD 1 -targeting gene editing system and method disclosed herein is an AAV particle. AAV is a small nonenveloped virus having a single-stranded linear DNA genome. Recombinant AAVs have emerged as one of the most effective vehicles for gene delivery due to their ability to transduce a variety of mammalian cells and their non-pathogenicity and low immunogenicity in humans. The genome of an AAV is a single-stranded DNA chain (ssDNA), which can be either positive (+)- or negative (-)-sensed. The AAV genome contains inverted terminal report (ITR) sequences at both ends of the DNA strand and two open reading frames, rep and cap, encoding the Rep protein and the capsid proteins, respectively. The ITR sequence in a naturally-occurring AAV genome is about 145 bp long and capable of forming a hairpin, allowing for self-priming and synthesis of the second DNA strand. The ITR sequence also plays a role in efficient packaging of the AAV genome into capsid to form a fully assembled AAV virus. The rep gene encodes Rep proteins, which enable viral DNA replication and integration into the host genome. The cap gene produces three overlapping messenger RNA sequences coding for three capsid proteins, VP1, VP2, and VP3. Typically, an AAV capsid is composed of a mixture of VP1, VP2, and VP3 arranged in icosahedral symmetry. AAV virus of different serotypes contain differentAttorney Docket No.: 063586-549001WOcapsid proteins.The ITR sequences contained in the AAV genome and AAV vectors for producing the AAV particles may be derived from a naturally-occurring AAV genome. In some embodiments, the ITR sequences can be naturally-occurring. In other embodiments, the ITR sequences can be modified relative to the naturally-occurring counterpart, for example, an internal ITR lacking a terminal resolution site. The ITR sequences for use in the AAV vectors disclosed herein may be derived from any serotype of AAV virus capable of infecting neuron cells. In some examples, the ITRs can be derived from AAV2. Exemplar ITR sequences for use in the AAV vectors are provided in Table 3 above.The AAV particles disclosed herein are of a serotype that can infect neuron cells, for example, AAV2, AAV9, or AAVrhlO. In some instances, the genetically modified AAV particle as disclosed herein is an AAV2 particle comprising AAV2 capsid proteins. In other instances, the genetically modified AAV particle as disclosed herein is an AAV9 particle comprising AAV9 capsid proteins. In some examples, the capsid of the AAV9 viral particle comprises blood-brain barrier (BBB)-penetrant capsid proteins such as those known in the art. Some examples are provided in Example 7 below.To produce AAV viral particles, any of the AAV vectors disclosed herein may be delivered to a suitable host cell, such as a packaging host cell, for producing AAV viral particles following routine practice. In some examples, the host cells are mammalian cells. Examples include, but are not limited to, A549, WEHI, 3T3, 10T1 / 2, BHK, MDCK, COS 1, COS 7, BSC 1, BSC 40, BMT 10, VERO, WI38, HeLa, 293 cells (which express functional adenoviral El), Saos, C2C12, L cells, HT1080, HepG2 and primary fibroblast, hepatocyte and myoblast cells.In some embodiments, one or more vectors carrying AAV rep gene and / or AAV cap gene may be introduced into the host cell together with the AAV vector. In some instances, the rep gene may be of the same serotype as the serotype of the ITRs in the AAV vector.Alternatively, the rep gene may be from a cross-complementing serotype relative to the serotype of the ITR sequences. The AAV vector and the one or more vectors carrying the rep gene and the cap gene may be introduced into the host cell by a conventional method.In some embodiment, the host cell may stably express capsid proteins such as the AAV2 or AAV9 capsid proteins (e.g., blood-brain barrier (BBB)-penetrant capsid proteins) disclosed herein under the control of a suitable promoter. In some instances, the capsid proteins may be under the control of an inducible promoter. Alternatively, or in addition, the host cell may stably express the Rep protein under the control of a suitable promoter. In some examples, expression of the Rep protein may be under the control of an inducible promoter.Attorney Docket No.: 063586-549001WOIn some embodiment, an AAV vector can be introduced into a packaging host cell, which may stably express both a Rep protein and capsid proteins such as the AAV2 or AAV9 capsid proteins (e.g., blood-brain barrier (BBB)-penetrant capsid proteins) disclosed herein. The packaging host cell may also have helper functions in order to package the recombinant AAV viral particles as disclosed herein. In some examples, these functions may be supplied by a herpesvirus. In some examples, the necessary helper functions can be provided by a human or non-human primate adenovirus, such as those known in the art, e.g., those available from the American Type Culture Collection (ATCC), Manassas, Va. (US).AAV replication uses the ITR elements to generate complementary strands and the packaging machinery recognizes the ITR structures, which exist on both strands. As such, the population of AAV particles generated from host cells or packaging host cells contain a mixture of (+) and (-) strand genomes.Any of the genetically modified viral particles such as AAV particles and any of the viral vectors such as AAV DNA vectors disclosed herein are also within the scope of the present disclosure.II. Methods for Genetic Editing of SOD1 GeneThe disclosure also provides methods of genetically editing the SOD1 gene in target cells such as liver cells to disrupt expression of SOD1.In some instances, the methods comprise introducing any of the gene editing systems disclosed herein into cultured target cells (in vitro editing). For example, an V7 / J 7 -targeting RNA guide and the CRISPR nuclease provided herein can be introduced into a population of cultured cells. Alternatively, the methods comprise introducing the gene editing system into a subject such as a human patient to achieve editing of SOD1 in vivo.The V7 / J / -targeting RNA guide and CRISPR nuclease polypeptide as disclosed herein can form a ribonucleoprotein complex, which can be introduced into target cells. Alternatively, the N / J / -targeting RNA guide and CRISPR nuclease can be encoded by a nucleic acid vector(s), which can be introduced into the target cells. In another example, an mRNA molecule encoding the CRISPR nuclease can be introduced into target cells. Alternatively, or in addition, the RNA guide can be introduced directly into the target cells.Any of the gene editing systems disclosed herein may be used to genetically engineered a SOD1 gene in target cells of interest (e.g., liver cells). The gene editing system may comprise an RNA guide and the CRISPR nuclease such as those provided herein, e.g., in Table 2 above. The RNA guide comprises a spacer sequence specific to a target sequence in the SOD1 gene,Attorney Docket No.: 063586-549001WOe.g., specific to a region in exon 1, exon 2, exon 3, or exon 4 of the SOD1 gene.A. Delivery of the Gene Editing SystemComponents of any of the gene editing systems disclosed herein may be formulated, for example, including a carrier, such as a carrier and / or a polymeric carrier, e.g., a liposome, and delivered by known methods to target cells (e.g., a prokaryotic, eukaryotic, plant, mammalian, etc.). In some examples, the target cells are liver cells. Such methods include, but not limited to, transfection (e.g., lipid-mediated, cationic polymers, calcium phosphate, dendrimers); electroporation or other methods of membrane disruption (e.g., nucleofection), viral delivery (e.g., lentivirus, retrovirus, adenovirus, adeno-associated virus (AAV)), microinjection, microprojectile bombardment (“gene gun”), fugene, direct sonic loading, cell squeezing, optical transfection, protoplast fusion, impalefection, magnetofection, exosome-mediated transfer, lipid nanoparticle-mediated transfer, and any combination thereof.In some embodiments, the method comprises delivering one or more nucleic acids (e.g., nucleic acids encoding the CRISPR nuclease disclosed herein, one or more RNA guides also disclosed herein, etc.), one or more transcripts thereof, and / or a pre-formed RNA guide / CRISPR nuclease complex to target cells. In some instances, an RNA guide and a nucleic acid encoding the CRISPR nuclease (e.g., mRNA) are delivered together in a single composition.Alternatively, an RNA guide and a nucleic acid encoding the CRISPR nuclease (e.g., mRNA) are delivered in separate compositions. For example, the RNA guide and the nucleic acid encoding the CRISPR nuclease (e.g., mRNA) delivered in separate compositions are delivered using the same delivery technology. In other examples, the RNA guide and the nucleic acid encoding the CRISPR nuclease (e.g., mRNA) delivered in separate compositions are delivered using different delivery technologies.Exemplary intracellular delivery methods, include, but are not limited to: viruses, such as AAV, or virus-like agents; chemical-based transfection methods, such as those using calcium phosphate, dendrimers, liposomes, lipid nanoparticles, or cationic polymers (e.g., DEAE-dextran or polyethylenimine); non-chemical methods, such as microinjection, electroporation, cell squeezing, sonoporation, optical transfection, impalefection, protoplast fusion, bacterial conjugation, delivery of plasmids or transposons; particle-based methods, such as using a gene gun, magnectofection or magnet assisted transfection, particle bombardment; and hybrid methods, such as nucleofection.In some embodiments, a lipid nanoparticle comprises an mRNA encoding the CRISPR nuclease (e.g., those provided herein such as the one in Table 2 above), and an RNA guide canAttorney Docket No.: 063586-549001WObe used for delivering the gene editing components to target cells such as to liver cells.Any suitable LNP components that have been used for delivering nucleic acids to cells can also be used in the instant disclosure, for example, the LNP particles used for delivering the COVID-19 mRNA vaccines as reported in Schoenmaker et al., International J. Pharmaceutics, 601 (2021) 120586, the relevant disclosures of which are incorporated by reference for the subject matter and purpose referenced herein.Effectiveness of SOD1 editing in the target cells can be examined via conventional technology and / or those provided in Examples below.B. Genetically Modified CellsAny of the gene editing systems disclosed herein can be delivered to a variety of cells to genetically edit the SOD1 gene, which can lead to substantially reduced or no expression of the SOD1 gene. In some embodiments, the target cells can be cultured cells or a co-culture of two or more types of cells. In some examples, the target cells can be obtained from a living organism (e.g., a mammal such as a human subject) and maintained in a cell culture.In some embodiments, the cell is derived from a cell line. A wide variety of cell lines for tissue culture are known in the art. Examples of cell lines include, but are not limited to, 293T, MF7, K562, HeLa, CHO, and transgenic varieties thereof. Cell lines are available from a variety of sources known to those with skill in the art (see, e.g., the American Type Culture Collection (ATCC) (Manassas, Va.)). In some embodiments, the cell is an immortal or immortalized cell.In some embodiments, the cell is a primary cell. In some embodiments, the cell is a stem cell such as a totipotent stem cell (e.g., omnipotent), a pluripotent stem cell, a multipotent stem cell, an oligopotent stem cell, or an unipotent stem cell. In some embodiments, the cell is an induced pluripotent stem cell (iPSC) or derived from an iPSC. In some embodiments, the cell is a differentiated cell. For example, in some embodiments, the differentiated cell is a liver cell (e.g., a hepatocyte), a biliary cell (e.g., a cholangiocyte), a stellate cell, a Kupffer cell, a liver sinusoidal endothelial cell, a muscle cell (e.g., a myocyte), a fat cell (e.g., an adipocyte), a bone cell (e.g., an osteoblast, osteocyte, osteoclast), a blood cell (e.g., a monocyte, a lymphocyte, a neutrophil, an eosinophil, a basophil, a macrophage, a erythrocyte, or a platelet), a nerve cell (e.g., a neuron), an epithelial cell, an immune cell (e.g., a lymphocyte, a neutrophil, a monocyte, or a macrophage), a fibroblast, or a sex cell. In some embodiments, the cell is a terminally differentiated cell. For example, in some embodiments, the terminally differentiated cell is a neuronal cell, an adipocyte, a cardiomyocyte, a skeletal muscle cell, an epidermal cell, or a gut cell. In some embodiments, the cell is an immune cell. In some embodiments, the immune cellAttorney Docket No.: 063586-549001WOis a T cell. In some embodiments, the immune cell is a B cell. In some embodiments, the immune cell is a Natural Killer (NK) cell. In some embodiments, the immune cell is a Tumor Infiltrating Lymphocyte (TIL). In some embodiments, the cell is a mammalian cell, e.g., a human cell or a murine cell. In some embodiments, the murine cell is derived from a wild-type mouse, an immunosuppressed mouse, or a disease-specific mouse model. In some embodiments, the cell is a cell within a living tissue, organ, or organism.C. Therapeutic ApplicationsAny of the gene editing systems generated using such a gene editing system as disclosed herein may be used for treating a disease associated with SOD1, for example, ALS such as familial ALS. It is reported that mutations in the SOD1 gene are associated with ALS.In some embodiments, provided herein is a method for treating a target disease associated with SOD1 such as ALS. The method may comprise administering to a subject (e.g., a human patient) in need of the treatment any of the gene editing systems disclosed herein. The gene editing system may be delivered to a specific tissue (e.g., neuron) or specific type of cells (e.g., neuron cells) where the gene edit is needed. The gene editing system may comprise LNPs encompassing one or more of the components, for example, an mRNA molecule encoding the CRISPR nuclease polypeptide and the gRNA. Alternatively, the gene editing system may comprise one or more viral particles carrying a viral genome genetically modified to encode one or more of the components, e.g., the CRISPR nuclease polypeptide and / or the gRNA.Components of the gene editing system may be formulated to form a pharmaceutical composition, which may further comprise one or more pharmaceutically acceptable carriers. In some examples, the viral particles such as AAV particles disclosed herein may be used in the therapeutic methods disclosed herein.In some embodiments, provided herein is a composition comprising the gene editing system disclosed herein or components thereof. Such a composition can be a pharmaceutical composition. A pharmaceutical composition that is useful may be prepared, packaged, or sold in a formulation for a suitable delivery route, e.g., parenteral, intra-lesional, intra-organ or another route of administration. A pharmaceutical composition of the disclosure may be prepared, packaged, or sold in bulk, as a single unit dose, or as a plurality of single unit doses. As used herein, a “unit dose” is discrete amount of the pharmaceutical composition (e.g., the gene editing system or components thereof), which would be administered to a subject or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.Attorney Docket No.: 063586-549001WOA formulation of a pharmaceutical composition suitable for parenteral administration may comprise the active agent (e.g., the gene editing system or components thereof) combined with a pharmaceutically acceptable carrier, such as sterile water or sterile isotonic saline. Such a formulation may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration. Some injectable formulations may be prepared, packaged, or sold in unit dosage form, such as in ampules or in multi -dose containers containing a preservative. Some formulations for parenteral administration include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Some formulations may further comprise one or more additional ingredients including, but not limited to, suspending, stabilizing, or dispersing agents.The pharmaceutical composition may be in the form of a sterile injectable aqueous or oily suspension or solution. This suspension or solution may be formulated according to the known art, and may comprise, in addition to the cells, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein. Such sterile injectable formulation may be prepared using a non-toxic parenterally-acceptable diluent or solvent, such as water or saline. Other acceptable diluents and solvents include, but are not limited to, Ringer’s solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono- or di-glycerides. Other parentally-administrable formulations that are useful include those which may comprise the cells in a packaged form, in a liposomal preparation, or as a component of a biodegradable polymer system. Some compositions for sustained release or implantation may comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt.In some instances, the gene editing system for the therapeutic applications disclosed herein may comprise a viral particle such as an AAV particle that comprises a coding sequence for the Type V nuclease polypeptide such as the Casl2i2 nuclease polypeptide disclosed herein, as well as a coding sequence for the gRNA. In some examples, any of the AAV particles disclosed herein (e.g., having the construct designs illustrated in FIG. 22A) can be used to deliver the gene editing systems disclosed herein to a subject such as a human patient in need of the treatment. In some instances, the AAV particle is an AAV9 particle, which may comprise Blood-brain barrier (BBB)-penetrant capsids as disclosed herein. In some examples, the AAV particle may also carry a coding sequence for the RNA guide so that the RNA guide can be produced in the host cells. Alternatively, the RNA guide may be co-delivered with the AAV particle to the subject in need of the treatment.Attorney Docket No.: 063586-549001WOIII. Kits for Genetic Editing of SOD1 Gene and Alleviating Target DiseasesThe present disclosure also provides kits that can be used, for example, to carry out a gene editing method described herein for genetical editing of the SOD1 gene as disclosed herein. In some embodiments, the kits include an RNA guide and the CRISPR nuclease (e.g., those provided herein such as the one provided in Table 2). In some embodiments, the kits include an RNA guide and the CRISPR nuclease. In other embodiments, the kits include a polynucleotide that encodes such the CRISPR nuclease, and optionally the polynucleotide is comprised within a vector, e.g., as described herein. In some embodiments, the kits include a polynucleotide that encodes an RNA guide disclosed herein. The CRISPR nuclease (or polynucleotide encoding the CRISPR nuclease) and the RNA guide (e.g., as a ribonucleoprotein) can be packaged within the same or other vessel within a kit or can be packaged in separate vials or other vessels, the contents of which can be mixed prior to use. In other examples, the kits may comprise any of the viral particles (e.g., AAV particles) as disclosed herein for delivering the gene editing system components to host cells.The kits can additionally include, optionally, a buffer and / or instructions for use of the RNA guide and CRISPR nuclease.General techniquesThe practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as Molecular Cloning: A Laboratory Manual, second edition (Sambrook, et al., 1989) Cold Spring Harbor Press; Oligonucleotide Synthesis (M. J. Gait, ed. 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (J. E. Cellis, ed., 1989) Academic Press; Animal Cell Culture (R. I.Freshney, ed. 1987); Introduction to Cell and Tissue Culture (J. P. Mather and P. E. Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (A. Doyle, J. B. Griffiths, and D. G. Newell, eds. 1993-8) J. Wiley and Sons; Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (D. M. Weir and C. C. Blackwell, eds.): Gene Transfer Vectors for Mammalian Cells (J. M. Miller and M. P. Calos, eds., 1987); Current Protocols in Molecular Biology (F. M. Ausubel, et al. eds. 1987); PCR: The Polymerase Chain Reaction, (Mullis, et al., eds. 1994); Current Protocols in Immunology (J. E. Coligan et al., eds., 1991); Short Protocols in Molecular Biology (Wiley and Sons, 1999); Immunobiology (C. A. Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: a practice approachAttorney Docket No.: 063586-549001WO(D. Catty., ed., IRL Press, 1988-1989); Monoclonal antibodies: a practical approach (P.Shepherd and C. Dean, eds., Oxford University Press, 2000); Using antibodies: a laboratory manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanetti and J. D. Capra, eds. Harwood Academic Publishers, 1995); DNA Cloning: A practical Approach, Volumes I and II (D.N. Glover ed. 1985); Nucleic Acid Hybridization (B.D. Hames & S.J. Higgins eds.(1985»; Transcription and Translation (B.D. Hames & S.J. Higgins, eds. (1984»; Animal Cell Culture (R.I. Freshney, ed. (1986»; Immobilized Cells and Enzymes (IRL Press, (1986»; and B. Perbal, A Practical Guide To Molecular Cloning (1984); F.M. Ausubel etal. (eds.).Without further elaboration, it is believed that one skilled in the art can, based on the above description, utilize the present invention to its fullest extent. The following specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. All publications cited herein are incorporated by reference for the purposes or subject matter referenced herein.EXAMPLESThe following examples are provided to further illustrate some embodiments of the present invention but are not intended to limit the scope of the invention; it will be understood by their exemplary nature that other procedures, methodologies, or techniques known to those skilled in the art may alternatively be used.Example 1: SOD1 Disruption Using CRISPR NucleasesThis example describes the identification and screening of CRISPR nucleases and guides for disruption of SOD1.A. Computational Identification and Production of SOD1 GuidesSOD1 guides were designed by tiling the coding sequence of human SOD1 (NG_008689) for PAM sequences for Casl2i2 (SEQ ID NO: 8), Type V CRISPR Nuclease A (SEQ ID NO: 9), CRISPR Nuclease K (SEQ ID NO: 12), CRISPR Nuclease A (SEQ ID NO: 14), and CRISPR Nuclease S (SEQ ID NO: 16) and designating a 20-bp target adjacent to the PAM. The PAM may be located 5’ to the target sequence or 3’ to the target sequence depending on the specific nuclease. All PAMs that overlap completely or partially with SOD1 coding regions were included, resulting in 267 target sequences. Targets with identical off-target matches elsewhere in the genome were excluded, resulting in 250 filtered targets. PlasmidsAttorney Docket No.: 063586-549001WOencoding the guide RNA were generated by Integrated DNA Technologies. The plasmids comprise a DNA guide sequence, followed by the motif TTTTTTGCG, was positioned downstream of the U6 promoter to enable expression in mammalian cells. The amino acid sequences of these exemplary CRISPR nucleases are provided in Table 2 above. Table 5 below provides the PAM sequences for each of the tested nucleases and the number of target sequences identified in SOD1. Table 6 provides exemplary guide RNAs corresponding to each of the tested nucleases.Table 5. In Silico Identification of Target sequences for CRISPRNuclease PAM position* PAM Sequence** # of Target Sequences Casl2i2 5’ NTTN 83Type V-Sx3 5’ NTTR 34NK 3’ NGG 66NA 3’ NGG 66NS 3’ ARCC 1*PAM position is relative to target sequence; **N is A, G, C or T; R is A or GTable 6. Guide Sequences for SOD1 DisruptionGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized} Cas l2 I2 GT TA TGGCGACGAAGGCCG UGGCGACGAAGGCC AGAAAUCCGUCUUUCAUUGACGGUGGCG _E1T1 TGTGC ( SEQ ID GUGUGC ( SEQ ID ACGAAGGCCGUGUGC ( SEQ ID NO :NO : 26 ) NO : 27 ) 28 )Cas l2 I2 CTTG CCTTCTGCTCGAAAT CCUUCUGCUCGAAA AGAAA UCCGUCUUUCA UUGA CGGC CUU C _E1T2 TGATG ( SEQ ID UUGAUG ( SEQ ID UGCUCGAAAUUGAUG ( SEQ ID NO :NO : 29 ) NO : 30 ) 31 )Cas l2 I2 CTTC TGCTCGAAATTGATG UGCUCGAAAUUGAU AGAAA UCCGUCUUUCA UUGA CGGU GCU C _E1T3 ATGCC ( SEQ ID GAUGCC ( SEQ ID GAAAUUGAU GAUGCC ( SEQ ID NO :NO : 32 ) NO : 33 ) 34 )Cas l2 I2 ATTG ATGATGCCCTGCACT AUGAUGCCCUGCAC AGAAA UCCGUCUUUCA UUGA CGGAU GAU _E1T4 GGGCC ( SEQ ID UGGGCC ( SEQ ID GCCCUGCACUGGGCC ( SEQ ID NO :NO : 35 ) NO : 36 ) 37 )Cas l2 I2 CTTC AGCACGCACACGGCC AGCACGCACACGGC AGAAA UCCGUCUUUCA UUGA CGGAGCAC _E1T5 TTCGT ( SEQ ID CUUCGU ( SEQ ID GCACACGGCCUUCGU ( SEQ ID NO :NO : 38 ) NO : 39 ) 40 )Cas l2 I2 CTTC CCCACACCTTCACTG CCCACACCUUCACU AGAAA UCCGUCUUUCA UUGA CGGC C CAC _E2T2 GTCCA ( SEQ ID GGUCCA ( SEQ ID ACCUUCACUGGUCCA ( SEQ ID NO :NO : 41 ) NO : 42 ) 43 )Cas l2 I2 TTTA ATGCTTCCCCACACC AUGCUUCCCCACAC AGAAA UCCGUCUUUCA UUGA CGGAU GCU _E2T3 TTCAC ( SEQ ID CUUCAC ( SEQ ID UCCCCACACCUUCAC ( SEQ ID NO :NO : 44 ) NO : 45 ) 46 )Cas l2 I2 CTTT AATGCTTCCCCACAC AAUGCUUCCCCACA AGAAA UCCGUCUUUCA UUGA CGGAAU GC _E2T4 CTTCA ( SEQ ID CCUUCA ( SEQ ID UUCCCCACACCUUCA ( SEQ ID NO :NO : 47 ) NO : 48 ) 49 )Cas l2 I2 CTTC AGTCAGTCCTTTAAT AGU CAGU C CUUUAA AGAAA UCCGUCUUUCA UUGA CGGAGU CAE2T5 GCTTC ( SEQ ID UGCUUC ( SEQ ID GUCCUUUAAUGCUUC ( SEQ ID NO :Attorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized}NO : 50 ) NO : 51 ) 52 )Cas l2 I2 ATTA TCTCCAAACTCATGA U CU C CAAACU CAU G AGAAA UCCGUCUUUCA UUGA CGGU CU C C _E2T6 ACATG ( SEQ ID AACAUG ( SEQ ID AAACUCAUGAACAUG ( SEQ ID NO :NO : 53 ) NO : 54 ) 55 )Cas l2 I2 GTTC ATGAGTTTGGAGATA AUGAGUUUGGAGAU AGAAA UCCGUCUUUCA UUGA CGGAU GAG _E2T8 ATACA ( SEQ ID AAUACA ( SEQ ID UUUGGAGAUAAUACA ( SEQ ID NO :NO : 56 ) NO : 57 ) 58 )Cas l2 I2 ATTA AAGGACT GACT GAAG AAGGACUGACUGAA AGAAA UCCGUCUUUCA UUGA CGGAAGGA _E2T10 GCCTG ( SEQ ID GGCCUG ( SEQ ID CUGACUGAAGGCCUG ( SEQ ID NO :NO : 59 ) NO : 60 ) 61 )Cas l2 I2 CTTA AAGGAAAGTAAT GGA AAGGAAAGUAAUGG AGAAA UCCGUCUUUCA UUGA CGGAAGGA _E2T11 CCAGT ( SEQ ID ACCAGU ( SEQ ID AAGUAAUGGACCAGU ( SEQ ID NO :NO : 62 ) NO : 63 ) 64 )Cas l2 I2 TTTC TTAAAGGAAAGTAAT UUAAAGGAAAGUAA AGAAA UCCGUCUUUCA UUGA CGGUUAAA _E2T12 GGACC ( SEQ ID UGGACC ( SEQ ID GGAAAGUAAUGGACC ( SEQ ID NO :NO : 65 ) NO : 66 ) 67 )Cas l2 I2 TTTT CTTAAAGGAAAGTAA CUUAAAGGAAAGUA AGAAA UCCGUCUUUCA UUGA CGGCUUAA _E2T13 TGGAC ( SEQ ID AUGGAC ( SEQ ID AGGAAAGUAAUGGAC ( SEQ ID NO :NO : 68 ) NO : 69 ) 70 )Cas l2 I2 CTTT TCTTAAAGGAAAGTA UCUUAAAGGAAAGU AGAAA UCCGUCUUUCA UUGA CGGU CUUA _E2T14 ATGGA ( SEQ ID AAUGGA ( SEQ ID AAGGAAAGUAAUGGA ( SEQ ID NO :NO : 71 ) NO : 72 ) 73 )Cas l2 I2 TTTG CACTTTTCTTAAAGG CACUUUU CUUAAAG AGAAA UCCGUCUUUCA UUGA CGGCACUU _E2T15 AAAGT ( SEQ ID GAAAGU ( SEQ ID UUCUUAAAGGAAAGU ( SEQ ID NO :NO : 74 ) NO : 75 ) 76 )Cas l2 I2 CTTT GCACTTTTCTTAAAG GCACUUUUCUUAAA AGAAA UCCGUCUUUCA UUGA CGGGCACU _E2T16 GAAAG ( SEQ ID GGAAAG ( SEQ ID UUUCUUAAAGGAAAG ( SEQ ID NO :NO : 77 ) NO : 78 ) 79 )Cas l2 I2 ATTC CAT GT T CAT GAGT T T CAU GUU CAU GAGUU AGAAA UCCGUCUUUCA UUGA CGGCAU GU _E2T17 GGAGA ( SEQ ID UGGAGA ( SEQ ID UCAUGAGUUUGGAGA ( SEQ ID NO :NO : 80 ) NO : 81 ) 82 )Cas l2 I2 GT TA CCTCTCTTCATCCTT CCUCUCUUCAUCCU AGAAA UCCGUCUUUCA UUGA CGGC CU CU _E3T1 TGGCC ( SEQ ID UUGGCC ( SEQ ID CUUCAUCCUUUGGCC ( SEQ ID NO :NO : 83 ) NO : 84 ) 85 )Cas l2 I2 CTTC ATCCTTTGGCCCACC AUCCUUUGGCCCAC AGAAA UCCGUCUUUCA UUGA CGGAU C CU _E3T2 GTGTT ( SEQ ID CGUGUU ( SEQ ID UUGGCCCACCGUGUU ( SEQ ID NO :NO : 86 ) NO : 87 ) 88 )Cas l2 I2 CTTT GGCCCACCGTGTTTT GGCCCACCGUGUUU A GAAA UCCGUCUUUCA UUGA CGGG G C C C _E3T3 CTGGA ( SEQ ID UCUGGA ( SEQ ID ACCGUGUUUUCUGGA ( SEQ ID NO :NO : 89 ) NO : 90 ) 91 )Cas l2 I2 TTTG GCCCACCGTGTTTTC GCCCACCGUGUUUU AGAAA UCCGUCUUUCA UUGA CGGGC C CA _E3T4 TGGAT ( SEQ ID CUGGAU ( SEQ ID CCGUGUUUUCUGGAU ( SEQ ID NO :NO : 92 ) NO : 93 ) 94 )Cas l2 I2 ATTA AAGTGAGGACCTGCA AAGUGAGGACCUGC AGAAA UCCGUCUUUCA UUGA CGGAAGU G _E3T5 CTGGT ( SEQ ID ACUGGU ( SEQ ID AGGACCUGCACUGGU ( SEQ ID NO :NO : 95 ) NO : 96 ) 97 )Cas l2 I2 TTTT CTGGATAGAGGATTA CUGGAUAGAGGAUU AGAAA UCCGUCUUUCA UUGA CGGCU GGA _E3T6 AAGTG ( SEQ ID AAAGUG ( SEQ ID UAGAGGAUUAAAGUG ( SEQ ID NO :NO : 98 ) NO : 99 ) 100 )Cas l2 I2 TTTC TGGATAGAGGATTAA UGGAUAGAGGAUUA AGAAA UCCGUCUUUCA UUGA CGGU GGAU _E3T7 AGTGA ( SEQ ID AAGUGA ( SEQ ID AGAGGAUUAAAGUGA ( SEQ ID NO :NO : 101 ) NO : 102 ) 103 )Cas l2 I2 CTTG TTACCTCTCTTCATC UUACCUCUCUUCAU AGAAA UCCGUCUUUCA UUGA CGGUUAC C _E3T8 CTTTG ( SEQ ID CCUUUG ( SEQ ID UCUCUUCAUCCUUUG ( SEQ ID NO :NO : 104 ) NO : 105 ) 106 )Cas l2 I2 GTTT TCTGGATAGAGGATT UCUGGAUAGAGGAU AGAAA UCCGUCUUUCA UUGA CGGU CU GG _E3T9 AAAGT ( SEQ ID UAAAGU ( SEQ ID AUAGAGGAUUAAAGU ( SEQ ID NO :NO : 107 ) NO : 108 ) 109 )Attorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized} Cas l2 I 2 GT TA AGCATCTTGTTACCT AGCAUCUUGUUACC AGAAA UCCGUCUUUCA UUGA CGGAGCAU _E3T 10 CTCTT ( SEQ I D UCUCUU ( SEQ I D CUUGUUACCUCUCUU ( SEQ I D NO :NO : 110 ) NO : 111 ) 112 )Cas l2 I 2 TTTT CTTCTTCTTATAAAT CUUCUUCUUAUAAA AGAAA UCCGUCUUUCA UUGA CGGCUU CU _E3T 11 AGGCT ( SEQ I D UAGGCU ( SEQ I D UCUUAUAAAUAGGCU ( SEQ I D NO :NO : 113 ) NO : 114 ) 115 )Cas l2 I 2 CTTT AATCCTCTATCCAGA AAU CCU CUAU C CAG AGAAA UCCGUCUUUCA UUGA CGGAAU C C _E3T 12 AAACA ( SEQ I D AAAACA ( SEQ I D UCUAUCCAGAAAACA ( SEQ I D NO :NO : 116 ) NO : 117 ) 118 )Cas l2 I 2 TTTA ATCCTCTATCCAGAA AU C CU CUAU C CAGA AGAAA UCCGUCUUUCA UUGA CGGAU CCU _E3T 13 AACAC ( SEQ I D AAACAC ( SEQ I D CUAUCCAGAAAACAC ( SEQ I D NO :NO : 119 ) NO : 120 ) 121 )Cas l2 I 2 TTTT TTCTTCTTCTTATAA UUCUUCUUCUUAUA AGAAA UCCGUCUUUCA UUGA CGGUU CUU _E3T 15 ATAGG ( SEQ I D AAUAGG ( SEQ I D CUUCUUAUAAAUAGG ( SEQ I D NO :NO : 122 ) NO : 123 ) 124 )Cas l2 I 2 TTTT TCTTCTTCTTATAAA UCUUCUUCUUAUAA AGAAA UCCGUCUUUCA UUGA CGGU CUU C _E3T 16 TAGGC ( SEQ I D AUAGGC ( SEQ I D UUCUUAUAAAUAGGC ( SEQ I D NO :NO : 125 ) NO : 126 ) 127 )Cas l2 I 2 TTTC TTCTTCTTATAAATA UU CUU CUUAUAAAU AGAAA UCCGUCUUUCA UUGA CGGUU CUU _E3T 18 GGCTG ( SEQ I D AGGCUG ( SEQ I D CUUAUAAAUAGGCUG ( SEQ I D NO :NO : 128 ) NO : 129 ) 130 )Cas l2 I 2 CTTC TTCTTATAAATAGGC UUCUUAUAAAUAGG AGAAA UCCGUCUUUCA UUGA CGGUU CUU _E3T 19 TGTAC ( SEQ I D CUGUAC ( SEQ I D AUAAAUAGGCUGUAC ( SEQ I D NO :NO : 131 ) NO : 132 ) 133 )Cas l2 I 2 CTTC TTATAAATAGGCTGT UUAUAAAUAGGCUG AGAAA UCCGUCUUUCA UUGA CGGUUAUA _E3T20 ACCAG ( SEQ I D UACCAG ( SEQ I D AAUAGGCUGUACCAG ( SEQ I D NO :NO : 134 ) NO : 135 ) 136 )Cas l2 I 2 CTTA TAAATAGGCTGTACC UAAAUAGGCUGUAC AGAAA UCCGUCUUUCA UUGA CGGUAAAU _E3T21 AGTGC ( SEQ I D CAGUGC ( SEQ I D AGGCUGUACCAGUGC ( SEQ I D NO :NO : 137 ) NO : 138 ) 139 )Cas l2 I 2 TTTG TCAGCAGTCACATTG UCAGCAGUCACAUU AGAAA UCCGUCUUUCA UUGA CGGU CAGC _E4T2 CCCAA ( SEQ I D GCCCAA ( SEQ I D AGUCACAUUGCCCAA ( SEQ I D NO :NO : 140 ) NO : 141 ) 142 )Cas l2 I 2 CTTT GTCAGCAGTCACATT GUCAGCAGUCACAU AGAAA UCCGUCUUUCA UUGA CGGGU CAG _E4T3 GCCCA ( SEQ I D UGCCCA ( SEQ I D CAGUCACAUUGCCCA ( SEQ I D NO :NO : 143 ) NO : 144 ) 145 )Cas l2 I 2 CTTC AATAGACACATCGGC AAUAGACACAUCGG AGAAA UCCGUCUUUCA UUGA CGGAAUAG _E4T4 CACAC ( SEQ I D CCACAC ( SEQ I D ACACAUCGGCCACAC ( SEQ I D NO :NO : 146 ) NO : 147 ) 148 )Cas l2 I 2 CTTA CCACCAGTGTGCGGC CCACCAGUGUGCGG AGAAA UCCGUCUUUCA UUGA CGGC CAC C _E4T5 CAATG ( SEQ I D CCAAUG ( SEQ I D AGUGUGCGGCCAAUG ( SEQ I D NO :NO : 149 ) NO : 150 ) 151 )Cas l2 I 2 TTTA TGAAAACTTACCACC U GAAAACUUAC CAC AGAAA UCCGUCUUUCA UUGA CGGU GAAA _E4T 6 AGTGT ( SEQ I D CAGUGU ( SEQ I D ACUUACCACCAGUGU ( SEQ I D NO :NO : 152 ) NO : 153 ) 154 )Cas l2 I 2 TTTT ATGAAAACTTACCAC AU GAAAACUUAC CA AGAAA UCCGUCUUUCA UUGA CGGAU GAA _E4T7 CAGTG ( SEQ I D CCAGUG ( SEQ I D AACUUACCACCAGUG ( SEQ I D NO :NO : 155 ) NO : 156 ) 157 )Cas l2 I 2 CTTT TATGAAAACTTACCA UAU GAAAACUUAC C AGAAA UCCGUCUUUCA UUGA CGGUAU GA _E4T 8 CCAGT ( SEQ I D ACCAGU ( SEQ I D AAACUUACCACCAGU ( SEQ I D NO :NO : 158 ) NO : 159 ) 160 )Cas l2 I 2 ATTG CATCATTGGCCGCAC CAUCAUUGGCCGCA AGAAA UCCGUCUUUCA UUGA CGGCAU CA _E4T 10 ACTGG ( SEQ I D CACUGG ( SEQ I D UUGGCCGCACACUGG ( SEQ I D NO :NO : 161 ) NO : 162 ) 163 )Cas l2 I 2 TTTT CATTATTAGGCATGT CAUUAUUAGGCAUG AGAAA UCCGUCUUUCA UUGA CGGCAUUA _E4T 11 TGGAG ( SEQ I D UUGGAG ( SEQ I D UUAGGCAUGUUGGAG ( SEQ I D NO :NO : 164 ) NO : 165 ) 166 )Cas l2 I 2 ATTG AAGATTCTGTGATCT AAGAUU CU GU GAU C AGAAA UCCGUCUUUCA UUGA CGGAAGAUAttorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized} _E4T12 CACTC ( SEQ ID UCACUC ( SEQ ID UCUGUGAUCUCACUC ( SEQ ID NO :NO : 167 ) NO : 168 ) 169 )Cas l2 I2 CTTG GGCAATGTGACTGCT GGCAAUGUGACUGC AGAAAUCCGUCUUUCAUUGACGGGGCAA _E4T13 GACAA ( SEQ ID UGACAA ( SEQ ID UGUGACUGCUGACAA ( SEQ ID NO :NO : 170 ) NO : 171 ) 172 )Cas l2 I2 GTTG GAGACTTGGGCAATG GAGACUUGGGCAAU AGAAA UCCGUCUUUCA UUGA CGGGAGAC _E4T14 TGACT ( SEQ ID GUGACU ( SEQ ID UUGGGCAAUGUGACU ( SEQ ID NO :NO : 173 ) NO : 174 ) 175 )Cas l2 I2 ATTA GGCATGTTGGAGACT GGCAUGUUGGAGAC AGAAAUCCGUCUUUCAUUGACGGGGCAU _E4T15 TGGGC ( SEQ ID UUGGGC ( SEQ ID GUUGGAGACUUGGGC ( SEQ ID NO :NO : 176 ) NO : 177 ) 178 )Cas l2 I2 ATTA TTAGGCATGTTGGAG UUAGGCAUGUUGGA AGAAA UCCGUCUUUCA UUGA CGGUUAGG _E4T16 ACTTG ( SEQ ID GACUUG ( SEQ ID CAUGUUGGAGACUUG ( SEQ ID NO :NO : 179 ) NO : 180 ) 181 )Cas l2 I2 TTTC ATTATTAGGCATGTT AUUAUUAGGCAUGU AGAAA UCCGUCUUUCA UUGA CGGAUUAU _E4T17 GGAGA ( SEQ ID UGGAGA ( SEQ ID UAGGCAUGUUGGAGA ( SEQ ID NO :NO : 182 ) NO : 183 ) 184 )Cas l2 I2 TTTT TCATTATTAGGCATG UCAUUAUUAGGCAU AGAAA UCCGUCUUUCA UUGA CGGU CAUU _E4T18 TTGGA ( SEQ ID GUUGGA ( SEQ ID AUUAGGCAUGUUGGA ( SEQ ID NO :NO : 185 ) NO : 186 ) 187 )Cas l2 I2 CTTT TTCATTATTAGGCAT UUCAUUAUUAGGCA AGAAA UCCGUCUUUCA UUGA CGGUU CAU _E4T19 GTTGG ( SEQ ID UGUUGG ( SEQ ID UAUUAGGCAUGUUGG ( SEQ ID NO :NO : 188 ) NO : 189 ) 190 )Cas l2 I2 ATTC TGTGATCTCACTCTC UGUGAUCUCACUCU AGAAA UCCGUCUUUCA UUGA CGGU GU GA _E4T20 AGGAG ( SEQ ID CAGGAG ( SEQ ID UCUCACUCUCAGGAG ( SEQ ID NO :NO : 191 ) NO : 192 ) 193 )Cas l2 I2 ATTA CACCACAAGCCAAAC CACCACAAGCCAAA AGAAA UCCGUCUUUCA UUGA CGGC AC CA _E5T1 GACTT ( SEQ ID CGACUU ( SEQ ID CAAGCCAAACGACUU ( SEQ ID NO :NO : 194 ) NO : 195 ) 196 )Cas l2 I2 CTTG CAGCGTTTCCTGTCT CAGCGUUUCCUGUC AGAAA UCCGUCUUUCA UUGA CGGCAGC G _E5T2 TTGTA ( SEQ ID UUUGUA ( SEQ ID UUUCCUGUCUUUGUA ( SEQ ID NO :NO : 197 ) NO : 198 ) 199 )Cas l2 I2 GTTT CCTGTCTTTGTACTT CCUGUCUUUGUACU AGAAA UCCGUCUUUCA UUGA CGGC CU GU _E5T3 TCTTC ( SEQ ID UUCUUC ( SEQ ID CUUUGUACUUUCUUC ( SEQ ID NO :NO : 200 ) NO : 201 ) 202 )Cas l2 I2 TTTC CTGTCTTTGTACTTT CUGUCUUUGUACUU AGAAA UCCGUCUUUCA UUGA CGGCU GU C _E5T4 CTTCA ( SEQ ID UCUUCA ( SEQ ID UUUGUACUUUCUUCA ( SEQ ID NO :NO : 203 ) NO : 204 ) 205 )Cas l2 I2 CTTT GTACTTTCTTCATTT GUACUUUCUUCAUU AGAAA UCCGUCUUUCA UUGA CGGGUACU _E5T5 CCACC ( SEQ ID UCCACC ( SEQ ID UUCUUCAUUUCCACC ( SEQ ID NO :NO : 206 ) NO : 207 ) 208 )Cas l2 I2 CTTC ATTTCCACCTTTGCC AUUUCCACCUUUGC AGAAA UCCGUCUUUCA UUGA CGGAUUU C _E5T6 CAAGT ( SEQ ID CCAAGU ( SEQ ID CACCUUUGCCCAAGU ( SEQ ID NO :NO : 209 ) NO : 210 ) 211 )Cas l2 I2 CTTT CTTCATTTCCACCTT CUUCAUUUCCACCU AGAAA UCCGUCUUUCA UUGA CGGCUU CA _E5T7 TGCCC ( SEQ ID UUGCCC ( SEQ ID UUUCCACCUUUGCCC ( SEQ ID NO :NO : 212 ) NO : 213 ) 214 )Cas l2 I2 TTTC TTCATTTCCACCTTT UUCAUUUCCACCUU AGAAA UCCGUCUUUCA UUGA CGGUU CAU _E5T8 GCCCA ( SEQ ID UGCCCA ( SEQ ID UUCCACCUUUGCCCA ( SEQ ID NO :NO : 215 ) NO : 216 ) 217 )Cas l2 I2 ATTG GGCGATCCCAATTAC GGCGAUCCCAAUUA A GAAA UCCGUCUUUCA UUGA CGGG G C GA _E5T9 ACCAC ( SEQ ID CACCAC ( SEQ ID UCCCAAUUACACCAC ( SEQ ID NO :NO : 218 ) NO : 219 ) 220 )Cas l2 I2 ATTT CCACCTTTGCCCAAG CCACCUUUGCCCAA AGAAA UCCGUCUUUCA UUGA CGGC CAC C _E5T10 TCATC ( SEQ ID GUCAUC ( SEQ ID UUUGCCCAAGUCAUC ( SEQ ID NO :NO : 221 ) NO : 222 ) 223 )Cas l2 I2 TTTC CACCTTTGCCCAAGT CACCUUUGCCCAAG AGAAA UCCGUCUUUCA UUGA CGGCAC CUE5T11 CAT CT UCAUCU ( SEQ ID UUGCCCAAGUCAUCU ( SEQ ID NO :Attorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized}( SEQ ID NO : NO : 225 ) 226 )224 )Cas l2 I2 TTTG TACTTTCTTCATTTC UACUUUCUUCAUUU AGAAA UCCGUCUUUCA UUGA CGGUACUU _E5T12 CACCT ( SEQ ID CCACCU ( SEQ ID UCUUCAUUUCCACCU ( SEQ ID NO :NO : 227 ) NO : 228 ) 229 )Cas l2 I2 TTTA TTGGGCGATCCCAAT UUGGGCGAUCCCAA AGAAA UCCGUCUUUCA UUGA CGGUU GGG _E5T13 TACAC ( SEQ ID UUACAC ( SEQ ID CGAUCCCAAUUACAC ( SEQ ID NO :NO : 230 ) NO : 231 ) 232 )Cas l2 I2 GTTT GGCTTGTGGTGTAAT GGCUUGUGGUGUAA AGAAAUCCGUCUUUCAUUGACGGGGCUU _E5T14 TGGGA SEQ ID UUGGGA ( SEQ ID GUGGUGUAAUUGGGA ( SEQ ID NO :NO : 233 ) NO : 234 ) 235 )Cas l2 I2 CTTG TGGTGTAATTGGGAT UGGUGUAAUUGGGA AGAAA UCCGUCUUUCA UUGA CGGU GGU G _E5T16 CGCCC ( SEQ ID UCGCCC ( SEQ ID UAAUUGGGAUCGCCC ( SEQ ID NO :NO : 236 ) NO : 237 ) 238 )Cas l2 I2 TTTG GCTTGTGGTGTAATT GCUUGUGGUGUAAU AGAAA UCCGUCUUUCA UUGA CGGGCUU G _E5T17 GGGAT ( SEQ ID UGGGAU ( SEQ ID UGGUGUAAUUGGGAU ( SEQ ID NO :NO : 239 ) NO : 240 ) 241 )Cas l2 I2 CTTG GGCAAAGGT GGAAAT GGCAAAGGUGGAAA AGAAAUCCGUCUUUCAUUGACGGGGCAA _E5T18 GAAGA ( SEQ ID UGAAGA ( SEQ ID AGGUGGAAAUGAAGA ( SEQ ID NO :NO : 242 ) NO : 243 ) 244 )Cas l2 I2 TTTA CAGGTCCATGAAAAA CAGGUCCAUGAAAA AGAAA UCCGUCUUUCA UUGA CGGCAGGU _E5T19 GCAGA ( SEQ ID AGCAGA ( SEQ ID CCAUGAAAAAGCAGA ( SEQ ID NO :NO : 245 ) NO : 246 ) 247 )Cas l2 I2 TTTT ACAGGTCCATGAAAA ACAGGUCCAUGAAA AGAAA UCCGUCUUUCA UUGA CGGACAGG _E5T20 AGCAG ( SEQ ID AAGCAG ( SEQ ID UCCAUGAAAAAGCAG ( SEQ ID NO :NO : 248 ) NO : 249 ) 250 )Cas l2 I2 TTTT TACAGGTCCATGAAA UACAGGUCCAUGAA AGAAA UCCGUCUUUCA UUGA CGGUACAG _E5T21 AAGCA ( SEQ ID AAAGCA ( SEQ ID GUCCAUGAAAAAGCA ( SEQ ID NO :NO : 251 ) NO : 252 ) 253 )Cas l2 I2 TTTT TTACAGGTCCATGAA UUACAGGUCCAUGA AGAAA UCCGUCUUUCA UUGA CGGUU ACA _E5T22 AAAGC ( SEQ ID AAAAGC ( SEQ ID GGUCCAUGAAAAAGC ( SEQ ID NO :NO : 254 ) NO : 255 ) 256 )Cas l2 I2 ATTT TTTACAGGTCCATGA UUUACAGGUCCAUG AGAAA UCCGUCUUUCA UUGA CGGUUU AC _E5T23 AAAAG ( SEQ ID AAAAAG ( SEQ ID AGGUCCAUGAAAAAG ( SEQ ID NO :NO : 257 ) NO : 258 ) 259 )Cas l2 I2 CTTA AAAT T T T T T AC AG GT AAAUUUUUUACAGG AGAAA UCCGUCUUUCA UUGA CGGAAAUU _E5T24 CCATG ( SEQ ID UCCAUG ( SEQ ID UUUUACAGGUCCAUG ( SEQ ID NO :NO : 260 ) NO : 261 ) 262 )Cas l2 I2 CTTC T T AAAAT T T T T T AC A UUAAAAUUUUUUAC AGAAA UCCGUCUUUCA UUGA CGGUUAAA _E5T25 GGTCC ( SEQ ID AGGUCC ( SEQ ID AUUUUUUACAGGUCC ( SEQ ID NO :NO : 263 ) NO : 264 ) 265 )Cas l2 I2 CTTT GCCCAAGTCATCTGC GCCCAAGUCAUCUG AGAAA UCCGUCUUUCA UUGA CGGGC C CA _E5T27 TTTTT ( SEQ ID CUUUUU ( SEQ ID AGUCAUCUGCUUUUU ( SEQ ID NO :NO : 266 ) NO : 267 ) 268 )Cas l2 I2 GTTT ATTGGGCGATCCCAA AUUGGGCGAUCCCA AGAAA UCCGUCUUUCA UUGA CGGAUU GG _E5T28 TTACA ( SEQ ID AUUACA ( SEQ ID GCGAUCCCAAUUACA ( SEQ ID NO :NO : 269 ) NO : 270 ) 271 )Cas l2 I2 TTTG CCCAAGTCATCTGCT CCCAAGUCAUCUGC AGAAA UCCGUCUUUCA UUGA CGGC C CAA _E5T29 TTTTC ( SEQ ID UUUUUC ( SEQ ID GUCAUCUGCUUUUUC ( SEQ ID NO :NO : 272 ) NO : 273 ) 274 )Type V— GT TA TGGCGACGAAGGCCG UGGCGACGAAGGCC CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_ElT TGTGC ( SEQ ID GUGUGC ( SEQ ID UAAACAACUGGCGACGAAGGCCGUGUGC 1 NO : 26 ) NO : 27 ) ( SEQ ID NO : 275 )Type V— CTTG CCTTCTGCTCGAAAT CCUUCUGCUCGAAA CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_ElT TGATG ( SEQ ID UUGAUG ( SEQ ID UAAA CAA CCCUUCUGCUC GAAAUU GAU G 2 NO : 29 ) NO : 30 ) ( SEQ ID NO : 276 )Type V— ATTG ATGATGCCCTGCACT AUGAUGCCCUGCAC CUUGUUGUAUAUGUCCUUUUAUAGGUAUSx3 E1T GGGCC ( SEQ ID UGGGCC ( SEQ ID UAAACAACAU GAU GCCCUGCACU GGGCCAttorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized} 3 NO : 35 ) NO : 36 ) ( SEQ I D NO : 277 )Type V— TTTG CACTTTTCTTAAAGG CACUUUU CUUAAAG CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E2T AAAGT ( SEQ I D GAAAGU ( SEQ I D UAAA CAA CCACUUUU CUUAAAGGAAAGU 1 NO : 74 ) NO : 75 ) ( SEQ I D NO : 278 )Type V— CTTA AAGGAAAGTAAT GGA AAGGAAAGUAAUGG CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E2T CCAGT ( SEQ I D ACCAGU ( SEQ I D UAAA CAA GAAG GAAAGU AAU G GAC C AGU 2 NO : 62 ) NO : 63 ) ( SEQ I D NO : 279 )Type V— ATTA AAGGACT GACT GAAG AAGGACUGACUGAA CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E2T GCCTG ( SEQ I D GGCCUG ( SEQ I D UAAA CAA GAAG GACU GACU GAAG G C CU G 3 NO : 59 ) NO : 60 ) ( SEQ I D NO : 280 )Type V— ATTA TCTCCAAACTCATGA U CU C CAAACU CAU G CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E2T ACATG ( SEQ I D AACAUG ( SEQ I D UAAA CAA GU CU C CAAACU CAU GAACAU G 5 NO : 53 ) NO : 54 ) ( SEQ I D NO : 281 )Type V— TTTA ATGCTTCCCCACACC AUGCUUCCCCACAC CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E2T TTCAC ( SEQ I D CUUCAC ( SEQ I D UAAA CAA CAU GCUU C C C CACAC CUU CAC 6 NO : 44 ) NO : 45 ) ( SEQ I D NO : 282 )Type V— TTTG GCCCACCGTGTTTTC GCCCACCGUGUUUU CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E3T TGGAT ( SEQ I D CUGGAU ( SEQ I D UAAA CAA CGC C CAC C GU GUUUU CU GGAU 2 NO : 92 ) NO : 93 ) ( SEQ I D NO : 283 )Type V— GT TA CCTCTCTTCATCCTT CCUCUCUUCAUCCU CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E3T TGGCC ( SEQ I D UUGGCC ( SEQ I D UAAA CAA CCCUCUCUUCAUCCUUUGGCC 3 NO : 83 ) NO : 84 ) ( SEQ I D NO : 284 )Type V— TTTA ATCCTCTATCCAGAA AU C CU CUAU C CAGA CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E3T AACAC ( SEQ I D AAACAC ( SEQ I D UAAA CAA CAU C CU CUAU C CAGAAAACAC 4 NO : 119 ) NO : 120 ) ( SEQ I D NO : 285 )Type V— GT TA AGCATCTTGTTACCT AGCAUCUUGUUACC CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E3T CTCTT ( SEQ I D UCUCUU ( SEQ I D UAAA CAA CAGCAUCUUGUUACCUCUCUU 5 NO : 110 ) NO : 111 ) ( SEQ I D NO : 286 )Type V— CTTA TAAATAGGCTGTACC UAAAUAGGCUGUAC CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E3T AGTGC ( SEQ I D CAGUGC ( SEQ I D UAAA CAA CU AAAU AG G CU GU AC C AGU G C 6 NO : 137 ) NO : 138 ) ( SEQ I D NO : 287 )Type V— CTTG TTACCTCTCTTCATC UUACCUCUCUUCAU CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E3T CTTTG ( SEQ I D CCUUUG ( SEQ I D UAAA CAA CUUAC CU CU CUU CAU C CUUU G 7 NO : 104 ) NO : 105 ) ( SEQ I D NO : 288 )Type V— TTTA TGAAAACTTACCACC U GAAAACUUAC CAC CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E4T AGTGT ( SEQ I D CAGUGU ( SEQ I D UAAA CAA CU GAAAACUUAC CAC CAGU GU 1 NO : 152 ) NO : 153 ) ( SEQ I D NO : 289 )Type V— ATTG CCCAAGTCTCCAACA CCCAAGUCUCCAAC CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E4T TGCCT ( SEQ I D AUGCCU ( SEQ I D UAAA CAA CC C CAAGU CU C CAACAU GC CU 2 NO : 290 ) NO : 291 ) ( SEQ I D NO : 292 )Type V— TTTG TCAGCAGTCACATTG UCAGCAGUCACAUU CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E4T CCCAA ( SEQ I D GCCCAA ( SEQ I D UAAA CAA CU C AG C AGU C AC AUU G C C CAA 3 NO : 140 ) NO : 141 ) ( SEQ I D NO : 293 )Type V— CTTA CCACCAGTGTGCGGC CCACCAGUGUGCGG CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E4T CAATG ( SEQ I D CCAAUG ( SEQ I D UAAA CAA CC CAC CAGU GU G C G G C C AAU G 4 NO : 149 ) NO : 150 ) ( SEQ I D NO : 294 )Type V— CTTG GGCAATGTGACTGCT GGCAAUGUGACUGC CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E4T GACAA ( SEQ I D UGACAA ( SEQ I D UAAA CAA CG G C AAU GU GACU G CU GAC AA 6 NO : 170 ) NO : 171 ) ( SEQ I D NO : 295 )Type V— ATTG AAGATTCTGTGATCT AAGAUU CU GU GAU C CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E4T CACTC ( SEQ I D UCACUC ( SEQ I D UAAA CAA CAAGAUU CU GU GAU CU CACU C 7 NO : 167 ) NO : 168 ) ( SEQ I D NO : 296 )Type V— GTTG GAGACTTGGGCAATG GAGACUUGGGCAAU CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E4T TGACT ( SEQ I D GUGACU ( SEQ I D UAAA CAA CGAGACUU G G G C AAU GU GACU 8 NO : 173 ) NO : 174 ) ( SEQ I D NO : 297 )Type V— ATTA GGCATGTTGGAGACT GGCAUGUUGGAGAC CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E4T TGGGC ( SEQ I D UUGGGC ( SEQ I D UAAA CAA CGGCAUGUUGGAGACUUGGGC9 NO : 176 ) NO : 177 ) ( SEQ I D NO : 298 )Attorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized} Type V— ATTA TTAGGCATGTTGGAG UUAGGCAUGUUGGA CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E4T ACTTG ( SEQ ID GACUUG ( SEQ ID UAAA CAA CUUAGGCAU GUU GGAGACUU G 10 NO : 179 ) NO : 180 ) ( SEQ ID NO : 299 )Type V— ATTG CATCATTGGCCGCAC CAUCAUUGGCCGCA CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E4T ACTGG ( SEQ ID CACUGG ( SEQ ID UAAA CAA CCAUCAUUGGCCGCACACUGG 11 NO : 161 ) NO : 162 ) ( SEQ ID NO : 300 )Type V— ATTA CACCACAAGCCAAAC CACCACAAGCCAAA CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E5T GACTT ( SEQ ID CGACUU ( SEQ ID UAAA CAA CCAC CACAAGC CAAAC GACUU 1 NO : 194 ) NO : 195 ) ( SEQ ID NO : 301 )Type V— ATTG GGCGATCCCAATTAC GGCGAUCCCAAUUA CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E5T ACCAC ( SEQ ID CACCAC ( SEQ ID UAAA CAA CGGC GAU C C C AAUU AC AC C AC 2 NO : 218 ) NO : 219 ) ( SEQ ID NO : 302 )Type V— TTTA TTGGGCGATCCCAAT UUGGGCGAUCCCAA CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E5T TACAC ( SEQ ID UUACAC ( SEQ ID UAAA CAA CUU G G G C GAU C C C AAUU AC AC 3 NO : 230 ) NO : 231 ) ( SEQ ID NO : 303 )Type V— CTTG TGGTGTAATTGGGAT UGGUGUAAUUGGGA CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E5T CGCCC ( SEQ ID UCGCCC ( SEQ ID UAAA CAA CUGGUGUAAUUGGGAUCGCCC 5 NO : 236 ) NO : 237 ) ( SEQ ID NO : 304 )Type V— CTTG GGCAAAGGT GGAAAT GGCAAAGGUGGAAA CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E5T GAAGA ( SEQ ID UGAAGA ( SEQ ID UAAACAACGGCAAAGGUGGAAAUGAAGA 6 NO : 242 ) NO : 243 ) ( SEQ ID NO : 305 )Type V— TTTA CAGGTCCATGAAAAA CAGGUCCAUGAAAA CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E5T GCAGA ( SEQ ID AGCAGA ( SEQ ID UAAA CAA CC AG GU C C AU GAAAAAG C AGA 7 NO : 245 ) NO : 246 ) ( SEQ ID NO : 306 )Type V— CTTA AAAT T T T T T AC AG GT AAAUUUUUUACAGG CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E5T CCATG ( SEQ ID UCCAUG ( SEQ ID UAAA CAA CAAAUUUUUUACAGGU C CAU G 8 NO : 260 ) NO : 261 ) ( SEQ ID NO : 307 )Type V— TTTG TACTTTCTTCATTTC UACUUUCUUCAUUU CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E5T CACCT ( SEQ ID CCACCU ( SEQ ID UAAA CAA CUACUUU CUU CAUUU C CAC CU 10 NO : 227 ) NO : 228 ) ( SEQ ID NO : 308 )Type V— TTTG GCTTGTGGTGTAATT GCUUGUGGUGUAAU CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E5T GGGAT ( SEQ ID UGGGAU ( SEQ ID UAAA CAA CGCUUGUGGUGUAAUUGGGAU 11 NO : 239 ) NO : 240 ) ( SEQ ID NO : 309 )Type V— TTTG CCCAAGTCATCTGCT CCCAAGUCAUCUGC CUUGUUGUAUAUGUCCUUUUAUAGGUAU Sx3_E5T TTTTC ( SEQ ID UUUUUC ( SEQ ID UAAA CAA CC C CAAGU CAU CU GCUUUUU C 12 NO : 272 ) NO : 273 ) ( SEQ ID NO : 310 )NK_E1T1 TGG CGGCGTGGCCTAGCG CGGCGUGGCCUAGC CGGCGUGGCCUAGCGAGUUAGUUACAGU AGTTA ( SEQ ID GAGUUA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 311 ) NO : 312 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGGACA UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 313 ) NK_E1T2 CGG GTCGCCCTTCAGCAC GUCGCCCUUCAGCA GUCGCCCUUCAGCACGCACAGUUACAGU GCACA ( SEQ ID CGCACA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 314 ) NO : 315 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGGACA UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 316 ) NK_E1T3 GGG AATTGATGATGCCCT AAUUGAUGAUGCCC AAUU GAU GAU GC C CU GCACU GUUA CAGU GCACT ( SEQ ID UGCACU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 317 ) NO : 318 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUUAGGACA UUUAAA UUUAAAAA CUAUUCAGAttorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized}CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 319 ) NK_E1T4 AGG TCAATTTCGAGCAGA UCAAUUUCGAGCAG UCAAUUUCGAGCAGAAGGCAGUUACAGU AGGCA ( SEQ ID AAGGCA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 320 ) NO : 321 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 322 ) NK_E1T5 AGG CAT CAT C AAT T T C GA CAU CAU CAAUUU C G CAU CAU CAAUUU C GAGCAGAGUUA CAGU GCAGA ( SEQ ID AGCAGA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 323 ) NO : 324 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 325 ) NK_E1T6 GGG AAGGGCGACGGCCCA AAGGGCGACGGCCC AAGGGCGACGGCCCAGU GC AGUUACAGU GTGCA ( SEQ ID AGUGCA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 326 ) NO : 327 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 328 ) NK_E1T7 TGG AAATTGATGATGCCC AAAUUGAUGAUGCC AAAUU GAU GAU GC C CU GCAC GUUA CAGU TGCAC ( SEQ ID CUGCAC ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 329 ) NO : 330 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 331 ) NK_E1T8 GGG GTGTGCGTGCTGAAG GUGUGCGUGCUGAA GUGUGCGUGCUGAAGGGCGAGUUACAGU GGCGA ( SEQ ID GGGCGA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 332 ) NO : 333 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 334 ) NK_E1T9 GGG AAGGCCGTGTGCGTG AAGGCCGUGUGCGU AAGGCCGUGUGCGUGCUGAAGUUACAGU CTGAA ( SEQ ID GCUGAA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 335 ) NO : 336 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 337 ) NK_E1T1 AGG GAAGGCCGTGTGCGT GAAGGCCGUGUGCG GAAGGCCGUGUGCGUGCUGAGUUACAGU 0 GCTGA ( SEQ ID UGCUGA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 338 ) NO : 339 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGCAGA ( SEQ ID NO : 340 )Attorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized} NK_E1T1 AGG CTAGCGAGTTATGGC CUAGCGAGUUAUGG CUAGCGAGUUAUGGCGACGAGUUACAGU 1 GACGA ( SEQ ID CGACGA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 341 ) NO : 342 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 343 ) NK_E1T1 AGG GAAGGGCGACGGCCC GAAGGGCGACGGCC GAAGGGCGACGGCCCAGUGCGUUACAGU 2 AGTGC ( SEQ ID CAGUGC ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 344 ) NO : 345 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 346 ) NK_E2T1 TGG GGATTCCATGTTCAT GGAUUCCAUGUUCA GGAUU C CAU GUU CAU GAGUU GUUA CAGU GAGTT ( SEQ ID UGAGUU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 347 ) NO : 348 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 349 ) NK_E2T2 TGG ATGCTTCCCCACACC AUGCUUCCCCACAC AU GCUU C C C CACAO CUU CAC GUUA CAGU TTCAC ( SEQ ID CUUCAC ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 44 ) NO : 45 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 350 ) NK_E2T3 AGG CAT GAACAT GGAAT C CAUGAACAUGGAAU CAUGAACAUGGAAUCCAUGCGUUACAGU CATGC ( SEQ ID CCAUGC ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 351 ) NO : 352 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 353 ) NK_E2T4 TGG TATCTCCAAACTCAT UAU CUC CAAACU CA UAU CUC CAAACU CAU GAACAGUUA CAGU GAACA ( SEQ ID UGAACA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 354 ) NO : 355 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 356 ) NK_E2T5 GGG TTGGAGATAATACAG UUGGAGAUAAUACA UUGGAGAUAAUACAGCAGGUGUUACAGU CAGGT ( SEQ ID GCAGGU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 357 ) NO : 358 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 359 ) NK_E2T6 TGG TTTGGAGATAATACA UUUGGAGAUAAUAC UUUGGAGAUAAUACAGCAGGGUUACAGU GCAGG ( SEQ ID AGCAGG ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUANO : 360 ) NO : 361 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CGAttorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized}CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 362 ) NK_E2T7 AGG GAGTTTGGAGATAAT GAGUUUGGAGAUAA GAGUUUGGAGAUAAUACAGCGUUACAGU ACAGC ( SEQ ID UACAGC ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 363 ) NO : 364 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 365 ) NK_E2T8 TGG GGACTGACTGAAGGC GGACUGACUGAAGG GGACUGACUGAAGGCCUGCAGUUACAGU CTGCA ( SEQ ID CCUGCA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 366 ) NO : 367 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 368 ) NK_E2T9 GGG TAATGGACCAGTGAA UAAUGGACCAGUGA UAAUGGACCAGUGAAGGUGU GUUA CAGU GGTGT ( SEQ ID AGGUGU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 369 ) NO : 370 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 371 ) NK_E2T1 AGG AAGGTGTGGGGAAGC AAGGUGUGGGGAAG AAGGUGUGGGGAAGCAUUAAGUUACAGU 0 ATTAA ( SEQ ID CAUUAA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 372 ) NO : 373 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 374 ) NK_E2T1 GGG AATGGACCAGTGAAG AAUGGACCAGUGAA AAU G GAO CAGU GAAG GU GU G GUUA CA GU 1 GTGTG ( SEQ ID GGUGUG ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 375 ) NO : 376 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 377 ) NK_E2T1 TGG GTAATGGACCAGTGA GUAAUGGACCAGUG GU AAU G GAO CAGU GAAG GU G GUUA CA GU 2 AGGTG ( SEQ ID AAGGUG ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 378 ) NO : 379 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 380 ) NK_E2T1 AGG GGAAAGTAATGGACC GGAAAGUAAUGGAC G GAAAGU AAU G GAC CAGU GAGUUA CA GU 3 AGTGA ( SEQ ID CAGUGA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 381 ) NO : 382 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUUAGG AC A UUUAAA UUUAAAAA CUAUUCAGAttorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized}CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 383 ) NK_E2T1 TGG CTTTTCTTAAAGGAA CUUUUCUUAAAGGA CUUUUCUUAAAGGAAAGUAAGUUACAGU 4 AGTAA ( SEQ ID AAGUAA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 384 ) NO : 385 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 386 ) NK_E2T1 AGG CAACTTTGCACTTTT CAACUUUGCACUUU CAACUUUGCACUUUUCUUAAGUUACAGU 5 CTTAA ( SEQ ID UCUUAA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 387 ) NO : 388 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 389 ) NK_E2T1 AGG AGCATTAAAGGACTG AGCAUUAAAGGACU AGCAUUAAAGGACUGACUGAGUUACAGU 6 ACTGA ( SEQ ID GACUGA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 390 ) NO : 391 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 392 ) NK_E3T1 TGG TGTTACCTCTCTTCA UGUUACCUCUCUUC UGUUACCUCUCUUCAUCCUUGUUACAGU TCCTT ( SEQ ID AUCCUU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 393 ) NO : 394 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 395 ) NK_E3T3 AGG CTGGATAGAGGATTA CUGGAUAGAGGAUU OU GGAUAGAGGAUUAAAGU G GUUA CAGU AAGTG ( SEQ ID AAAGUG ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 98 ) NO : 99 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 396 ) NK_E3T4 AGG CCACCGTGTTTTCTG CCACCGUGUUUUCU C CAO C GU GUUUU OU GGAU AG GUUA CAGU GAT AG ( SEQ ID GGAUAG ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 397 ) NO : 398 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 399 ) NK_E3T5 TGG CTTTGGCCCACCGTG CUUUGGCCCACCGU CUUUGGCCCACCGU GUUUUCGUUACAGU TTTTC ( SEQ ID GUUUUC ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 400 ) NO : 401 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGCAGA ( SEQ ID NO : 402 )Attorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized} NK_E3T6 AGG GTGGGCCAAAGGATG GUGGGCCAAAGGAU GUGGGCCAAAGGAUGAAGAGGUUACAGU AAGAG ( SEQ ID GAAGAG ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 403 ) NO : 404 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GC CAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 405 ) NK_E3T7 AGG CAGAAAACACGGTGG CAGAAAACACGGUG CAGAAAACACGGUGGGCCAAGUUACAGU GCCAA ( SEQ ID GGCCAA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 406 ) NO : 407 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GC CAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 408 ) NK_E3T8 GGG CTCTATCCAGAAAAC OU CUAU C CAGAAAA CU CUAU C CAGAAAACAC GGU GUUA CAGU ACGGT ( SEQ ID CACGGU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 409 ) NO : 410 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GC CAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 411 ) NK_E3T9 TGG CCTCTATCCAGAAAA CCU CUAU C CAGAAA CCU CUAU C CAGAAAACAC GG GUUA CAGU CACGG ( SEQ ID ACACGG ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 412 ) NO : 413 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GC CAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 414 ) NK_E3T1 GGG AATCCTCTATCCAGA AAU CCU CUAU C CAG AAU CCU CUAU C CAGAAAACAGUUA CAGU 0 AAACA ( SEQ ID AAAACA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 116 ) NO : 117 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GC CAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 415 ) NK_E3T1 AGG TAAATAGGCTGTACC UAAAUAGGCUGUAC UAAAUAGGCUGUACCAGUGCGUUACAGU 1 AGTGC ( SEQ ID CAGUGC ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 137 ) NO : 138 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GC CAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 416 ) NK_E3T1 AGG TTTTTCTTCTTCTTA UUUUUCUUCUUCUU UUUUUCUUCUUCUUAUAAAU GUUA CAGU 2 TAAAT ( SEQ ID AUAAAU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 417 ) NO : 418 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GC CAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 419 ) NK_E4T1 GGG AGAATCTTCAATAGA AGAAU CUU CAAUAG AGAAU CUU CAAUAGACACAU GUUA CAGU CACAT ( SEQ ID ACACAU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUANO : 420 ) NO : 421 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CGAttorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized}CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 422 ) NK_E4T2 TGG GTGTGCGGCCAATGA GUGUGCGGCCAAUG GUGUGCGGCCAAUGAUGCAAGUUACAGU TGCAA ( SEQ ID AUGCAA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 423 ) NO : 424 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 425 ) NK_E4T3 TGG CATCATTGGCCGCAC CAUCAUUGGCCGCA CAUCAUUGGCCGCACACUGGGUUACAGU ACTGG ( SEQ ID CACUGG ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 161 ) NO : 162 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 426 ) NK_E4T4 TGG TTGCATCATTGGCCG UUGCAUCAUUGGCC UUGCAUCAUUGGCCGCACACGUUACAGU CACAO ( SEQ ID GCACAC ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 427 ) NO : 428 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 429 ) NK_E4T5 TGG TCAGGAGACCATTGC UCAGGAGACCAUUG U CAGGAGAC CAUU GCAU CAU GUUA CAGU ATCAT ( SEQ ID CAUCAU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 430 ) NO : 431 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 432 ) NK_E4T6 AGG GATTCTGTGATCTCA GAUUCUGUGAUCUC GAUU CU GU GAU CU CACU CU C GUUA CAGU CTCTC ( SEQ ID ACUCUC ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 433 ) NO : 434 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 435 ) NK_E4T7 CGG GAAAACTTACCACCA GAAAACUUAC CAC C GAAAACUUAC CAC CAGU GU G GUUA CAGU GTGTG ( SEQ ID AGUGUG ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 436 ) NO : 437 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 438 ) NK_E4T8 TGG AAT GT GACT GCT GAC AAUGUGACUGCUGA AAU GU GACU GCU GACAAAGAGUUA CAGU AAAGA ( SEQ ID CAAAGA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 439 ) NO : 440 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUUAGG AC A UUUAAA UUUAAAAA CUAUUCAGAttorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized}CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 441 ) NK_E4T9 GGG ATTAGGCATGTTGGA AUUAGGCAUGUUGG AUUAGGCAUGUUGGAGACUU GUUA CAGU GACTT ( SEQ ID AGACUU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 442 ) NO : 443 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 444 ) NK_E4T1 TGG TATTAGGCATGTTGG UAUUAGGCAUGUUG UAUUAGGCAUGUUGGAGACUGUUACAGU 0 AGACT ( SEQ ID GAGACU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 445 ) NO : 446 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 447 ) NK_E4T1 TGG TTTTTCATTATTAGG UUUUUCAUUAUUAG UUUUUCAUUAUUAGGCAUGUGUUACAGU 1 CATGT ( SEQ ID GCAUGU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 448 ) NO : 449 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 450 ) NK_E4T1 AGG TCTGATGCTTTTTCA UCUGAUGCUUUUUC UCUGAUGCUUUUUCAUUAUU GUUA CAGU 2 TTATT ( SEQ ID AUUAUU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 451 ) NO : 452 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 453 ) NK_E4T1 TGG GACT GOT GACAAAGA GACUGCUGACAAAG GACU GCU GACAAAGAU GGU G GUUA CAGU 3 TGGTG ( SEQ ID AUGGUG ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 454 ) NO : 455 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 456 ) NK_E5T1 TGG ACATCCAAGGGAATG ACAUCCAAGGGAAU ACAUCCAAGGGAAU GUUUAU GUUA CAGU TTTAT ( SEQ ID GUUUAU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 457 ) NO : 458 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 459 ) NK_E5T2 GGG GTTTGGCTTGTGGTG GUUUGGCUUGUGGU GUUUGGCUUGUGGU GUAAUU GUUA CAGU TAATT ( SEQ ID GUAAUU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 460 ) NO : 461 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGCAGA ( SEQ ID NO : 462 )Attorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized} NK_E5T3 TGG CGTTTGGCTTGTGGT CGUUUGGCUUGUGG CGUUUGGCUUGUGGUGUAAU GUUA CAGU GTAAT ( SEQ ID UGUAAU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 463 ) NO : 464 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 465 ) NK_E5T4 TGG GCTGGAAGTCGTTTG GCUGGAAGUCGUUU GCUGGAAGUCGUUUGGCUUGGUUACAGU GCTTG ( SEQ ID GGCUUG ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 466 ) NO : 467 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 468 ) NK_E5T5 TGG AGGAAACGCTGGAAG AGGAAACGCUGGAA AGGAAACGCUGGAAGUCGUU GUUA CAGU TCGTT ( SEQ ID GUCGUU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 469 ) NO : 470 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 471 ) NK_E5T6 TGG AGTACAAAGACAGGA AGUACAAAGACAGG AGUACAAAGACAGGAAACGCGUUACAGU AACGC ( SEQ ID AAACGC ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 472 ) NO : 473 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 474 ) NK_E5T7 AGG AAAGCAGATGACTTG AAAGCAGAUGACUU AAAGCAGAUGACUUGGGCAAGUUACAGU GGCAA ( SEQ ID GGGCAA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 475 ) NO : 476 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 477 ) NK_E5T8 TGG GCAGATGACTTGGGC GCAGAUGACUUGGG GCAGAUGACUUGGGCAAAGGGUUACAGU AAAGG ( SEQ ID CAAAGG ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 478 ) NO : 479 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 480 ) NK_E5T9 GGG CAT GAAAAAGCAGAT CAUGAAAAAGCAGA CAU GAAAAAGCAGAU GACUU GUUA CAGU GACTT ( SEQ ID UGACUU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 481 ) NO : 482 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 483 ) NK_E5T1 TGG CCATGAAAAAGCAGA CCAUGAAAAAGCAG C CAU GAAAAAGCAGAU GACU GUUA CAGU 0 TGACT ( SEQ ID AUGACU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUANO : 484 ) NO : 485 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CGAttorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized}CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 486 ) NK_E5T1 AGG ATCTTCTTAAAATTT AU CUU CUUAAAAUU AUCUUCUUAAAAUUUUUUACGUUACAGU 1 TTTAC ( SEQ ID UUUUAC ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 487 ) NO : 488 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 489 ) NK_E5T1 GGG CATCCAAGGGAATGT CAUCCAAGGGAAUG CAUCCAAGGGAAUGUUUAUU GUUA CAGU 2 TTATT ( SEQ ID UUUAUU ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 490 ) NO : 491 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 492 ) NK_E5T1 AGG AAT GAAGAAAGT ACA AAU GAAGAAAGU AC AAU GAAGAAAGU ACAAAGAC GUUA CAGU 3 AAGAC ( SEQ ID AAAGAC ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 493 ) NO : 494 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 495 ) NK_E5T1 TGG CCAAGTCATCTGCTT CCAAGUCAUCUGCU CCAAGUCAUCUGCUUUUUCAGUUACAGU 4 TTTCA ( SEQ ID UUUUCA ( SEQ ID UAAGGCUCUGAAAAGAGCCUUAAUUGUA NO : 496 ) NO : 497 ) AAA CGCCUA UA CAGUGAAGGGA UA UA CG CUUGGGUUUGUCCAGCCUGAGCCUCUAU GCCAGAAA UGGCGCCUUCA UCGUGGGUU AGG AC A UUUAAA UUUAAAAA CUAUUCAG CACUGUUUGCUCUUGUCAGCUUGGUGGC AGA ( SEQ ID NO : 498 ) NA_E1T1 TGG CGGCGTGGCCTAGCG CGGCGUGGCCUAGC CGGCGUGGCCUAGCGAGUUAGUUACAGU AGTTA ( SEQ ID GAGUUA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 311 ) NO : 312 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 499 )NA_E1T2 GGG GTCGCCCTTCAGCAC GUCGCCCUUCAGCA GUCGCCCUUCAGCACGCACAGUUACAGU GCACA ( SEQ ID CGCACA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 314 ) NO : 315 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 500 )NA_E1T3 GGG AATTGATGATGCCCT AAUUGAUGAUGCCC AAUU GAU GAU GC C CU GCACU GUUA CAGU GCACT ( SEQ ID UGCACU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 317 ) NO : 318 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUGAUGUACGUUUGGGUAUAUAUCGCCAGCCAttorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized}UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 501 )NA_E1T4 AGG TCAATTTCGAGCAGA UCAAUUUCGAGCAG UCAAUUUCGAGCAGAAGGCAGUUACAGU AGGCA ( SEQ ID AAGGCA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 320 ) NO : 321 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 502 )NA_E1T5 AGG CAT CAT C AAT T T C GA CAU CAU CAAUUU C G CAU CAU CAAUUU C GAGCAGAGUUA CAGU GCAGA ( SEQ ID AGCAGA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 323 ) NO : 324 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 503 )NA_E1T6 GGG AAGGGCGACGGCCCA AAGGGCGACGGCCC AAGGGCGACGGCCCAGU GC AGUUACAGU GTGCA ( SEQ ID AGUGCA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 326 ) NO : 327 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 504 )NA_E1T7 TGG AAATTGATGATGCCC AAAUUGAUGAUGCC AAAUU GAU GAU GC C CU GCAC GUUA CAGU TGCAC ( SEQ ID CUGCAC ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 329 ) NO : 330 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 505 )NA_E1T8 GGG GTGTGCGTGCTGAAG GUGUGCGUGCUGAA GUGUGCGUGCUGAAGGGCGAGUUACAGU GGCGA ( SEQ ID GGGCGA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 332 ) NO : 333 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 506 )NA_E1T9 GGG AAGGCCGTGTGCGTG AAGGCCGUGUGCGU AAGGCCGUGUGCGUGCUGAAGUUACAGU CTGAA ( SEQ ID GCUGAA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 335 ) NO : 336 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( SEQ ID NO : 507 )Attorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized} NA_E1T1 AGG GAAGGCCGTGTGCGT GAAGGCCGUGUGCG GAAGGCCGUGUGCGUGCUGAGUUACAGU 0 GCTGA ( SEQ ID UGCUGA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 338 ) NO : 339 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 508 )NA_E1T1 AGG CTAGCGAGTTATGGC CUAGCGAGUUAUGG CUAGCGAGUUAUGGCGACGAGUUACAGU 1 GACGA ( SEQ ID CGACGA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 341 ) NO : 342 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 509 )NA_E1T1 AGG GAAGGGCGACGGCCC GAAGGGCGACGGCC GAAGGGCGACGGCCCAGUGCGUUACAGU 2 AGTGC ( SEQ ID CAGUGC ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 344 ) NO : 345 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 510 )NA_E2T1 TGG GGATTCCATGTTCAT GGAUUCCAUGUUCA GGAUU C CAU GUU CAU GAGUU GUUA CAGU GAGTT ( SEQ ID UGAGUU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 347 ) NO : 348 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 511 )NA_E2T2 TGG ATGCTTCCCCACACC AUGCUUCCCCACAC AU GCUU C C C CACAO CUU CAC GUUA CAGU TTCAC ( SEQ ID CUUCAC ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 44 ) NO : 45 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 512 )NA_E2T3 AGG CAT GAACAT GGAAT C CAUGAACAUGGAAU CAUGAACAUGGAAUCCAUGCGUUACAGU CATGC ( SEQ ID CCAUGC ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 351 ) NO : 352 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 513 )NA_E2T4 TGG TATCTCCAAACTCAT UAU CUC CAAACU CA UAU CUC CAAACU CAU GAACAGUUA CAGU GAACA ( SEQ ID UGAACA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 354 ) NO : 355 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUGAUGUACGUUUGGGUAUAUAUCGCCAGCCUGAACCUCUACGCCAGAAAUGGCAGCUUAttorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized}UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 514 )NA_E2T5 GGG TTGGAGATAATACAG UUGGAGAUAAUACA UUGGAGAUAAUACAGCAGGUGUUACAGU CAGGT ( SEQ ID GCAGGU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 357 ) NO : 358 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 515 )NA_E2T6 TGG TTTGGAGATAATACA UUUGGAGAUAAUAC UUUGGAGAUAAUACAGCAGGGUUACAGU GCAGG ( SEQ ID AGCAGG ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 360 ) NO : 361 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 516 )NA_E2T7 AGG GAGTTTGGAGATAAT GAGUUUGGAGAUAA GAGUUUGGAGAUAAUACAGCGUUACAGU ACAGC ( SEQ ID UACAGC ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 363 ) NO : 364 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 517 )NA_E2T8 TGG GGACTGACTGAAGGC GGACUGACUGAAGG GGACUGACUGAAGGCCUGCAGUUACAGU CTGCA ( SEQ ID CCUGCA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 366 ) NO : 367 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 518 )NA_E2T9 GGG TAATGGACCAGTGAA UAAUGGACCAGUGA U AAU G GAG C AGU GAAG GU GU GUUA GA GU GGTGT ( SEQ ID AGGUGU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 369 ) NO : 370 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 519 )NA_E2T1 AGG AAGGTGTGGGGAAGC AAGGUGUGGGGAAG AAGGUGUGGGGAAGCAUUAAGUUACAGU 0 ATTAA ( SEQ ID CAUUAA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 372 ) NO : 373 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( SEQ ID NO : 520 )Attorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized} NA_E2T1 GGG AATGGACCAGTGAAG AAUGGACCAGUGAA AAU G GAO C AGU GAAG GU GU G GUUA CA GU 1 GTGTG ( SEQ ID GGUGUG ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 375 ) NO : 376 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 521 )NA_E2T1 TGG GTAATGGACCAGTGA GUAAUGGACCAGUG GU AAU G GAO C AGU GAAG GU G GUUA CA GU 2 AGGTG ( SEQ ID AAGGUG ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 378 ) NO : 379 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 522 )NA_E2T1 AGG GGAAAGTAATGGACC GGAAAGUAAUGGAC G GAAAGU AAU G GAO C AGU GAGUUA CA GU 3 AGTGA ( SEQ ID CAGUGA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 381 ) NO : 382 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 523 )NA_E2T1 TGG CTTTTCTTAAAGGAA CUUUUCUUAAAGGA CUUUUCUUAAAGGAAAGUAAGUUACAGU 4 AGTAA ( SEQ ID AAGUAA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 384 ) NO : 385 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 524 )NA_E2T1 AGG CAACTTTGCACTTTT CAACUUUGCACUUU CAACUUUGCACUUUUCUUAAGUUACAGU 5 CTTAA ( SEQ ID UCUUAA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 387 ) NO : 388 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 525 )NA_E2T1 AGG AGCATTAAAGGACTG AGCAUUAAAGGACU AGCAUUAAAGGACUGACUGAGUUACAGU 6 ACTGA ( SEQ ID GACUGA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 390 ) NO : 391 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 526 )NA_E3T1 TGG TGTTACCTCTCTTCA UGUUACCUCUCUUC UGUUACCUCUCUUCAUCCUUGUUACAGU TCCTT ( SEQ ID AUCCUU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 393 ) NO : 394 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUGAUGUACGUUUGGGUAUAUAUCGCCAGCCUGAACCUCUACGCCAGAAAUGGCAGCUUAttorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized}UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 527 )NA_E3T3 AGG CTGGATAGAGGATTA CUGGAUAGAGGAUU OU GGAUAGAGGAUUAAAGU G GUUA CAGU AAGTG ( SEQ ID AAAGUG ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 98 ) NO : 99 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 528 )NA_E3T4 AGG CCACCGTGTTTTCTG CCACCGUGUUUUCU CCACCGUGUUUUCUGGAUAGGUUACAGU GAT AG ( SEQ ID GGAUAG ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 397 ) NO : 398 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 529 )NA_E3T5 TGG CTTTGGCCCACCGTG CUUUGGCCCACCGU CUUUGGCCCACCGU GUUUUCGUUACAGU TTTTC ( SEQ ID GUUUUC ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 400 ) NO : 401 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 530 )NA_E3T6 AGG GTGGGCCAAAGGATG GUGGGCCAAAGGAU GUGGGCCAAAGGAU GAAGAGGUUA CAGU AAGAG ( SEQ ID GAAGAG ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 403 ) NO : 404 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 531 )NA_E3T7 AGG CAGAAAACACGGTGG CAGAAAACACGGUG CAGAAAACACGGUGGGCCAAGUUACAGU GCCAA ( SEQ ID GGCCAA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 406 ) NO : 407 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 532 )NA_E3T8 GGG CTCTATCCAGAAAAC OU CUAU C CAGAAAA CU CUAU C CAGAAAACAC GGU GUUA CAGU ACGGT ( SEQ ID CACGGU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 409 ) NO : 410 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( SEQ ID NO : 533 )Attorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized} NA_E3T9 TGG CCTCTATCCAGAAAA CCU CUAU C CAGAAA CCU CUAU C CAGAAAACAC GG GUUA CAGU CACGG ( SEQ ID ACACGG ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 412 ) NO : 413 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 534 )NA_E3T1 CGG AATCCTCTATCCAGA AAU CCU CUAU C CAG AAU CCU CUAU C CAGAAAACAGUUA CAGU 0 AAACA ( SEQ ID AAAACA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 116 ) NO : 117 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 535 )NA_E3T1 AGG TAAATAGGCTGTACC UAAAUAGGCUGUAC UAAAUAGGCUGUACCAGUGCGUUACAGU 1 AGTGC ( SEQ ID CAGUGC ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 137 ) NO : 138 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 536 )NA_E3T1 AGG TTTTTCTTCTTCTTA UUUUUCUUCUUCUU UUUUUCUUCUUCUUAUAAAUGUUACAGU 2 TAAAT ( SEQ ID AUAAAU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 417 ) NO : 418 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 537 )NA_E4T1 CGG AGAATCTTCAATAGA AGAAU CUU CAAUAG AGAAU CUU CAAUAGACACAU GUUA CAGU CACAT ( SEQ ID ACACAU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 420 ) NO : 421 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 538 )NA_E4T2 TGG GTGTGCGGCCAATGA GUGUGCGGCCAAUG GUGUGCGGCCAAUGAUGCAAGUUACAGU TGCAA ( SEQ ID AUGCAA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 423 ) NO : 424 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 539 )NA_E4T3 TGG CATCATTGGCCGCAC CAUCAUUGGCCGCA CAUCAUUGGCCGCACACUGGGUUACAGU ACTGG ( SEQ ID CACUGG ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 161 ) NO : 162 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUGAUGUACGUUUGGGUAUAUAUCGCCAGCCUGAACCUCUACGCCAGAAAUGGCAGCUUAttorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized}UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 540 )NA_E4T4 TGG TTGCATCATTGGCCG UUGCAUCAUUGGCC UUGCAUCAUUGGCCGCACACGUUACAGU CACAC ( SEQ ID GCACAC ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 427 ) NO : 428 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 541 )NA_E4T5 TGG TCAGGAGACCATTGC UCAGGAGACCAUUG UCAGGAGACCAUUGCAUCAU GUUA CAGU ATCAT ( SEQ ID CAUCAU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 430 ) NO : 431 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 542 )NA_E4T6 AGG GATTCTGTGATCTCA GAUUCUGUGAUCUC GAUUCUGUGAUCUCACUCUCGUUACAGU CTCTC ( SEQ ID ACUCUC ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 433 ) NO : 434 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 543 )NA_E4T7 CGG GAAAACTTACCACCA GAAAACUUAC CAO C GAAAACUUAC CAC CAGU GU G GUUA CAGU GTGTG ( SEQ ID AGUGUG ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 436 ) NO : 437 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 544 )NA_E4T8 TGG AAT GT GACT GOT GAO AAUGUGACUGCUGA AAU GU GACU GCU GACAAAGAGUUA CAGU AAAGA ( SEQ ID CAAAGA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 439 ) NO : 440 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 545 )NA_E4T9 GGG ATTAGGCATGTTGGA AUUAGGCAUGUUGG AUUAGGCAUGUUGGAGACUU GUUA CAGU GACTT ( SEQ ID AGACUU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 442 ) NO : 443 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( SEQ ID NO : 546 )Attorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized} NA_E4T1 TGG TATTAGGCATGTTGG UAUUAGGCAUGUUG UAUUAGGCAUGUUGGAGACU GUUA CAGU 0 AGACT ( SEQ ID GAGACU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 445 ) NO : 446 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 547 )NA_E4T1 TGG TTTTTCATTATTAGG UUUUUCAUUAUUAG UUUUUCAUUAUUAGGCAUGUGUUACAGU 1 CATGT ( SEQ ID GCAUGU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 448 ) NO : 449 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 548 )NA_E4T1 AGG TCTGATGCTTTTTCA UCUGAUGCUUUUUC UCUGAUGCUUUUUCAUUAUU GUUA CAGU 2 TTATT ( SEQ ID AUUAUU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 451 ) NO : 452 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 549 )NA_E4T1 TGG GACT GOT GACAAAGA GACUGCUGACAAAG GACU GCU GACAAAGAU GGU G GUUA CAGU 3 TGGTG ( SEQ ID AUGGUG ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 454 ) NO : 455 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 550 )NA_E5T1 TGG ACATCCAAGGGAATG ACAUCCAAGGGAAU ACAUCCAAGGGAAU GUUUAU GUUA CAGU TTTAT ( SEQ ID GUUUAU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 457 ) NO : 458 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 551 )NA_E5T2 GGG GTTTGGCTTGTGGTG GUUUGGCUUGUGGU GUUUGGCUUGUGGU GUAAUU GUUA CAGU TAATT ( SEQ ID GUAAUU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 460 ) NO : 461 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 552 )NA_E5T3 TGG CGTTTGGCTTGTGGT CGUUUGGCUUGUGG CGUUUGGCUUGUGGUGUAAU GUUA CAGU GTAAT ( SEQ ID UGUAAU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 463 ) NO : 464 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUGAUGUACGUUUGGGUAUAUAUCGCCAGCCUGAACCUCUACGCCAGAAAUGGCAGCUUAttorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized}UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 553 )NA_E5T4 TGG GCTGGAAGTCGTTTG GCUGGAAGUCGUUU GCUGGAAGUCGUUUGGCUUGGUUACAGU GCTTG ( SEQ ID GGCUUG ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 466) NO : 467 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 554 )NA_E5T5 TGG AGGAAACGCTGGAAG AGGAAACGCUGGAA AGGAAACGCUGGAAGUCGUUGUUACAGU TCGTT ( SEQ ID GUCGUU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 469 ) NO : 470 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 555 )NA_E5T6 TGG AGTACAAAGACAGGA AGUACAAAGACAGG AGUACAAAGACAGGAAACGCGUUACAGU AACGC ( SEQ ID AAACGC ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 472 ) NO : 473 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 556)NA_E5T7 AGG AAAGCAGATGACTTG AAAGCAGAUGACUU AAAGCAGAUGACUUGGGCAAGUUACAGU GGCAA ( SEQ ID GGGCAA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 475 ) NO : 476) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 557 )NA_E5T8 TGG GCAGATGACTTGGGC GCAGAUGACUUGGG GCAGAUGACUUGGGCAAAGGGUUACAGU AAAGG ( SEQ ID CAAAGG ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 478 ) NO : 479 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 558 )NA_E5T9 GGG CAT GAAAAAGCAGAT CAUGAAAAAGCAGA CAU GAAAAAGCAGAU GACUU GUUA CAGU GACTT ( SEQ ID UGACUU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 481 ) NO : 482 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( SEQ ID NO : 559 )Attorney Docket No.: 063586-549001WOGuide PAM Target sequence Spacer Guide Sequence (RNA) Name* Sequence (Scaffold sequences are italicized) NA_E5T1 TGG CCATGAAAAAGCAGA CCAUGAAAAAGCAG C CAU GAAAAAGCAGAU GACU GUUA CAGU 0 TGACT ( SEQ ID AUGACU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 484 ) NO : 485 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 560 )NA_E5T1 AGG ATCTTCTTAAAATTT AU CUU CUUAAAAUU AUCUUCUUAAAAUUUUUUACGUUACAGU 1 TTTAC ( SEQ ID UUUUAC ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 487 ) NO : 488 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 561 )NA_E5T1 GGG CATCCAAGGGAATGT CAUCCAAGGGAAUG CAUCCAAGGGAAUGUUUAUUGUUACAGU 2 TTATT ( SEQ ID UUUAUU ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 490 ) NO : 491 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 562 )NA_E5T1 AGG AAT GAAGAAAGT ACA AAU GAAGAAAGU AC AAU GAAGAAAGU ACAAAGAC GUUA CAGU 3 AAGAC ( SEQ ID AAAGAC ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 493 ) NO : 494 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 563 )NA_E5T1 TGG CCAAGTCATCTGCTT CCAAGUCAUCUGCU CCAAGUCAUCUGCUUUUUCAGUUACAGU 4 TTTCA ( SEQ ID UUUUCA ( SEQ ID UAAGGCUCUUUGGAAACAAAGAAGCCUU NO : 496) NO : 497 ) AA UUGUAAAA CGCCUA UA UGGUAAAGUG AUGUACGUUUGGGUAUAUAUCGCCAGCC UGAACCUCUACGCCAGAAAUGGCAGCUU UAUCAUGGGUUAGGACGA UA UUUAAAAA A CUUUCUGCGGCUUGCUUA CUUUAGUAA GCUUUGUGGCUGAGGCAGAAUUCCUU ( S EQ ID NO : 564 )NS_E5T1 AGCC GCGATCCCAATTACA GCGAUCCCAAUUAC GC GAU C C CAAUUACAC CACAGUUGUA UU CCACA ( SEQ ID ACCACA ( SEQ ID CGGAUGGGAGUAAAAGGUUGAGUACACC NO : 565 ) NO : 566) UGGAAA CAAAA CGA CA UAAAGGUGUUCU CCCA UCUGUGUA CAAAGAGCAGA UA UA U GAGUUGA UAAGUAA UA UGUUGCA CGUA U GGACUUUGACAGUCUGUACCUCUGCGUG AAAGA CA UA UUGCGUUA UUCA UA UA UCU GUGAGUCUGUUCUAAAUUUAAAGGUUUAGGGAA ( SEQ ID NO : 567 ) *The guide name indicates the Nuclease that it can be paired with for editing S0D1 (e.g., gRNA, Casl2I2 E4T10 is paired with Casl2i2 nuclease)Attorney Docket No.: 063586-549001WOB. SOD1 Target Screening in HEK293T CellsSOD1 disruption was assessed by transient co-transfection of plasmids encoding a guide RNA and a CRISPR nuclease in HEK293T cells. Cells were cultured in DMEM containing 10% fetal bovine serum (DIO). Approximately 16 hours prior to transfection, a cell suspension containing 25,000 cells was seeded in each well of a 96-well plate, resulting in 70-90% confluency at the time of transfection. For each well to be transfected, a mixture of Lipofectamine 2000 and Opti-Mem (Thermo Fisher Scientific) was prepared and incubated at room temperature (Solution 1). A separate mixture containing plasmid expressing nuclease and plasmid expressing guide was prepared (Solution 2). Solutions 1 and 2 were mixed by pipetting, and the mixture was incubated at room temperature before being added to 96-well plates seeded with HEK293T cells. Negative control conditions including vehicle only or pmaxGFP (Lonza) were also administered.Transfected cells were cultured for 72 hours at 37°C with 5% CO2. Following removal of the culture media, cells were then detached by adding trypLE (Thermo Fisher Scientific), incubating 5 minutes, followed by D10 media, and mixing. Cells were then pelleted by centrifugation, resuspended in QuickExtract™ DNA Extraction Solution (Biosearch Technologies) and incubated at 65°C for 15 minutes, 68°C for 15 minutes, and 98°C for 10 minutes.C. Next Generation Sequencing and Bioinformatic Analysis of SOD1 Gene Disruption.For NGS analysis, the indel mapping function used a sample’s fastq file, the amplicon reference sequence, and the forward primer sequence. For each read, a kmer-scanning algorithm was used to calculate the edit operations (match, mismatch, insertion, deletion) between the read and the reference sequence. In order to remove small amounts of primer dimer present in some samples, the first 30 nt of each read was required to match the reference and reads where over half of the mapping nucleotides are mismatches were filtered out as well. Up to 50,000 reads passing those filters were used for analysis, and reads were counted as an indel read if they contained an insertion Samples for Next Generation Sequencing (NGS) were prepared by two rounds of PCR. The first round (PCR I) was used to amplify the genomic regions flanking the target site and to add NGS adapters. The second round (PCR II) was used to add NGS indexes. Reactions were then pooled, purified by column purification, and quantified on a fluorometer (Qubit). Sequencing runs were performed using a NovaSeq™ 6000 S2 Reagent Kit vl.5 (100 cycles) and run on a NovaSeq™ 6000 instrument (Illumina®), or deletion. The %Attorney Docket No.: 063586-549001WOindels was calculated as the number of indel-containing reads divided by the number of reads analyzed (reads passing filters up to 50,000). The QC standard for the minimum number of reads passing filters was 10,000.The results demonstrate that Casl2i2 exhibited the highest level of editing greater than 60%, and 44 of the 83 guides exhibited >30% editing (FIG. 1). One NA gRNA also exhibited editing > 60% (FIG. 4). However, only 19 of the 66 guides tested generated indels >10%. For the remaining nucleases, 12 of 34 guides paired with nuclease Type V-Sx3 exhibited editing >25% (FIG. 2) and 10 of the 66 NEC guides tested exhibited editing >10% (FIG. 3). The single NS guide was capable of generating 25% indels in HEK293T cells (FIG. 5).In sum, results from this study demonstrate different gene editing efficiencies of the nucleases and the guide RNAs of the disclosure, with Casl2i2 exhibiting the highest level of gene editing as determined by % raw indels in SOD1.Example 2: CRISPR Nuclease-Mediated Gene Editing of SOD1 in NeuronsThis example evaluates CRISPR-mediated gene editing of SOD1 in neurons using different Casl2i2 guides and further assesses the decrease in SOD1 protein in the neurons as a consequence of SOD 1 editing.Human motor neurons derived from Induced pluripotent stem cells (iPSCs) were purchased from BrainXCell and cultured in the laboratory using manufacturer’s protocols. Briefly, motor neurons were thawed from liquid nitrogen and 75,000 cells were seeded on 96-well microplates coated with poly-D-lysine (Thermo Fisher #A3890401) in motor neuron seeding media. Motor neuron seeding media was prepared using 1 : 1 DMEM / F12 (Thermo Fisher #11330-32): Neurobasal medium (Life Technologies #21103-049), supplemented with lx B27 (Thermo Fisher #17504-044), lx N2 (Thermo Fisher #17502-048), 0.5 mM GlutaMAX (Thermo Fisher #35050-061), 10 ng / ml BDNF (Peprotech #450-02), 10 ng / ml GDNF (Peprotech #450-10), 1 ng / ml TGF-pi (Peprotech #100-21C), 15 pg / ml Geltrex (Life Technologies #A1413201), and lx Motor Neuron Seeding Supplement (BrainXell). Four days after plating, neurons were transduced with Casl2i2 or Type V-Sx3 at an MOI of 20 and RNA guide lentiviruses at MOI 10. Based on >40% editing observed in HEK293 cells, eleven Casl2i2 guides and seven Type V-Sx3 guides were chosen for further screening in human motor neurons.Cells were harvested twenty days post transduction with nuclease and guide for measurement of editing and SOD1 protein reduction. For editing, cells were directly resuspended in 40 mL QuickExtract™ DNA Extraction Solution (Biosearch Technologies) andAttorney Docket No.: 063586-549001WOsamples were incubated at 65°C for 15 minutes, 68°C for 15 minutes, and 98°C for 10 minutes. DNA harvested from the samples above were used to measure SOD1 gene disruption using next generation sequencing methodologies described above. For measuring SOD1 protein levels, cells were directly resuspended in 100 mL RIPA buffer (Thermo Fisher 89901) containing protease inhibitor (Millipore Sigma, 11836170001) and phosphatase inhibitor (Millipore Sigma, 4906845001). SOD1 protein levels were measured using the Jess automated western blot system (Protein Simple) using the SOD1 antibody (MAB3418, Biotechne). The results demonstrate up to -80% indels for both Casl2i2 (FIG. 6A) and Type V CRISPR Nuclease A (FIG. 7A) and a proportional decrease in total SOD1 protein levels (FIGs. 6B and 7B). The amount of SOD1 protein knockdown was proportional to indel percentage, suggesting that protein knockdown is independent of guide location (FIGs. 8A and 8B).All Casl2i2 guides were further tested in iPSC derived motor neurons with a dose titration to identify the most potent guides. Briefly, cells were seeded as per the protocol mentioned above. Four days post seeding, cells were treated with lentivirus encoding Casl2i2 at an MOI of 20 and RNA guide at an MOI of 0.1, 0.3, 1, 3, 10, 30. Cells were harvested at twenty days post transduction with lentivirus and DNA and protein were collected for downstream analysis as per protocols mentioned above. Indel analysis demonstrated a dose dependent increase in editing and subsequent protein reduction was observed for all guides except E3T10 that had low editing. Casl2i2 guides E1T3, E2T2, E4T4, E3T20, E2T14 and E4T12 were identified as high potency guides that showed strong editing and SOD1 protein knockdown at lower MOIs (FIG. 9). Guides E3T10, E3T19, E3T21, E4T19 and E5T27 were identified as guides with lower potency (FIG. 10). The high potency guides were advanced for evaluation in AAVs.All nuclease and guide containing constructs were cloned into rAAVDJ vectors with expression driven by PolII and PolIII promoters respectively. The recombinant AAV was produced in HEK293T cells using transient transfection, purified and titrated using standard methodologies known in the field. Human motor neurons were transduced with the purified virus. Cells were then harvested at various timepoints for indel and protein measurement at days 5, 10, 15, 20, 30, 45 and 60 days post dosing. Longitudinal increase in indels and subsequent decrease in SOD1 protein was observed in cells treated with the AAV (FIGs. HA and 11B).In sum, results from this study demonstrate CRISPR-mediated SOD1 gene editing using different Casl2i2 guides in neurons.Attorney Docket No.: 063586-549001WOExample 3: Evaluation of Potency of Guides using HEK293T CellsIn this example, the potency of the lead guides was evaluated in HEK293T cells using ribonuclear protein complex carrying Casl2i2 and guide RNAs of the disclosure. Briefly, nuclease (40 pM) and guide (100 pM) were mixed in a ratio of 2.5: 1 and serially diluted 1:1 for 10 different concentrations and incubated for 45 minutes. HEK293T cells cultured in a flask were trypsinized using TrypLE and a cell suspension was generated carrying -300,000 cells per condition. 1 pl of enhancer oligo was added to each condition. The prepared RNP complex was added to the cell suspension and was added into the electroporation plate and electroporated using the Lonza 4D-nucleofector. The cells were then plated at 30,000 cells per well into a 96 well plate. Cells were harvested 72 hours post treatment and resuspended in QuickExtract™ DNA Extraction Solution (Biosearch Technologies) and submitted to NGS as per methods mentioned above. Dose dependent increase in indels was observed for all the lead guides. Based on editing efficiency, EC90 (pM) values were determined, and guides were rank ordered for potency (FIG. 12 and Table 7 below).The results from this study show that all guides tested, except E3T10, showed increasing indels of SOD1 with increasing concentrations of the guides.Table 7: EC90 Values of Casl2i2 Guides in HEK293T cellsGuide EC90 (pM)E3T20 0.02227E2T14 10.09E2T2 7.806E4T4 0.00296E1T3 0.4991E5T18 1.921E-06E3T10 7198734Example 4: Screening for CRISPR Nuclease-Mediated Gene Editing of SOD1 in hG93A SOD1 Transgenic Mouse ModelThis example describes CRISPR-mediated SOD1 editing in a SOD1 Transgenic mouse model. Neonatal pups derived from breeding male hG93A SOD1 transgenic mice with wildtype (WT) females were dosed for evaluation of guide potency in vivo. This model is the gold standard for SOD1-ALS in vivo pharmacology. Guo et al., Exp Mol Med, 41:140-150 (2009) and Gurney et al., Science, 264:1772-1775 (1994).Constructs carrying nuclease and guides were packaged into rAAV9 using standardAttorney Docket No.: 063586-549001WOprotocols in the field and as described in Example 2. Treatment groups are provided in Table 8.Table 8: Treatment GroupsGroup Mouse Vector Construct Nuclease Guide 1 hG93 A SOD mouse rAAV9 Casl2i2 E1T32 hG93 A SOD mouse rAAV9 Casl2i2 E2T23 hG93 A SOD mouse rAAV9 Casl2i2 E2T144 hG93 A SOD mouse rAAV9 Casl2i2 E3T205 hG93 A SOD mouse rAAV9 Casl2i2 E4T46 hG93 A SOD mouse NA - Vehicle NA NAPBS Control7 Wild type (SOD+ mouse) NA NA NAControlAt PO - P2 days of age, were anesthetized using cryo-anesthesia. Following cessation of movement, vehicle or AAV constructs were delivered directly to the intracerebral lateral ventricle of the mouse brain via intracerebral ventricular injection (ICV) at a volume of 2 pl per hemisphere, 4 pl total using a Hamilton syringe attached to a syringe pump. Following dosing animals were placed on a heating pad to recover and then returned to their home cages. At 3 - 4 weeks of age, mice were weaned, tagged and genotyped for the SOD1 transgene. At 6 weeks of age mice were euthanized via general anesthesia followed by vital tissue removal. Mice were perfused with IX PBS, and the following tissues were collected brain, liver, spinal cord, and tail for both molecular biology and histology applications.FIG. 13A shows the vector genomes per diploid genome (VG / DGE) observed in animals treated with AAV constructs carrying the guides in the cerebral cortex. A significant reduction of SOD1 protein was observed in animals treated with AAV constructs carrying guides Casl2i2 guides E2T14, E2T2, E4T4 and E1T3 in the cerebral cortex. FIG. 13B.Similarly, FIG. 13C shows VG / DGE observed in animals treated with AAV constructs carrying the guides in the spinal cord. A significant reduction of SOD1 protein was observed in the spinal cord of animals treated with AAVs carrying Guides E3T20, E2T2, E4T4 and E1T3. FIG.13D. In short, reduction in SOD1 protein was observed in the hG93A SOD1 mice at comparable levels of VGs across the groups.Further, DNA was extracted from the brain tissue using the All Prep® DNA / RNA Kit (Qiagen, ID 80204). Briefly, tissue was homogenized and bound to the AllPrep DNA spinAttorney Docket No.: 063586-549001WOcolumn. Ethanol was added to the spin column and the flow through was collected and saved for RNA extraction. The column was washed with wash buffers provided in the kit to elute the DNA. Droplet digital PCR (Biorad) was run on 50 ng of eluted DNAto measure the vector genomes using primer probes that bind to the polyA sequence. A strong correlation between the vector genomes harvested from the brain and the level of editing observed in the cerebral cortex for each of the guides was noted. The results facilitate stratification of the guides based on editing efficiency at similar VG range (FIGs. 14A and 14B).In sum, the results from this study demonstrate SOD1 gene editing and a significant reduction of SOD1 protein in both the brain and the spinal cord using AAVs carrying several guides of the disclosure.Example 5: Evaluation of Efficacy of Lead Guides on Behavioral End Points in hG93A SOD1 Transgenic MiceThis example evaluates the efficacy of SOD1 editing on behavioral endpoints relevant to ALS using a transgenic mouse model, including grip strength, response to nerve stimulation, motor responses, and the survival of the mice dosed with either vehicle or AAV constructs comprising the guide RNA sequences of the disclosure.A. Grip StrengthAs described previously in Example 4, neonatal pups derived from breeding hG93 A transgenic males and wildtype females were dosed with vehicle or AAV constructs. Following dosing animals were placed on a heating pad to recover and then returned to their home cages. At 3 - 4 weeks of age, mice were weaned, tagged and genotyped for the SOD1 transgene. Starting at 6 weeks of age, grip strength and body weights were measured every two weeks. Hind limb grip strength was measured using a Maze Engineers Grip Strength Test with a mouse hind limb attachment and Maze Engineers software (Conduct Science, Skokie, IL). Mice were placed at the top of the grip strength attachment and then pulled by the base of their tail across the attachment. Average grip strength and body weight for the mice were reported. Males from animals treated with Guide E3T20 showed increased grip strength compared to vehicle treated transgenic mice (FIG. 15A). No significant differences were observed between Guide E3T20 treated and non-transgenic animals. Results were represented as Mean ^SEM. One way ANOVA was used to determine statistical significance.In sum, the results show that the guide E3T20 showed increased grip strength compared to the vehicle.Attorney Docket No.: 063586-549001WOB. Survival studyFor the survival study, animals were observed for hindlimb paralysis and survival endpoint criteria. Animals were deemed to have met humane endpoint criteria when any one of the following criteria were met: 1) weight loss of greater than or equal to 20% from baseline 2) a body condition score of 2 minus 3) inability to eat / drink 4) respiratory distress / labored breathing 5) lethargy or persistent recumbency or 6) loss of righting reflex or other abnormal neurological behaviors. Males and females were included in the study. No decrease in survival was observed in the wildtype animals. Median survival in the vehicle treated transgenic mice was 152 days. Animals treated with 1.6Ellvgs of guide E3T20 showed a 35-day improvement in survival, with a median survival of -190 days (FIG. 15B). The difference between vehicle (PBS) treated and E3T20 guide treated transgenic animals was statistically significant with p<0.0001. Results are shown as a Kaplan Meier curve and statistics were run using the Log rank (Mantel Cox) test.AAVs carrying Casl2i2 and Casl2i2 gRNA, E2T2, E1T3 or E4T4 (Casl2i2 and gRNA collectively, editing cargo) were also evaluated for their impact on survival in the hG93 A mouse model at two different doses. At a low dose of 5.8E10 vg / animal, median survival for the vehicle treated group was reached at 128 days and 137 days for ElT3-treated animals. At the time of the study (150 days in life), 100% survival was observed in animals treated with guide E2T2 and 60% survival was observed in animals treated with E4T4 (FIG. 15C). In the high dose group (4E11 vg / animal), an increase in survival was observed in all animals treated with AAV carrying the editing cargo relative to control. At -220 days, 100% survival was observed in E2T2, 93% survival in E1T3 and 65% survival in E4T4 treated animals (FIG. 15D).AAVs carrying Casl2i2 with Casl2i2 guides E2T2, E1T3 and E4T4 were also evaluated for their impact on survival in the hG93 A mouse model at three different doses. Dose dependent effects on survival was observed. At a low dose of 5.8E10 vg / animal, median survival for the vehicle treated group was reached at 128 days and 137 days for ElT3-treated animals. In addition, at the low dose, treatment with any of the three guides, E2T2, E4T4 and E1T3, showed an improvement in median survival respectively compared to controls, 21, 71 and 9 days, respectively (Table 9). At 150 days in life of the study, 100% survival was observed in animals treated with guide E2T2 and 60% survival was observed in animals treated with E4T4 (FIG. 15C)At a medium dose of 1.6E11 vg / animal, further increase survival was observed in all treatment groups relative to control (Table 9). In the high dose group (4E11 vg / animal), an increase in survival was observed in all animals treated with AAV carrying editing cargoAttorney Docket No.: 063586-549001WOrelative to control. At -220 days, 100% survival was observed in E2T2, 93% survival in E1T3 and 65% survival in E4T4 treated animals (FIG. 15D). The greatest increase in median survival was seen with AAV carrying Casl2i2 guide E2T2 (Table 9) where long-term survival was assessed over an extended period of up to 350 days (FIG. 15D).Table 9. Median survival in the hG93A mouse model treated AAV carrying gene editing cargo targeting SOD.Dose Low Medium HighTreatment Median Change Median Change Median Change Survival relative to Survival relative to Survival relative to Control Control Control (days) (days) (days) Vehicle 128 - - - - - E2T2 149 21 190 62 242 114 E4T4 199 71 199 71 204 76E1T3 137 9 158 30 207 79These data demonstrate that genetic editing of the SOD1 gene using several guides significantly increased survival in the hG93A SOD1 mouse model. They also show that there is a dose-dependent increase in survival in the guide treated animals compared to vehicle groups.C. Compound Muscle Action Potential (CMAP) and Repetitive Nerve Stimulation (RNS)Male, neonatal pups derived from the SOD1 breeders were dosed for these studies. Within 24 hours of birth mice were sexed and genotyped for assignment to WT and SOD1+ treatment groups. Following verification of genotype, mice were dosed with vehicle or one of two treatments: 1) AAV carrying Casl2i2 and Casl2i2 guide E2T2, or 2) AAV carrying Casl2i2 and Casl2i2 guide E4T4. Treatment was delivered via ICV injection. Starting at Pl mice were weighed weekly.Starting at 6 weeks of age, ALS neurological scores were collected. Score for both legs are measured for each mouse, the average of the two legs is used for analysis. Scores were measured as follows: 0 - Full extension of hind legs away from the lateral midline when the mouse is suspended by its tail, and the mouse can hold this extension for 2 seconds, being suspended 3 times consecutively; 1 - Collapse or partial collapse of the leg extension toward the lateral midline or trembling of hind legs during the tail suspension; 2 - Toes curl under at least twice during walking of 12 inches, or any part of the foot is dragging along the cage bottom or table; 3 - Rigid paralysis or minimal joint movement, the foot is not being used for forward motion; 4 - The mouse cannot right itself within 30 sec from either side. No significantAttorney Docket No.: 063586-549001WOdifferences in body weight or neuroscores were observed through the course of the study (FIGs. 16Aand l6B)At 6, 8, 12, and 14 weeks of age, CMAP and RNS were measured. Mice were anesthetized with 2-3% isoflurane in 02 for up to 15 minutes. Stimulating electrodes are placed on each side of the sciatic nerve at the / proximal end of the thigh. Positive and negative electrodes are placed in belly of the tibialis anterior (TA) and the subcutaneously in the foot, respectively. After placement, current is passed from the stimulating electrodes to the recording electrode in the TA. Stimulus intensity is increased until the CMAP is maximized, the amplitude of the CMAP and its corresponding simulation intensity at this point are documented. No differences between groups were observed at 6 and 8 weeks of age. At 12 and 14 weeks of age, a significant decline in CMAP amplitude was observed in vehicle treated transgenic animals compared to age matched guide treated transgenic animals or non-transgenic controls (FIG. 17 and Tables 9 and 10 below). No significant differences were observed between animals treated with Guide Casl2i2_E2T2 or Guide Casl2i2_E4T4 and non-transgenic animals (FIG. 17 and Tables 9 and 10 below)Next, motor responses were recorded from an intramuscular needle electrode in the TA. For RNS, stimulation intensity is increased to 120% of the intensity required to record the CMAP. Four trains of 10 stimuli were administered at 3, 6, 10, and 20 Hz, while muscle action potentials were recorded. Decrement was expressed at the percentage of decrease of the max amplitude from baseline between the first and lowest response of each train. Increase in RNS decrement was observed for 3, 6, 10 and 20 Hz stimuli in the vehicle treated transgenic animals. No change in baseline was observed in Guide Casl2i2_E2T2 or Guide Casl2i2_E4T4 treated animals and non-transgenic controls (FIGs. 18A-18D).Following the 14-week electromyography measures, animals were euthanized via CO2 inhalation. Blood was collected via cardiac puncture and processed to serum. Brain and spinal cord tissues were harvested for further analysis. Gene editing is measured as described herein. In the cortex, -43% average editing was observed in both treatment groups (FIG. 18E).Corresponding to the editing, -88% reduction in SOD1 protein was observed relative to vehicle treated hG93A SOD1 animals (FIG. 18F). Comparable vector genomes were obtained from animals from both treatment groups (FIG. 18G).Statistical analyses were performed with GraphPad Prism, Version 9.2 or later. Two-way ANOVAs, with Sidak’s multiple comparisons post hoc tests, was used to test effects of genotype or treatment on longitudinal variables (e.g. data collected at multiple timepoints). T-tests and ANOVAs were used to test genotype or treatment effect at a particular timepoint.Attorney Docket No.: 063586-549001WOMantel-Cox’s log-rank test was used to test the effects of genotype or treatment on survival, if necessary. Results of statistical tests are summarized in Tables 10 and 11.In sum, the results demonstrated higher CMAP and no decrement in RNS following stimuli of different frequencies in Guide Casl2i2_E2T2 or Guide Casl2i2_E4T4-treated animals compared to the vehicle, indicating superior motor responses. These improved motor responses correspond with > 40% gene editing and a significant reduction in SOD protein.Table 10: ANOVA Results: Effect of GenotypeANOVA Table SS DE MS F (DFn, DFd) P value Age x Genotype 16673 3 5558 F (3, 78) = 34.76 P< 0.0001 Age 15526 3 5175 F (3, 78) = 32.37 P< 0.0001Genotype 24549 1 24549 F (1, 26) = 56.16 P< 0.0001Table 11: ANOVA Results: Effect of TreatmentANOVA Table SS DF MS F (DFn, DFd) P value Age x Treatment 25531 6 4255 F (6, 120) = 23.44 P< 0.0001 Age 7654 3 2551 F (3, 120) = 14.06 P< 0.0001Treatment 34573 2 17286 F (2, 40) = 46.69 P< 0.0001Example 6: Off-tar et Testing in Wild-Type Motor NeuronsHuman motor neurons derived from induced pluripotent stem cells (iPSCs) were purchased from BrainXCell and cultured as described previously in Example 2. Four days after plating, neurons were transduced with Casl2i2 at an MOI of 10 and RNA guide lentiviruses for guides Casl2i2 SOD1-E1T3, Casl2i2 SOD1-E2T2, Casl2i2 SOD1-E4T4 and Casl2i2 SOD1-E3T20 at an MOI 10. Cells were harvested at Day 10 and Day 30 post dosing and indels were verified prior to off-target assessment.Genomic coordinates for potential off-target sites nominated by in silico prediction and sent to Integrated DNA Technologies (IDT) for rhAmpSeq design and rhAmp primer synthesis. Pooled rhAmp primers were resuspended in IDTE (Integrated DNA Technologies 10 mM Tris, 0.1 mM Ethylenediaminetetraacetic acid), pH 7.5 to a 50 pM stock concentration. 10X rhAmp primer pools were diluted from the stock, made at varying concentrations, depending on the number of primers within a given pool per manufacturer’s instructions. Primer pools were validated for amplification by performing rhAmpSeq using untreated gDNA. Briefly, gDNA extracts for each condition were quantified by Qubit and diluted to 9 ng / pL. 99ng of purified gDNA was input into each PCR reaction. The PCR reaction was performed to amplify genomic regions surrounding potential off-target sites.Attorney Docket No.: 063586-549001WOThe PCR products were then purified by Solid phase reversible immobilization (SPRI) per manufacturer’s instructions (Bulldog-Bio) with 90 pL of purification beads to remove excess primers and eluted in 15 pL of IDTE, pH 8.0. Index primers were diluted to 5 pM in IDTE, pH 8.0. A second PCR reaction was performed to add Illumina sequencing handles and indices to the first PCR product. The products from the second PCR were SPRI purified per manufacturer’s instructions with 20 pL of purification beads to remove excess primers and eluted in 22 pL of IDTE, pH 8.0. Samples were run on a 2% agarose gel to confirm amplification, quantified by Qubit, normalized, and technical replicates were pooled. The average library size of each pool was determined by HS DI 000 TapeStation. Pools were combined based on required sequencing length and number of amplicons per pool. Libraries were sequenced using NovaSeq 6000 S4 Reagent. Sequencing data was analyzed and potential off-target sites with fewer than 10,000 aligned reads were considered dropouts.Sequencing reads were demultiplexed using BCL Convert based on unique dual indexes for each sample. Paired-end reads were merged using fastp. Reads were retained if they met the following criteria: at least 40% of the bases need to have a Phred quality score of 15 or more, at least 15 nucleotides long, and at least a 30 nucleotide overlap between the forward and reverse reads, with no more than 5 mismatched base pairs within the overlapping sequence. Demultiplexed reads were first assigned to an amplicon only if the first 30 nucleotides of the read perfectly matched the first 30 nucleotides of the amplicon. Reads where over half of the mapping nucleotides are mismatches were filtered out as well.A Bayesian classifier adapted from CRISPECTOR (Amit 2021) was used to separate editing events from background noise by comparison between treated and control conditions. The editing activity was examined in a ± 10-nucleotide window around the cut site. Reads were classified as edited when the Bayesian classifier determined its indel resulted from an editing event. Finally, the editing activity for a potential off-target site is quantified by the frequency of the edited reads out of the total number of reads. For a given sample, a potential off target site was only marked as edited if the indel frequency exceeded the limit of detection of 0.012% and there were at least 10K reads. Verified off-targets were defined as those with editing activity in at least 2 of the 3 technical replicates.The off-target data shown in Table 12 below indicate high fidelity of SOD-targeting guides. Cultured motor neurons subjected to supersaturating doses of lentivirus containing nuclease and SOD-targeting guides show low numbers of putative off-targets at low frequencies (Table 12 and FIGs. 20A-20C) relative to the on-target rates (FIG. 19). The low number of off-targets identified, the low indel frequency of positively called off-targets, andAttorney Docket No.: 063586-549001WOthe location of the putative off-targets indicate that SOD-targeting guides pose low to no risk for adverse genotoxic outcomes.In brief, the Casl2i2 SOD1-E1T3 guide exhibits an average indel rate of 13.1% 10 days after transduction and 33.9% 30 days after transduction (FIG. 19), while only one intronic off-target was detected (Table 12, FIG. 20A). The SOD1-E2T2 guide exhibits an average indel rate of 23.4% 10 days after transduction and 50.6% 30 days after transduction (FIG. 19).Three off targets were detected (Table 12, FIG. 20B) with this guide in either intronic or intergenic gene regions. Finally, the SOD1-E4T4 guide exhibits an average indel rate of 37.8% 10 days after transduction and 51.9% 30 days after transduction (FIG. 19). For this guide, two off targets were detected, S0Dl-E4T4_0ff-Target-l and SODl-E4T4_Off-Target-17 (Table 12, FIG. 20C) These two off-targets occur in the exon of a pseudogene and intergenic region of chromosome 18, respectively. Overall, the specificity of these three guides suggests these guides have a potential therapeutic utility for gene editing. Although SOD1-E3T20 guide exhibited an average indel rate of 28.18% 10 days after transduction and 42.33% 30 days after transduction (FIG. 19), a significant number of off-targets were identified for this guide, suggesting the need for additional de-risking to determine the therapeutic potential of this guide.In sum, the results from this study demonstrate high on-target gene editing of SOD1 and low off-target liability using the Casl2i2 nuclease and the guides of the disclosure. Overall, these findings strongly support the continued development of Type V CRISPR-Cas enzymes for the potential treatment of CNS diseases.Table 12: On-target Indel Rates on Day 10 and Day 30Day 10 Day 30Guides Off-target Genomic location Annotation activity activityCasl2i2 SOD1-E1T3-Off- 3:124536773- Intron of 0.118% 0.503%SOD1-E1T3 Target-1 124536792 KALRN Casl2i2 SOD1-E2T2-Off- Below 11:78967812- Intron of 0.038%SOD1-E2T2 Target-28 LoD 78967831 TENM4 Casl2i2 S0Dl-E2T2_0ff- 2:107072390- 0.019% 0.047%SOD1-E2T2 Target-73 107072409 Intergenic Casl2i2 S0Dl-E2T2_0ff- Below 6:68826341- Intron of 0.023%SOD1-E2T2 Target-115 LoD 68826360 ADGRB3Exon of Casl2i2 S0Dl-E4T4_0ff- Below 6:53196875- 0.058% SOD1P1 SOD1-E4T4 Target-1 LoD 53196894psuedogene Casl2i2 SODl-E4T4_Off- 18:10380117- 0.256% 1.49% IntergenicSOD1-E4T4 Target-17 10380136Attorney Docket No.: 063586-549001WOExample 7: Engineered Casl2i2 Nuclease Variant with Reduced Off-Target Editing EffectThis example explores further Casl2i2 nuclease variants for reducing off-target editing effects.Casl2i2 Nuclease Variants ScreeningBriefly, a low-n learning model was trained on historical data and controls (Casl2i2-WT, Casl2i2_A, Casl2i2_B) across CATL and CNS targets. The model generated a second-round library of 84 variants, including predicted novel single mutants, combination mutants, novel multi -mutants, and a manually designed combinatorial mutant. A representative pooled screen evaluates Casl2i2 mutants (e.g., designed via the MPNN methods) across a number of guides targeting SOD1 and other genes, including Casl2i2 guides SOD1 E3T20, EMX1-T4, and AAVS1-T5. The sequences of the guides are provided in Table 13 below.Table 13. Casl2i2 Guide RNA SequencesGuide RNA Sequences* SEQ ID SOD1- See Table 6 136 E3T20EMX1-T4 AGAAA UCCGTCUUUCA C77G4CGGGGGGAGGCCUGGAGUC 584AUGG AAVS1-T5 AGAAA UCCGUCUUUCA UUGA CGGA ACUGGCCCUCCG U U U 585GGCA*: italicized segment refers to the scaffold sequence and the segment in boldface refers to the spacer sequenceFor each guide, the following features are investigated: (i) on-target editing efficiency, (ii) off-target editing efficiency at 2-5 active off-target loci identified in previous studies as active, and (iii) off-target editing efficiency at 2-3 off-target loci identified in previous studies as inactive (which are used to monitor baseline noise and non-specific events). This configuration enables quantitation of activity (e.g., indel frequency at the on-target locus) and specificity (e.g., suppression of editing at known active off-targets) for each mutant under matched conditions.Variants were cloned into a standardized backbone (START-Casl2i2 nuclease-GSlink-HiBiT-NLS) under CMV promoter, with gRNAs delivered via a separate U6-driven vector. Assays were conducted in induced HEK cells. Cells were maintained in DMEM, high glucose with supplements GlutaMAX, pyruvate, fetal bovine serum (FBS) and penicillin-streptomycin. Transfection was conducted using lipid-based reagents (e.g., Lipofectamine® 2000) and Opti-MEM® for complex formation.Attorney Docket No.: 063586-549001WOFollowing a 3-day transfection window, cells were harvested and genomic DNA (gDNA) was isolated using standard lysis and proteolysis conditions (e.g., EDTA, Triton X-100, Proteinase K) and buffered with Tris-HCl (pH 7.5-8.0). Purified gDNA is quantified and used as template for amplicon generation.Targeted amplicons are produced using RhAmpSeq primers in conjunction with hot-start master mixes (Platinum™ II or SuperFi II) under cycling parameters that yield locus-specific products suitable for next-generation sequencing (NGS). RNase H2 was included per vendor specifications to support blocked-primer activation. Primer singletons were reconstituted in IDTE (pH 7.5-8.0) prior to pooling. Amplicons for the entire locus panel (on-target and off-targets across the five guides) were generated in parallel and pooled post-PCR.Pooled amplicons were converted to sequencing libraries using a RhAmpSeq Library Kit. Libraries underwent SPRI bead cleanup (AMPure XP) to remove primer dimers and short fragments. TapeStation HS DI 000 analysis and / or agarose gel verification (E Gel 2%) was done to confirm size distribution and absence of contamination. Libraries were quantified and normalized to the appropriate loading concentration. Prepared libraries were sequenced on an Illumina NovaSeq 6000 (SI reagent kit, 300 cycles) with PhiX spike in for diversity and calibration.Reads were demultiplexed and aligned to amplicon-specific reference sequences for each panel locus. Editing outcomes (indel frequencies) were calculated within predefined windows around the cut site. The results are provided in Tables 14 and 15 below.Table 14. On-Target Editing EfficiencyCasl2i2 Guides Average Indel % (Casl2i2 B) Average Indel % (Casl2i2 C) AAVS1 T5 20.86 25.23 EMX T4 16.63 19.61 SOD1 E3T30 24.30 33.74Table 15. Off-Target Editing EfficiencyCasl2i2 Guides Average Indel % (Casl2i2 Average Indel %B) (Casl2i2 C) AAVS1 T5 off-target 1 5.33 2.78 AAVS1 T5 off-target 11 0.00 0.00 AAVS1 T5 off-target 25 0.00AAVS1 T5 off-target 76 0.00 0.00EMX T4 off-target 135 0.48 0.01Attorney Docket No.: 063586-549001WOEMX T4 off-target 136 8.76 1.87EMX T4 off-target 137 6.77 0.42EMX T4 off-target 4 0.00 0.00EMX T4 off-target 41 1.86 0.05EMX T4 off-target 92 0.02 0.00SOD1 E3T30 off-target 150 1.87 0.18SOD1 E3T30 off-target 17 0.13 0.02SOD1 E3T30 off-target 171 8.06 4.35SOD1 E3T30 off-target 31 3.01 1.34SOD1 E3T30 off-target 6 12.78 3.52Variant designated nuclease Casl2i2 C, comprising N840R mutation in the RuvC-II domain, exhibited robust on target activity across the guide panel tested and reduced editing at previously active off target loci relative to the Casl2i2 B comparator, with suppression observed at nearly all profiled off targets (with a single exception in the panel).Validation of Casl2i2 C Nuclease in Human Motor NeuronsCasl2i2 Nuclease C variant was validated in human motor neuron cultures using AAV-mediated delivery. This approach models CNS-relevant cellular environments and enables assessment of editing performance under conditions approximating therapeutic delivery.Human motor neurons were cultured DIO media supplemented with penicillin / streptomycin). Cells were plated in 96-well plates and transduced with adeno-associated virus (AAV) vectors encoding the effector nuclease (Casl2i2 B or Casl2i2 C) and gRNA Casl2i2_E2T2. AAVs were produced following conventional methods and characterized by genome copy concentration prior to dilution. Transduction was performed when cultures reached approximately 70-90% confluence to maximize uniform delivery. A portion of existing media was replaced with a 2* AAV dilution, prepared based on vendor-provided titers and desired multiplicity of infection (MOI). Negative controls received media only. Following transduction, plates were incubated under standard conditions (e.g., 37 °C, 5% CO2).Cells were harvested by aspirating media and resuspending in a lysis solution (e.g., QuickExtract®) to release genomic DNA. Lysates were transferred to high-density plates for downstream processing. Editing outcomes are quantified using the RhAmpSeq pooled amplicon sequencing workflow described above, enabling simultaneous evaluation of on-target and off-target loci across the guide panel. Data analysis may employ alignment and variantcalling pipelinesto compute indel frequencies and specificity metrics.Casl2i2 Nuclease C variant demonstrated strong on -target activity in human motor neurons and maintains the specificity profile observed in HEK293T pooled screens, withAttorney Docket No.: 063586-549001WOreduced cleavage at previously active off-target sites relative to Casl2i2 B (FIG. 21). These findings support the transferability of Casl2i2 C performance from screening conditions to CNS-relevant cellular contexts.Example 8: Evaluation of Editing Efficacy of Optimized Viral Construct Producing CRISPR Nuclease and Guide RNA in hG93A SOD1 Transgenic Mice This example investigates editing efficiency of the SOD1 gene in hG93A SOD1 transgenic mice using an optimal AAV construct illustrated in FIG. 22A. The AAV construct comprises AAV2 ITR sequences, a codon-optimized Casl2i2 C nuclease polypeptide under the control of a Ula promoter, and a coding sequence for guide RNA Casl2i2_E2T2 under the control of a U6 promoter. The AAV construct further comprises an miR122 binding site following the Casl2i2 C nuclease polypeptide, followed by a bGH poly A signal sequence. The Casl2i2 C polypeptide further comprises a Nucleoplasmin NLS sequence (SEQ ID NO: 19), which is linked to the nuclease moiety via a peptide linker of SEQ ID NO: 576. The whole Casl2i2 nuclease polypeptide comprises the amino acid sequence of SEQ ID NO: 574. The coding sequence for the Casl2i2 nuclease is codon optimized (opt35, SEQ ID NO: 575). The relevant sequences are provided in Table 2 and Table 3 above.The Ula promoter was selected for the AAV construct due to its demonstrated tropism for neurons and astrocytes, both of which are cell types implicated in the disease pathology. Given that Ula is a ubiquitous promoter and systemic biodistribution to the liver was anticipated, the construct was further engineered to include miR122 binding sites. miR122 is highly expressed in hepatic tissue, and incorporation of these binding sites enables miR122-mediated attenuation of transgene expression in the liver, thereby effectively de-targeting hepatic expression. Xie et al., 2010, 19(3):526-535, the relevant disclosures of which are incorporated by reference for the subject matter and purposes referenced herein. This optimal AAV construct has exhibited enhanced potency relative to other AAV constructs.Neonatal animals (postnatal days P0-P2) were administered AAV particles comprising the AAV construct disclosed above at a dose of 5E10 vg / animal and 1.6E11 vg / animal to evaluate impact on editing in bulk cortex tissue. As shown in FIG. 22B, dose dependent increase in editing was observed with saturation in bulk editing observed at ~30 VG / DGE. Comparison of guide potency across several studies demonstrates that in neonate animals, no difference in potency was observed due to the improved architecture.Intracerebroventricular (ICV) administration of AAV9 in neonatal animals provides broad biodistribution of transgenes. In contrast, intra-cerebrospinal fluid (CSF) administrationAttorney Docket No.: 063586-549001WOof AAV9 in adult mice does not achieve comparable biodistribution. Rosario et al., PLoS ONE 8(6):e67680 (2013). Blood-brain barrier (BBB)-penetrant capsids, including PHP.B, PHP.eB et al, have demonstrated broad biodistribution in adult mice. Nonnenmacher et al., Molecular Therapy (2020) 20:366-378. As shown in Example 5 above, a dose-dependent increase in survival was observed in animals treated with P0-P2 ICV injections of SOD 1 -targeting cargo packaged in AAV9. Collectively, these findings suggest that utilization of BBB -penetrant capsids in adult hG93A SOD1 mice with lead construct described above is likely to provide similar therapeutic effects.OTHER EMBODIMENTSAll of the features disclosed in this specification may be combined in any combination. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.From the above description, one skilled in the art can easily ascertain the essential characteristics of the present disclosure, and without departing from the spirit and scope thereof, can make various changes and modifications of the present disclosure to adapt it to various usages and conditions. Thus, other embodiments are also within the claims.EQUIVALENTSWhile several inventive embodiments have been described and illustrated herein, those of ordinary skill in the art will readily envision a variety of other means and / or structures for performing the function and / or obtaining the results and / or one or more of the advantages described herein, and each of such variations and / or modifications is deemed to be within the scope of the inventive embodiments described herein. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary and that the actual parameters, dimensions, materials, and / or configurations will depend upon the specific application or applications for which the inventive teachings is / are used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific inventive embodiments described herein. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed. Inventive embodiments of the present disclosure are directed to eachAttorney Docket No.: 063586-549001WOindividual feature, system, article, material, kit, and / or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits, and / or methods, if such features, systems, articles, materials, kits, and / or methods are not mutually inconsistent, is included within the inventive scope of the present disclosure.All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and / or ordinary meanings of the defined terms.All references, patents and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which each is cited, which in some cases may encompass the entirety of the document.The indefinite articles “a” and “an,” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean “at least one.” The phrase “and / or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with “and / or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and / or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and / or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and / or” as defined above. For example, when separating items in a list, “or” or “and / or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of’ or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e., “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law.Attorney Docket No.: 063586-549001WOAs used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and / or B”) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.
Claims
Attorney Docket No.: 063586-549001WOWHAT IS CLAIMED IS:
1. A gene editing system for genetic editing of a human superoxide dismutase 1 (SOD1) gene, comprising:(a) a CRISPR nuclease polypeptide or a first nucleic acid encoding the CRISPR nuclease polypeptide; and(b) an RNA guide (gRNA) or a second nucleic acid encoding the RNA guide, wherein the gRNA comprises a spacer sequence specific to a target sequence within the SOD1 gene, the target sequence being adjacent to a protospacer adjacent motif (PAM) recognizable by the CRISPR nuclease polypeptide;wherein the CRISPR nuclease polypeptide is a Type V CRISPR nuclease or a CRISPR nuclease that comprises an amino acid sequence at least 90% identical to SEQ ID NO: 12, 14, or 16.
2. The gene editing system of claim 1, wherein the CRISPR nuclease polypeptide is a Type V CRISPR nuclease.
3. The gene editing system of claim 2, wherein the Type V CRISPR nuclease polypeptide comprises an amino acid sequence at least 90% identical to SEQ ID NO: 6 or SEQ ID NO: 9.
4. The gene editing system of claim 3, wherein the Type V CRISPR nuclease polypeptide is a Casl2i2 polypeptide comprising an amino acid sequence at least 95% identical to SEQ ID NO: 6 and optionally comprises one or more mutations relative to SEQ ID NO: 6; and wherein the PAM comprises the motif of 5’-NTTN-3’, in which each N independently represents any nucleotide residue, the PAM being located 5’ to the target sequence.
5. The gene editing system of claim 4, wherein the Casl2i2 polypeptide comprises the one or more mutations, which are at positions D581, G624, F626, N840, P868, 1926, V1030, E1035, and / or S1046 of SEQ ID NO: 6.
6. The gene editing system of claim 5, wherein the one or more mutations are amino acid substitutions, which optionally are D581R, G624R, F626R, N840R, P868T, I926R, V1030G, E1035R, S1046G, or a combination thereof.Attorney Docket No.: 063586-549001WO7. The gene editing system of claim 6, wherein the Casl2i2 polypeptide comprises:(i) mutations at positions D581, D911, 1926, and VI 030, which optionally are amino acid substitutions of D581R, D911R, I926R, and V1030G;(ii) mutations at positions D581, 1926, and VI 030, which optionally are amino acid substitutions ofD581R, I926R, and V1030G;(iii) mutations at positions D581, 1926, VI 030, and SI 046, which optionally are amino acid substitutions of D581R, I926R, V1030G, and S1046G;(iv) mutations at positions D581, G624, F626, 1926, V1030, E1035, and S1046, which optionally are amino acid substitutions of D581R, G624R, F626R, I926R, V1030G, E1035R, and S1046G;(v) mutations at positions D581, G624, F626, P868, 1926, V1030, E1035, and S1046, which optionally are amino acid substitutions of D581R, G624R, F626R, P868T, I926R, V1030G, E1035R, and S1046G; or(vi) mutations at positions D581, G624, F626, N840, P868, 1926, V1030, E1035, and S1046, which optionally are amino acid substitutions of D581R, G624R, F626R, N840R, P868T, I926R, V1030G, E1035R, and S1046G8. The gene editing system of claim 7, wherein the Casl2i2 polypeptide comprises the amino acid sequence of SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 573.
9. The gene editing system of any one of claims 4-8, wherein spacer sequence is specific to a target sequence within or near Exon 1, Exon 2, Exon 3 or Exon 4 of the SOD1 gene.
10. The gene editing system of claim 9, wherein spacer sequence is specific to a target sequence within the nucleotide sequence of any one of SEQ ID NOs: 1-5 or SEQ ID NOs: 1-5 and568-572.
11. The gene editing system of any one of claims 4-8, wherein the target sequence comprises:(i) 5’- CCCACACCTTCACTGGTCCA-3’ (SEQ ID NO: 41);(ii) 5’- TGCTCGAAATTGATGATGCC-3’ (SEQ ID NO: 32);(iii) 5’- TCTTAAAGGAAAGTAATGGA-3’ (SEQ ID NO: 71);Attomey Docket No.: 063586-549001WO(iv) 5’- TTATAAATAGGCTGT ACC AG-3’ (SEQ ID NO: 134);(v) 5’- AATAGACACATCGGCCACAC-3’ (SEQ ID NO: 146); or(vi) 5’- AAGATTCTGTGATCTCACTC-3’ (SEQ ID NO: 167).
12. The gene editing system of claim 9, wherein the spacer sequence comprises: (i) 5’- CCCACACCUUCACUGGUCCA-3’ (SEQ ID NO: 42);(ii) 5’- UGCUCGAAAUUGAUGAUGCC-3’ (SEQ ID NO: 33);(iii) 5’ - UCUUAAAGGAAAGUAAUGGA-3’ (SEQ ID NO: 72);(iv) 5’ - UUAUAAAUAGGCUGUACCAG-3’ (SEQ ID NO: 135);(v) 5’- AAUAGACACAUCGGCCACAC-3’ (SEQ ID NO: 147); or(vi) 5’ - AAGAUUCUGUGAUCUCACUC-3’ (SEQ ID NO: 168).
13. The gene editing system of any one of claims 4-12, wherein the spacer sequence is 20-30 nucleotide in length, optionally 20-nucleotide in length.
14. The gene editing system of any one of claims 4-13, wherein the gRNA comprises the spacer sequence and a scaffold sequence, which is 23-36-nucleotide in length.
15. The gene editing system of claim 14, wherein the scaffold sequence comprises 5'-AGAAAUCCGUCUUUCAUUGACGG-3' (SEQ ID NO: 21).
16. The gene editing system of any one of claims 4-8, wherein the gRNA comprises the nucleotide sequence of:(a) 5 ’ - AGAAAUCCGUCUUUC AUUGACGGCCC AC ACCUUCACUGGUCCA-3’ (SEQ ID NO: 43);(b) 5 ’ - AGAAAUCCGUCUUUC AUUGACGGUGCUCGAAAUUGAUGAUGCC-3’ (SEQ ID NO: 34);(c) 5 ’ - AGA AAUCCGUCUUUC AUUGACGGUCUUAAAGGAAAGU AAUGGA-3’ (SEQ ID NO: 73);(d) 5 ’ - AGAAAUCCGUCUUUC AUUGACGGUU AU AAAUAGGCUGU ACC AGS’ (SEQ ID NO: 136);(e) 5 ’ - AGAAAUCCGUCUUUC AUUGACGGAAUAGAC AC AUCGGCC AC AC-3’ (SEQ ID NO: 148); or(f) 5 ’ - AGAAAUCCGUCUUUC AUUGACGGAAGAUUCUGUGAUCUC ACUC-Attorney Docket No.: 063586-549001WO3’ (SEQ ID NO: 169).
17. The gene editing system of claim 2, wherein the Type V CRISPR nuclease polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO: 9 and optionally comprises one or more mutations relative to SEQ ID NO: 9; and wherein the PAM comprises the motif of 5’-NTTR-3’, in which N represents any nucleotide residue and R is A or G, the PAM being located 5’ to the target sequence.
18. The gene editing system of claim 17, wherein the CRISPR nuclease polypeptide comprises the one or more mutations, which are amino acid substitutions at positions P14, D32, 161, E311, T338, and / or E736 in SEQ ID NO: 9; optionally wherein the one or more amino acid substitutions are P14R, D32R, I61R, E311R, T338G, and / or E736G.
19. The gene editing system of claim 17, wherein the CRISPR nuclease comprises the amino acid sequence of SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11.
20. The gene editing system of claim 1, wherein the CRISPR nuclease polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO: 12; and wherein the PAM comprises the motif of 5’-NGG-3’, in which each N independently represents any nucleotide residue, the PAM being located 3’ to the target sequence.
21. The gene editing system of claim 1, wherein the CRISPR nuclease polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO: 14; and wherein the PAM comprises the motif of 5’-NGG-3’, in which each N independently represents any nucleotide residue, the PAM being located 3’ to the target sequence.
22. The gene editing system of claim 1, wherein the CRISPR nuclease polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO: 16; and wherein the PAM comprises the motif of 5’-ARCC-3’, in which R represents A or G, the PAM being located 3’ to the target sequence.
23. The gene editing system of any one of claims 1-22, wherein the CRISPR nuclease polypeptide further comprises a nuclear localization signal (NLS), which optionally is located at the C-terminus of the CRISPR nuclease polypeptide.Attorney Docket No.: 063586-549001WO24. The gene editing system of claim 23, wherein the CRISPR nuclease polypeptide further comprises a peptide linker connecting the CRISPR nuclease and the NLS.
25. The gene editing system of any one of claims 1-24, wherein the gene editing system comprises the first nucleic acid encoding the CRISPR nuclease polypeptide and the second nucleic acid encoding the gRNA.
26. The gene editing system of claim 25, wherein (a) the first nucleic acid and a complementary sequence of the second nucleic acid, or (b) a complementary sequence of the first nucleic acid and the second nucleic acid are located in a genetically modified viral genome.
27. The gene editing system of claim 26, wherein the genetically modified viral genome is a genetically modified adeno-associated viral (AAV) genome, which comprises inverted terminal repeats (ITRs) at both 5’ and 3’ ends.
28. The gene editing system of claim 26 or claim 27, wherein in the genetically modified viral genome, the first nucleic acid encoding the CRISPR nuclease polypeptide is in operable linkage to a first promoter and the second nucleic acid encoding the gRNA is in operable linkage to a second promoter; optionally wherein the first promoter and the second promoter are different promoters and / or wherein the first and second promoters are in opposite orientation.
29. The gene editing system of claim 28, wherein the first promoter is a Ula promoter and the second promoter is a U6 promoter.
30. The gene editing system of claim 28 or claim 29, wherein the first nucleic acid further comprises a nucleotide sequence encoding one or more miRNA bindings sites; optionally wherein the one or more miRNA binding sites comprise miR122 binding site(s), miR183 binding site(s) or a combination thereof; optionally wherein the one or more miRNA binding sites comprise three miR122 binding sites; and / or wherein the second nucleic acid may further comprise a transcription terminator sequence downstream to the coding sequence of the gRNA.Attorney Docket No.: 063586-549001WO31. The gene editing system of any one of claims 28-30, wherein the first nucleic acid further comprises a polyA signal sequence, optionally downstream to the nucleotide sequence encoding the miRNA binding site(s).
32. The gene editing system of any one of claims 28-31, wherein the first nucleic acid encodes the Casl2i2 nuclease polypeptide comprising the amino acid sequence of SEQ ID NO: 573, optionally wherein the first nucleic acid comprises the nucleotide sequence of SEQ ID NO: 575.
33. The gene editing system of claim 32, wherein the Casl2i2 nuclease polypeptide further comprises a peptide linker of SEQ ID NO: 576 and an NLS of SEQ ID NO: 19.
34. The gene editing system of any one of claims 28-33, wherein the genetically modified viral genome comprises(a), from 5’ to 3’, a Ula promoter, a nucleotide sequence encoding the Casl2i2 nuclease polypeptide, a nucleotide sequence encoding one or more miRNA binding sites, optionally 3 miR122 binding sites, a polyA signal sequence, a nucleotide sequence complementary to the coding sequence of the gRNA, which optionally comprises the nucleotide sequence of SEQ ID NO: 43, and a nucleotide sequence complementary to a U6 promoter; or(b) a complementary sequence of (a).
35. The gene editing system of any one of claims 28-34, wherein the genetically modified viral genome comprises AAV2 inverted terminal repeats at both the 5’ end and the 3’ end.
36. A gene editing system for genetic editing of a human superoxide dismutase 1 (SOD1) gene, comprising a genetically modified viral particle, which comprises a viral capsid encapsulating a viral genome, wherein the viral genome is set forth in any one of claims 26-35.
37. The gene editing system of claim 36, wherein the genetically modified viral particle is an engineered AAV viral particle, which optionally comprises AAV2 capsid or AAV9 capsid.Attorney Docket No.: 063586-549001WO38. The gene editing system of claim 37, wherein the viral particle is an engineered AAV viral particle comprising AAV9 capsid.
39. The gene editing system of claim 38, wherein the AAV9 capsid comprises blood-brain barrier (BBB)-penetrant capsid proteins.
40. A pharmaceutical composition comprising the gene editing system set forth in any one of claims 1-39.
41. A kit comprising the elements of (i) and (ii) the gene editing system set forth in any one of claims 1-39.
42. A method for editing a human superoxide dismutase 1 (SODF) gene, the method comprising contacting a host cell with the gene editing system set forth in any one of claims 1-39 to edit the SOD1 gene in the host cell.
43. The method of claim 42, wherein the host cell is cultured in vitro.
44. The method of claim 42, wherein the contacting step is performed by administering the gene editing system to a subject comprising the host cell.
45. A method for treating amyotrophic lateral sclerosis (ALS) in a subject, the method comprising administering an effective amount of a gene editing system set forth in any one of claims 1-39 or a pharmaceutical composition comprising such to a subject in need thereof.
46. The method of claim 45, wherein the subject is a human patient having familial ALS.
47. The method of claim 46, wherein the human patient carries the D90A mutation in the SOD1 gene.
48. An RNA guide (gRNA), comprising a spacer sequence that is specific to a target sequence in a human superoxide dismutase 1 (SOD1) gene, wherein the target sequenceAttorney Docket No.: 063586-549001WOis 3’ to a protospacer adjacent motif (PAM) comprising the motif of 5’-TTN-3’, in which N represents any nucleotide residue;wherein the target sequence comprises:(a) 5’ - CCCACACCTTCACTGGTCCA-3’ (SEQ ID NO: 41);(b) 5’- TGCTCGAAATTGATGATGCC-3’ (SEQ ID NO: 32);(c) 5’ - TCTTAAAGGAAAGTAATGGA-3’ (SEQ ID NO: 71);(d) 5’- TTATAAATAGGCTGTACCAG-3’ (SEQ ID NO: 134);(e) 5’- AATAGACACATCGGCCACAC-3’ (SEQ ID NO: 146); or(f) 5’- AAGATTCTGTGATCTCACTC-3’ (SEQ ID NO: 167).
49. The gRNA of claim 48, wherein the spacer sequence comprises:(a) 5’- CCCACACCUUCACUGGUCCA-3’ (SEQ ID NO: 42);(b) 5’- UGCUCGAAAUUGAUGAUGCC-3’ (SEQ ID NO: 33);(c) 5’- UCUUAAAGGAAAGUAAUGGA-3’ (SEQ ID NO: 72);(d) 5’- UUAUAAAUAGGCUGU ACC AG-3’ (SEQ ID NO: 135);(e) 5’- AAUAGACACAUCGGCCACAC-3’ (SEQ ID NO: 147); or(f) 5’ - AAGAUUCUGUGAUCUCACUC-3’ (SEQ ID NO: 168).
50. The gRNA of claim 48 or claim 49, wherein the spacer sequence is 20-30 nucleotide in length, optionally 20-nucleotide in length.
51. The gRNA of any one of claims 48-50, wherein the gRNA comprises the spacer sequence and a scaffold sequence, which is 23-36-nucleotide in length.
52. The gRNA of claim 51, wherein the scaffold sequence comprises 5'-AGAAAUCCGUCUUUCAUUGACGG-3' (SEQ ID NO: 21).
53. The gRNA of claim 48, wherein the gRNA comprises the nucleotide sequence of:(a) 5 ’ - AGAAAUCCGUCUUUC AUUGACGGCCC AC ACCUUC ACUGGUCC A-3 ’ (SEQ ID NO: 43);(b) 5 ’ - AGAAAUCCGUCUUUC AUUGAC GGUGCUCGAAAUUGAUGAUGCC-3’ (SEQ ID NO: 34);(c) 5’- AGAAAUCCGUCUUUC AUUGAC GGUCUUAAAGGAAAGUAAUGGA-Attorney Docket No.: 063586-549001WO3’ (SEQ ID NO: 73);(d) 5’- AGAAAUCCGUCUUUCAUUGACGGUUAUAAAUAGGCUGUACCAG-3’ (SEQ ID NO: 136);(e) 5 ’ - AGAAAUCCGUCUUUC AUUGACGGAAUAGAC AC AUCGGCC AC AC-3 ’ (SEQ ID NO: 148); or(f) 5 ’ - AGAAAUCCGUCUUUC AUUGACGGAAGAUUCUGUGAUCUC ACUC-3’ (SEQ ID NO: 169).
54. A viral vector, comprising a first nucleic acid comprising a nucleotide sequence encoding a CRISPR nuclease polypeptide, optionally a Casl2i2 nuclease polypeptide, and a second nucleic acid comprising a nucleotide sequence encoding a gRNA targeting a human SOD1 gene, wherein the first nucleic acid is in operable linkage to a first promoter and the second nucleic acid is in operable linkage to a second promoter; the first and second promoter optionally being in opposite orientation and different from each other.
55. The viral vector of claim 54, wherein the first nucleic acid further comprises a nucleotide sequence encoding one or more miRNA binding sites, optionally three miR122 binding sites; and / or wherein the second nucleic acid further comprises a transcription terminator sequence downstream to the encoding sequence for the gRNA.
56. The viral vector of claim 54 or claim 55, wherein the first promoter is a Ula promoter and the second promoter is a U6 promoter.
57. The viral vector of any one of claims 54-56, wherein the first nucleic acid further comprises a polyA signal sequence; optionally downstream to the nucleotide sequence encoding the miRNA binding site(s).
58. The viral vector of any one of claims 54-57, wherein the CRISPR nuclease polypeptide is the Casl2i2 nuclease polypeptide, which is set forth in any one of claims 4-8, 23-24, and 32-33, optionally wherein the Casl2i2 nuclease polypeptide comprises the amino acid sequence of SEQ ID NO: 573 or SEQ ID NO: 574; and / orwherein the gRNA is set forth in any one of claims 9-16; optionally wherein the gRNA comprises the nucleotide sequence of SEQ ID NO: 43.Attorney Docket No.: 063586-549001WO59. The viral vector of any one of claims 54-58, wherein the viral vector comprises, from 5’ to 3’, a U1 a promoter, a nucleotide sequence encoding the CRISPR nuclease polypeptide, optionally the Casl2i2 nuclease polypeptide, a nucleotide sequence encoding one or more miRNA binding sites, optionally three miR122 binding sites, a polyA signal sequence, a nucleotide sequence complementary to a coding sequence for the gRNA, and a nucleotide sequence complementary to a U6 promoter; optionally wherein viral vector further comprise a complementary sequence of a transcription terminator 5’ of the complementary sequence of the gRNA coding sequence..
60. The viral vector of claim 59, which is an AAV vector further comprising a 5’ end inverted terminal repeat (ITR) and a 3 ’ end ITR.
